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 I 
Abstract	
Pseudomonas	 aeruginosa,	 Staphylococcus	 aureus	 and	 Haemophilus	 influenzae	 are	the	 most	 notorious	 pathogens	 associated	 with	 pulmonary	 infections	 in	 Cystic	 Fibrosis	(CF)	 lung.	 Treatment	 is	 problematic	 and	 re-infection	 is	 relatively	 common.	 It	 is	 vital	 to	develop	 alternative	 therapies.	 Antimicrobial	 peptides	 are	 predominant	 candidates	 for	combatting	 pathogenic	 bacteria.	 Free	 Living	 Amoebae	 is	 widely	 distributed	 in	 the	environment	and	may	also	contaminate	CF	lung.	It	is	well	known	that	Acanthamoeba	feed	on	and	protect	bacteria.	The	role	of	Acanthamoeba	in	CF	lung	infections	has	not	yet	been	investigated.	It	is	possible	that	the	presence	of	Acanthamoeba	in	CF	lung	is	one	of	the	key	factors	for	such	re-infections.		In	 this	 study,	 antimicrobial	 peptide,	 magainin	 II,	 was	 tested	 against	 clinical	bacterial	strains	isolated	from	CF	patients	and	Acanthamoeba.	Magainin	II	has	been	shown	to	have	antimicrobial	efficacy	on	microorganisms	employed	in	this	study.			
P.	 aeruginosa,	 Escerichia	 coli,	 methicillin-sensitive	 Staphylococcus	 aureus,	
Staphylococcus	epidermidis	from	CF	lung	showed	ability	to	bind	with,	invade,	survive	and	multiply	 inside	 Acanthamoeba.	 However,	 other	 two	 clinical	 isolates	 H.	 influenzae	 and	
Streptococcus	 pneumoniae	were	 able	 to	 bind.	 They	 were	 found	 to	 have	 capsules	 that	enables	bacteria	remain	un-phagocytized	by	predators.	In	nature,	bacteria	living	together	with	Acanthamoeba	compete	 for	nutrition	and	space.	They	develop	strategies	to	combat	each	 other.	 Bacterial	 conditioned	 media	 were	 tested	 for	 amoebicidal	 and	 amoebistatic	abilities.	 	 P.	 aeruginosa,	 Str.	 pneumoniae	 and	 H.	 influenzae	 conditioned	 media	demonstrated	 amoebistatic	 and	 amoebicidal	 effects.	 Acanthamoeba	 conditioned	 media	exhibited	 bactericidal	 efficacy	 only	 against	 Str.	pneumoniae.	Magainin	 II	 in	 combination	with	silver	nitrate	or	vancomycin/ciprofloxacin	was	successful	 in	eradicating	bacteria.	It	was	essential	to	perform	experiments	in	environment	similar	to	CF	lung.	For	this	purpose	artificial	sputum	medium	was	prepared.	All	bacteria	and	Acanthamoeba	were	able	to	grow	in	it.	Results	revealed	sub-lethal	concentrations	of	magainin	II	inhibited	bacterial	biofilm	formation	in	artificial	medium.					
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1.1	Cystic	Fibrosis	CF	 is	 a	 disorder	 with	 an	 autosomal	 recessive	 pattern	 of	 inheritance	 with	complications	 in	 multiple	 organs.	 According	 to	 the	 World	 Health	 Organization	 (WHO)	there	 are	 about	 70 000	 people	 with	 cystic	 fibrosis	 (CF)	 worldwide,	 with	 incidence	fluctuating	 by	 location	 and	 ethnic	 background.	 It	 is	 most	 common	 amongst	 people	 of	Northern	 European	 origin	 and	 therefore	 its	 occurrence	 is	 highest	 in	 Europe,	 North	America,	 and	 Australia	 (~1/3000	 births).	 The	 occurrence	 is	 considerably	 lower	 in	 the	Middle	 East	 (Bahrain	 1/6000),	 South	 America	 (Brazil	 1/7000),	 Africa	 (South	 Africa	1/12 000),	and	Asia	(Japan	1/350 000)	(Macneill,	2015).		Mutations	 in	 the	 gene,	 which	 code	 for	 the	 cystic	 fibrosis	 transmembrane	conductance	regulator	(CFTR)	protein	result	in	clinical	manifestations	of	the	disorder.	The	CFTR	 is	 a	 c-AMP	 controlled	 anion	 channel	 expressed	 on	 the	 apical	 surface	 of	 epithelial	cells	 that	 line	 the	 airways,	 pancreatic	 ducts,	 and	 other	 tissues	 (Bear	 et	 al.,	 1992).	 In	situations	where	its	activity	is	reduced	or	is	absent,	bicarbonate	and	chloride	passage	are	both	reduced	(Rich	et	al.,	1990),	which	leads	to	thick,	mucoid	secretions,	impediment,	and	eventually	organ	death	(Rowe	et	al.,	2005)	(Figure	1.1).	So	far,	medical	treatments	for	CF	are	solely	aimed	at	organ	specific	complication	of	the	 disease.	 In	 the	 airways,	 inhaled	 dornase	 alfa	 (Fuchs	 et	al.,	 1994),	 hypertonic	 saline	(Elkins	 et	 al.,	 2006),	 and	 mannitol	 (Bilton	 et	 al.,	 2013)	 are	 applied	 to	 improve	 airway	mucociliary	 clearance;	 inhaled	 antibiotics	 are	 utilized	 to	 supress	 bacterial	 infection	(McCoy	 et	 al.,	 2008);	 and	 oral	 macrolide	 antibiotics	 and	 high	 doses	 of	 ibuprofen	 are	employed	 to	 control	 inflammation	 (Saiman	 et	 al.,	 2010).	 Recent	 novel	 findings	 in	advanced	technologies	have	facilitated	high	throughput	screening	(HTS)	methods	to	drug	discovery.	And	these	in	turn	have	produced	orally	bioavailable	tiny	chemical	compounds	that	are	able	to	target	the	underlying	defects	in	CF	(Saiman	et	al.,	2010).		Approximately	 2000	 mutations	 have	 been	 found	 in	 the	 CFTR	 gene	 since	 its	discovery	 in	 1989	 (Kerem	 et	al.,	 1989),	 and	 nearly	 242	mutations	 have	 presently	 been	identified	to	cause	CF.	Earlier,	CF	patients	were	genotyped	only	to	verify	the	diagnosis	or	to	 forecast	 disease	 difficulty	 (McKone	 et	al.,	 2003),	 but	with	 the	 latest	 authorization	 of	mutation	exclusive	treatments,	genotypic	data	are	considered	fundamental	(Ramsey	et	al.,	2011).	 To	 design	 novel	 therapies,	 an	 investigation	 of	 CFTR	 structure	 and	 function	 and	how	the	diverse	mutational	classes	result	in	ion	channel	malfunction	is	essential.	
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	Figure	1.1	A)	The	organs	affected	by	CF,	with	short	descriptions	of	the	difficulties	related	to	it.	B)	Healthy	airway	showing	open	passages.	C)	A	CF	airway	 illustrating	 the	accumulation	of	mucus,	 inflammation,	and	bacterial	infection	that	will	result	in	further	difficulties	(adapted	from	Mcdaniel	et	al.,	2015).		
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1.1.1	CFTR	physiology	in	healthy	people	CFTR	 is	 a	 representative	 of	 the	 adenosine	 triphosphate	 binding	 cassette	 (ABC)	family	 of	 transporter	 proteins,	 categorized	 by	 two	 membrane	 spanning	 domains	 that	construct	the	channel	pore	and	two	nucleotide	binding	domains	that	bind	and	hydrolyze	ATP	(Riordan	et	al.,	1989).	In	contrast	to	other	ABC	transporters,	CFTR	has	an	additional	regulatory	 domain	 which	 regulates	 channel	 opening	 and	 locking	 (Riordan,	 2008).	Phosphorylation	of	 the	monitoring	domain	by	protein	kinase	A,	continued	by	binding	of	ATP	 and	 its	 hydrolysis	 by	 the	 nucleotide	 binding	 domains	 (Hwang	 &	 Sheppard,	 2009)	results	 in	 dimerization	 of	 the	 nucleotide	 binding	 domains	 and	 compartmental	realignment	of	the	membrane	spanning	domains	to	enable	opening	of	the	CFTR	channel	pore	(Kanelis	et	al.,	2010).	The	principal	role	of	the	CFTR	protein	is	to	transfer	anions	(such	as	chloride	and	bicarbonate)	via	the	apical	membrane	of	epithelial	cells,	thus	creating	an	osmotic	gradient	for	 fluid	 discharge	 (Quinton,	 1990).	 Moreover,	 the	 CFTR	 has	 an	 absorptive	 function	 in	particular	epithelial	structures,	such	as	the	sweat	gland.	Deficiency	or	dysfunction	of	the	CFTR	lead	to	dehydrated,	thickened	secretions	that	block	epithelium	lined	ducts	causing	tissue	damage.	In	the	airways	of	CF	patients,	abridged	airway	surface	liquid	(ASL)	volume	triggers	impaired	mucociliary	clearance	and	hindrance	of	airways	with	thick	secretions	(Cantin	et	
al.,	2015).	Inherent	anomalies	of	CF	mucus	that	intensify	its	gluiness	and	adhesion	to	the	epithelial	surface	also	impede	the	lungs	and	other	organs.	This	builds	a	malicious	cycle	of	mucus	 retention,	 infection,	 and	 inflammation,	 which	 additionally	 extends	 the	 airway	damage.	Furthermore,	besides	damage	to	mucociliary	clearance,	there	is	solid	belief	that	CFTR	dysfunction	 itself	 results	 in	 innate	 and	 adaptive	 immune	deficiencies	 that	 lead	 to	compromised	bacterial	clearance	and	uncontrollable	inflammation	(Birket	et	al.,	2014).		
1.1.2	Classification	of	CFTR	mutations	
CFTR	 mutations	 can	 be	 largely	 classified	 into	 six	 categories	 according	 to	 the	mechanisms	that	cause	aberrant	CFTR	synthesis	or	function	(Haardt	et	al.,	1999).	Class	I	mutations	 include	 in-frame	UAA,	 UAG,	 or	 UGA	 stop	 codons	 in	 the	mRNA	preceding	 the	built-in	 stop	 codon	 at	 the	 3′	 end	 of	 mRNA,	 and	 are	 therefore	 suggested	 as	 premature	termination	codons	(PTCs).	The	transcribed	mRNA	is	condensed	and	unstable	resulting	in	lack	of	protein	manufacture	(Mendell	&	Dietz,	2001).	This	category	also	comprises	other	
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main	insertions	and	deletions	that	disturb	natural	translation.	Class	 II	mutations	produce	anomalous	CFTR	processing	or	trafficking,	which	 lead	to	lower	quantities	of	CFTR	at	the	cell	surface.	For	instance,	the	F508del-CFTR	mutation	is	a	three	base	pair	deletion,	which	results	in	an	amino	acid	deletion	with	consequent	mis-folding	of	 the	CFTR	protein.	The	mis-folded	protein	 fails	 to	 transport	 to	 the	cell	 surface	because	of	premature	degradation	by	the	proteasome	(Welch,	2004).	Class	 III	 mutations	 are	 regularly	 described	 as	 “gating”	 mutations	 because	 they	result	in	chaotic	activation	of	the	CFTR	channel.	Class	IV	mutations	display	normal	gating,	but	alterations	in	conductivity	of	the	channel	pore	trigger	irregular	chloride	permeability.	Class	V	mutations	are	positioned	within	promoter	or	splice	sites	in	the	gene;	they	lead	to	scarcer	CFTR	transcripts	and	abridged	protein	manufacture.		Class	 VI	 mutations	 are	 the	 latest	 to	 be	 discovered	 category	 and	 lead	 to	 lower	stability	of	CFTR	at	the	cell	surface,	resulting	in	increased	turnover	(Haardt	et	al.,	1999).	Numerous	 mutations	 demonstrate	 features	 of	 more	 than	 one	 category.	 For	 instance,	though	 the	 primary	 malfunction	 of	 F508del	 is	 aberrant	 cellular	 processing,	 it	 also	expresses	malfunctioning	gating	and	an	abridged	surface	half	life	(Dalemans	et	al.,	1991).	R117H	 is	 generally	 defined	 as	 a	 partially	 active	 conductance	 alteration,	 but	 it	 similarly	reveals	partially	disordered	gating	and	is	 located	in	cis	with	mutations	that	 influence	 its	expression	(Castellani	et	al.,	2008).		
1.1.3	Disease	causing	alleles	and	CFTR	activity	Individually	 a	 patient’s	 disease	 phenotype	 is	 partially	 defined	 by	 overall	 CFTR	activity,	which	in	turn	is	defined	by	the	net	effect	of	both	of	the	disease	producing	alleles	on	 the	 amount	 and	 function	 of	 the	 CFTR.	Usually,	 individuals	with	 two	 loss	 of	 function	alleles	 (classes	 I-III)	 have	 reduced	 levels	 of	 CFTR	 activity	 (<10%	 of	 normal)	 and	more	serious	 lung	 disorder	 and	 pancreatic	 deficiency	 consistent	with	 classic	 CF.	 By	 contrast,	those	with	at	least	one	residual	functional	allele	(classes	II-VI)	are	likely	to	have	residual	CFTR	 activity	 (>10%	 of	 normal)	 and	moderate	 lung	 disease	 and	 pancreatic	 sufficiency	consistent	 with	 non-classic	 or	 moderate	 CF	 (McKone	 et	 al.,	 2003).	 Furthermore,	considerable	phenotypic	variation	occurs	even	for	patients	with	the	identical	combination	of	 CFTR	 mutations	 due	 to	 environmental	 impacts	 and	 additional	 genetic	 variation	 that	contributes	to	the	ultimate	phenotype	(Kerem	et	al.,	1990).			
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1.1.4	Bacteria	associated	with	CF	
Malfunctioning muco-ciliary clearance in the lung makes CF patients vulnerable to 
opportunistic infections (De Soyza et al., 2013b). With	the	introduction	of	upgraded	culture	methods	and	culture-independent	techniques,	comprising	deep	sequencing	technology,	it	is	 obvious	 that	 the	 airways	 of	 patients	with	CF	 are	 chronically	 colonized	with	 complex,	poly-microbial	infections.	In	2003,	Rogers	and	colleagues	transformed	the	understanding	of	 CF	 lung	 infections	 through	 their	 identification	 of	 complex	 bacterial	 communities	 in	sputum	 and	 bronchoscopy	 samples	 exploiting	 a	 culture-independent,	 molecular-based	procedure,	 terminal	 restriction	 fragment	 length	 polymorphism	 profiling	 (Rogers	 et	 al.,	2003).	These	poly-microbial	communities	were	found	to	be	highly	individualized	to	each	patient	 and	 promote	 tangled	 inter-microbial	 and	 host—pathogen	 interactions,	 which	change	 the	 lung	 environment,	 effect	 response	 to	 treatment,	 and	 affect	 the	 course	 of	disorder.	
	
1.1.4.1	Staphylococcus	aureus	
Staphylococcus	aureus	(S.	aureus)	 is	 a	Gram-positive	 coccus	of	 about	1	µm	diameter.	Generally	having	a	role	as	a	commensal	organism	it	inhabits	skin,	skin	glands,	and	mucous	membranes,	predominantly	 in	 the	nose	of	healthy	people	 (Crossley	&	Archer,	1997).	 	S.	
aureus	is	one	of	the	leading	agents	causing	hospital-	and	community-associated	infections	which	 can	 result	 in	 serious	 consequences	 (Diekema	 et	 al.,	 2001).	 In	 various	 studies	investigating	pathogens	in	CF,	S.	aureus	was	identified	in	4	to	60%	of	patients	commonly	in	 association	with	 other	 bacteria,	 such	 as	P.	aeruginosa.	 Methicillin-susceptible	 strains	(MSSA)	cause	a	risk	in	CF	sufferers,	predominantly	because	of	the	production	of	biofilms	in	the	infected	lung	in	which	they	can	escape	from	antibiotic	therapy	(Davies	and	Bilton,	2009).			
1.1.4.2	Haemophilus	influenzae		
Haemophilus	inﬂuenzae	(H.	inﬂuenzae)	is	a	Gram-negative	bacterium,	playing	a	major	role	in	causing	community-acquired	respiratory	tract	infections	in	adults	and	might	lead	to	 severe	 sinusitis	 and/or	 severe	 otitis	 media	 (Tristram	 et	 al.,	 2007).	 H.	 inﬂuenzae	 is	isolated	from	the	lungs	of	CF	patients	and	in	2009	research	stated	that	between	1995	and	2005	the	prevalence	of	H.	inﬂuenzae	rose	in	these	patients	(Razvi	et	al.,	2009).			In	the	last	few	 decades,	 macrolides	 have	 been	 employed	 for	 the	 treatment	 of	 a	 variety	 of	 H.	
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inﬂuenzae	 infections	 (Phaff	 et	 al.,	 2006).	 Antibiotics	 have	 also	 become	 significant	 in	dealing	 with	 CF	 patients	 and	 attempts	 at	 employing	 azithromycin	 in	 CF	 patients	chronically	 infected	 with	 P.	 aeruginosa	 have	 revealed	 enhancements	 in	 lung	 function	(Saiman	et	al.,	2003).	The	employment	of	long-term	azithromycin	maintenance	treatment	in	 CF	 patients	 has	 been	 related	 to	 increased	 macrolide	 resistance	 in	 CF	 H.	 inﬂuenzae	isolates	(Tazumi	et	al.,	2009).		
	
1.1.4.3	Pseudomonas	aeruginosa	
Pseudomonas	 aeruginosa	 (P.	 aeruginosa)	 is	 a	 Gram-negative	 bacterium,	 a	 major	opportunistic	 causative	 agent	 in	 CF	 patients	 and	 induces	 a	 variety	 of	 infections	 among	other	vulnerable	people.	Its	intrinsic	resistance	to	a	range	of	antimicrobial	agents	makes	it	problematic	to	treat	infections.	Although	the	latest	evidence	has	emphasized	the	diversity	of	 this	species,	 the	majority	of	research	on	virulence	and	pathogenesis	concentrate	on	a	small	number	of	strains	(De	Soyza	et	al.,	2013a).	P.	aeruginosa	infects	up	to	80%	of	adult	CF	 patients	 population.	 Although	 it	 is	 still	 commonly	 presumed	 that	 the	majority	 of	 CF	patients	acquire	their	infecting	strains	of	P.	aeruginosa	from	environmental	sources,	there	is	 increasing	 evidence	 for	 the	 emergence	 of	 mainly	 effective	 transmissible	 strains	(Fothergill	et	al.,	2012),		some	of	which	have	been	related	to	increased	patient	morbidity,	mortality	(Aaron	et	al.,	2010)	or	antimicrobial	resistance	(Ashish	et	al.,	2012).	Infections	of	the	CF	lung	by	P.	aeruginosa	have	been	related	to	development	of	a	number	of	essential	bacterial	 features	 such	 as	 induction	 of	 mucoid	 condition	 (Govan	 and	 Deretic,	 1996),	hypermutability	(Oliver	et	al.,	2000)	and	alterations	in	cell	surface	virulence	determinants	(Cigana	 et	al.,	 2009).	 It	 is	 vital	 to	 note	 that	 during	 chronic	 infections	 of	 the	 CF	 lung,	P.	
aeruginosa	populations	are	of	great	diversity.	Therefore,	there	is	substantial	variability	in	virulence	factor	expression	or	antibiotic	resistance	between	CF	 isolates	of	P.	aeruginosa,	even	when	 they	 are	 isolated	 from	 the	 same	 sputum	 sample	 and	 the	 patient	 is	 infected	with	a	single	strain	(Mowat	et	al.,	2011).				
1.1.4.4	Streptococcus	pneumoniae	
Streptococcus	pneumoniae	(Str.	pneumoniae)		is	a	pathogen	of	acute	infections,	many	of	which	may	possess	strong	epidemiological	consequences,	such	as	meningitis,	otitis	media,	pneumonia,	 and	 sinusitis.	 The	 major	 area	 of	 colonization	 of	 this	 agent	 is	 the	nasopharyngeal	 epithelium,	where	 it	 remains	 as	part	 of	 the	 commensal	 flora.	 The	main	
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cause	of	pneumonia	is	movement	of	the	bacterium	towards	the	lungs	through	inhalation	(Zeiher	&	Hornick,	1996).	The	disease-causing	role	of	Str.	pneumoniae	in	CF	is	disputable,	and	 very	 few	 records	 were	 reported	 on	 its	 possible	 participation	 in	 pulmonary	 injury	(Bauernfeind	et	al.,	1987).	Isolation	took	place	mainly	in	infants	and	young	children.	The	isolation	 of	Str.	pneumoniae	was	 related	 to	 5%	of	 the	 acute-exacerbation	 incidents	 (del	Campo	et	al.,	2005).	Nevertheless,	the	outcomes	found	by	del	Campo	et	al.,	suggest	that	CF	isolates	 possess	 singular	 features,	 comprising	 high	 antibiotic	 resistance	 rates,	 certain	clonal	 relationships,	 and	 predominantly	 increased	 rates	 of	 mutation	 frequencies	 in	contrast	to	non-CF	Str.	pneumoniae	isolates	defined	beforehand	from	the	same	institution	(Morosini	 et	 al.,	 2003).	 Taking	 into	 account	 the	 probability	 that	 some	 clones	 of	 Str.	
pneumoniae	may	be	implicated	in	the	initial	stages	of	lung	inflammation	in	CF	patients,	a	precautionary	therapeutic	attitude	could	eventually	be	sensible	to	guarantee	eradication,	as	is	recommended	for	P.	aeruginosa	(Rosenfeld	et	al.,	2003).		
	
1.1.4.5	Escherichia	coli	
Escherichia	coli	(E.	coli)	is	typically	found	in	animal	and	human	intestines.	Despite	the	 fact	 that	 E.	 coli	 generally	 behaves	 as	 an	 innocuous	 commensal,	 certain	 strains	 are	noticeably	 pathogenic	 and	 have	 been	 documented	 as	 causes	 of	 food-borne	 enteritis.	Almost	 every	 part	 of	 the	 human	 organism	 can	 be	 infected	 by	 E.	 coli	 but	 the	 urinary	pathway	 is	a	commonly	 infected	extra-intestinal	 location,	 triggering	85–95%	of	cases	of	mild	 cystitis	 and	 pyelonephritis	 in	 premenopausal	 women	 (Smith	 et	 al.,	 2007).	 The	virulence	potential	of	E.	coli	 is	due	 to	 fimbriae,	 adhesins,	 toxins,	 siderophores,	 capsules,	hemolysins	and	 invasins	 (Croxen	and	Finlay,	2010,	 Smith	et	al.,	 2007).	The	evolution	of	colonies	manufacturing	extended-spectrum	β-lactamases	(ESBLs)	has	grown	into	a	severe	problem	for	clinicians,	severely	decreasing	the	therapeutic	choices.	ESBLs	are	capable	of	neutralizing	 β-lactamic	 antibiotics	 at	 diverse	 levels	 (Paterson	 and	 Bonomo,	 2005).	According	to	definite	antibiograms	antibiotic	choices	have	to	be	personalized,	which	may	vary	 from	 one	 hospital	 to	 another,	 one	 city	 to	 another	 and	 one	 geographical	 region	 to	another	 (Pitout	 &	 Laupland,	 2008).	 Ultimately	 carbapenems,	 including	 imipenem,	meropenem,	and	ertapenem,	have	become	widely	accepted	as	a	primary	choice	drug	class	against	infections	induced	by	ESBL-producing	Enterobacteriaceae	(Paterson,	2000).			
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1.1.4.6	Staphylococcus	epidermidis		Staphylococci	 are	mutualistic	 inhabitants	 of	 the	 skin	 and	mucous	membranes	 of	human	 organism	 (Williams	 &Wilkins,	 Baltimore,	 1986).	 Staphylococcus	 epidermidis	 (S.	
epidermidis)	 is	 the	major	 group	 to	 inhabit	 human	epithelia,	 and	primarily	 colonizes	 the	armpits,	 head	 and	 nares	 (Kloos	 &	Musselwhite,	 1975).	 S.	 epidermidis	 species	 possesses	genes	that	are	expected	to	be	responsible	for	defence	from		undesirable	conditions	(Gill	et	
al.,	2005,	Zhang	et	al.,	2003):	 for	 instance,	 to	survive	 in	 life-threatening	salty	conditions	and	 osmotic	 pressure	 (Gill	 et	 al.,	 2005).	 S.	 epidermidis	 is	 representative	 of	 coagulase-negative	 staphylococci.	 (Wang	 et	 al.,	 2003,	 Wisplinghoff	 et	 al.,	 2003).	 By	 means	 of	 a	recently	 upgraded	 scheme	 (Thomas	 et	 al.,	 2007),	 74	 sequence	 types	 of	 S.	 epidermidis	strains	were	recognised	(Miragaia	et	al.,	2007).	S.	epidermidis	is	the	major	causative	agent	found	on	medical	equipment,	such	as	peripheral	or	central	intravenous	catheters.		
	
1.1.5	CF	lung	disease	treatments		Usual	pulmonary	 treatment	of	CF	has	 targeted	 the	consequences	of	 the	disorder,	specifically	mucus	plugging	and	infection.	The	last	few	years	have	seen	the	development	of	 more	 advanced	 therapeutic	 agents,	 numbers	 of	 which	 are	 in	 clinical	 trials,	 or	 have	proceeded	 to	 approved	 treatments.	 Here,	 pulmonary	 treatment	 opportunities	 are	concentrated	 on,	 categorized	 by	 their	 type	 of	 action,	 giving	 information	 on	 those	 in	present	clinical	use,	and	emphasizing	progress	 in	research.	Treatments	 for	other	organs	damaged	in	CF	(for	example,	the	pancreas,	 liver,	bones	and	sinuses)	can	be	found	in	the	research	of	Plant	and	collaborators	(Plant	et	al.,	2013).			
1.1.5.1	Mucolytic	agents	The	 mucolytic	 agent,	 Dornase	 alfa	 is	 a	 recombinant	 human	 deoxyribonuclease	(DNase).	 As	 contributor	 for	 the	 inflammatory	 progression	 in	 CF	 there	 is	 a	 substantial	buildup	 and	 breakdown	 of	 neutrophils	 in	 the	 lungs	 resulting	 in	 great	 quantities	 of	extracellular	DNA,	which	 significantly	 intensifies	 the	 gluiness	 of	 the	 sputum.	DNase	has	been	shown	to	cleave	the	extracellular	DNA	and	consequently	assist	 in	airway	clearance	(Konstan	&	Ratjen,	2012)	.	Another	 agent,	 N-acetyl-L-cysteine	 (NAC)	 has	 formerly	 been	 considered	 to	 be	mucolytic	 in	 CF	 and	 may	 also	 raise	 levels	 of	 the	 intracellular	 antioxidant	 glutathione	(GSH),	thus	protecting	from	the	neutrophil-driven	tissue	destruction	in	the	lungs.	Clinical	
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trials	 have	 however	 produced	 slightly	 conflicting	 results	 (Dauletbaev	 et	 al.,	 2009),	consequently	agreement	is	lacking	on	the	clinical	utility	of	NAC	for	CF.		
1.1.5.2	Airway	clearance	One	 of	 the	 mainstays	 of	 treatment	 for	 CF	 is	 physiotherapy,	 which	 helps	 in	clearance	 of	 airway	 secretions.	Multiple	 diverse	mimicking	 techniques	 are	 also	 applied,	but	the	optimal	approach	is	not	equaled.	A	recent	report	found	no	indication	in	support	of	high-frequency	 chest	 wall	 oscillating	 devices	 when	 compared	 to	 positive	 expiratory	pressure	 and	 essentially	 found	 a	 higher	 level	 of	 pulmonary	 exacerbations	 (PEs)	demanding	 antibiotics	 related	 to	 their	 administration	 (McIlwaine	 et	 al.,	 2013).	 Various	interventions	 to	 endorse	 health	 and	 exercise	 have	 been	 trialed	 although	 there	 is	 no	unanimous	 conclusion	 over	 which	 technique	 has	 been	 the	 most	 efficacious	 (Cox	 et	 al.,	2013).		
1.1.5.3	Rehydration	strategies	for	airway	surface	Hypertonic	 saline	 (HS)	 contributes	 impaired	 muco-ciliary	 clearance	 (MCC)	 by	raising	 hydration	 of	 the	 airway	 surface	 in	 the	 short	 term.	 As	 it	 might	 cause	bronchoconstriction,	it	is	regularly	administered	with	an	associated	bronchodilator.	When	compared	 with	 a	 placebo,	 HS	 was	 nontoxic,	 economical	 and	 efficient	 in	 reducing	 the	number	of	PEs	involving	intravenous	(IV)	antibiotics	(Donaldson	et	al.,	2006).	Mannitol	 is	a	non-absorbable	sugar	alcohol	 that	provides	an	osmotic	gradient	on	the	 airway	 surface	 resulting	 in	 rehydration,	 and	 an	 increase	 in	 surface	 liquid	 volume,	which	 helps	 in	 the	 clearance	 of	 mucus.	 An	 international	 phase	 III	 trial	 presented	 a	sustained	and	clinically	important	advantage	even	with	concomitant	DNase	utilization	in	patients	 18	 years	 of	 age	 and	 older.	 Nevertheless	 it	 additionally	 exhibited	 an	 increased	quantity	 of	 adverse	 events	 such	 as	 hemoptysis	 and	 cough.	 Existing	 evidence	 suggests	mannitol	is	nontoxic	to	use	in	patients	who	are	capable	of	tolerating	it	(Bilton	et	al.,	2011).	Denufosol	 tetrasodium,	 a	 P2Y2	 purinergic	 receptor	 agonist,	 induces	 chloride	secretion	 and	 ciliary	 beat	 frequency	 independent	 of	 CFTR.	 Phase	 III	 study	 results	were	primarily	 promising,	 exhibiting	 a	 small	 but	 statistically	 significant	 increase	 in	 lung	function	in	contrast	to	the	placebo	(Accurso	et	al.,	2011).			
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1.1.5.4	Antibiotics	against	infections	Antibiotics	 are	 administered	 in	 four	 different	 conditions	 in	 CF:	 prophylaxis,	suppression	 of	 early	 infection,	 eradication	 of	 chronic	 infection	 and	 in	 the	 treatment	 of	exacerbations.	The	pathogens	isolated	in	CF	lungs	differ	with	patient’s	age.	In	infancy	the	most	 common	 bacteria	 identified	 is	 S.	 aureus,	 with	 H.	 influenzae	 increasing	 during	childhood;	 by	 adolescence	 and	 young	 adulthood	 by	 far	 the	 commonest	 pathogen	identified	 is	 P.	 aeruginosa.	 Nevertheless,	 the	 introduction	 of	 culture-independent	molecular	tools	to	identify	bacterial	strains	has	shown	the	poly-microbial	nature	of	the	CF	lower	 airway.	 The	 association	 of	 the	 micro-biome	 to	 patients’	 health	 and	 disease	development	 is	 currently	 the	 focus	 of	 numerous	 research	 efforts	 (Rogers	 et	 al.,	 2015).	Whilst	 clinicians	 will	 often	 treat	 an	 early	 bacterial	 infection	 with	 an	 intention	 of	 both	handling	 symptoms	and	decreasing	 the	 likelihood	of	 chronic	 infection,	 the	organism	 for	which	the	 latter	outcome	is	most	strongly	supported	 is	P.	aeruginosa	 (Langton	Hewer	&	Smyth,	2014).	If	not	identified	and	treated	aggressively,	this	Gram-negative,	opportunistic	bacterium	will	be	converted	to	chronicity;	the	resulting	inflammatory	response	is	strongly	related	to	a	decline	in	lung	function.	Eradication	approaches	differ	between	countries	and	even	 amongst	 sites	 but	 involve	 inhaled	 +/−	 systemic	 antibiotics.	 In	 North	 America,	inhaled	tobramycin	 is	 the	first	 line	treatment	(Mogayzel	et	al.,	2014),	while	 in	Europe,	a	multicenter	 trial	 is	 presently	 assessing	 whether	 oral	 antibiotics	 are	 better,	 when	 used	with	nebulized	colistin	(Edmondson	&	Davies,	2016).	When	bacterial	 infection	has	become	chronic,	 the	focus	shifts	 from	eradication	to	chronic	 suppression	 in	 the	 expectation	 of	 decreasing	 the	 inflammatory	 response.	Conventionally-delivered	antibiotics	carry	with	them	possible	side	effects	and	may	result	in	 suboptimal	 sputum	 concentrations	 (Waters	 &	 Ratjen,	 2014).	 Consequently	 much	research	 has	 concentrated	 on	 inhalation	 as	 a	 route	 of	 antimicrobial	 delivery,	 which	 by	distributing	 the	 drug	 directly	 to	 the	 site	 of	 infection	 and	 in	 high	 dosages,	 can	 enhance	bacterial	 killing	 at	 the	 same	 time	 as	 limiting	 side	 effects	 (Hewer,	 2012).	 Difficulties	involved,	in	particular	cases,	are	an	un-palatable	taste,	possible	bronchospasm,	especially	with	the	dry	powder	formulations,	and	the	time	required	both	to	use	the	drug	and	care	for	the	 equipment,	 which	 may	 influence	 adherence.	 The	 most	 commonly	 administered	nebulized	 antibiotics	 against	 P.	 aeruginosa	 are	 tobramycin,	 colistin	 and	 more	 recently,	aztreonam;	in	numerous	circumstances,	a	cycling	approach	is	applied,	administering	on	a	month-on,	month-off	basis	or	alternating	drugs.	
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In	an	effort	to	decrease	the	time	desirable	to	deliver	the	drug	to	the	airway	and	the	preparation	 and	 cleaning	 essential,	 dry	 powder	 formulations	 have	 been	 developed	 for	both	colistin	and	tobramycin.	Colistin	(Schuster	et	al.,	2013)	and	tobramycin	(Konstan	et	
al.,	2011)	were	carried	using	a	dry	powder	inhaler	(DPI)	and	short	term	results	exhibited	they	were	non-inferior	to	the	nebulized	forms	of	tobramycin.	There	was	no	indication	of	boosted	adherence,	though	this	is	a	problematic	outcome	to	measure.	It	seemed	there	was	an	intensification	in	the	reporting	of	cough	in	the	DPI	group	(Uttley	et	al.,	2013).	Advance	research	must	be	carried	out	to	consider	the	long	term	consequences	of	using	a	DPI	rather	than	the	more	conventional	nebulized	medicines	(Tappenden	et	al.,	2013).	Nevertheless,	Harrison	 and	 colleagues	 did	 show	 improved	 adherence	 to	 inhaled	 tobramycin	 when	compared	with	the	nebulized	form	in	adults	with	CF	(Harrison	et	al.,	2014).		Numerous	later	agents	are	currently	under	investigation.	A	liposomal	formulation	of	 amikacin	 is	being	 trialed	as	a	new	once-a-day	 substitute.	An	appealing	 feature	of	 the	liposome	 is	 its	 breakdown	 by	 bacterial	 rhamno-lipids,	 meaning	 the	 drug	 becomes	efficiently	delivered	to	the	site	of	demand.	In	both	phase	II	and	III	trials	similar	increases	in	the	forced	expiratory	volume	in	one	second	(FEV1)	were	seen	as	for	tobramycin	(Ehsan	
et	al.,	2014).	Levofloxacin	inhalation	solution	(MP-376)	has	lately	been	revealed	to	be	well	tolerated	 and	 non-inferior	 to	 tobramycin	 (Stuart	 Elborn	 et	 al.,	 2015).	 Lastly,	 a	 double-blind,	placebo-controlled	trial	compared	a	combination	antibiotic	fosfomycin/tobramycin	with	 a	 placebo	 after	 a	 28-day	 open-label	 run-in	 course	 of	 aztreonam	 and	 showed	maintenance	 of	 the	 substantial	 improvement	 in	 FEV1	 in	 patients	 after	 the	 aztreonam	course	 (Trapnell	 et	 al.,	 2012).	 This	 proposes	 that	 constant	 antibiotic	 treatment	 using	alternating	 antibiotics	 may	 be	 attractive	 in	 future	 for	 the	 treatment	 of	 P.	 aeruginosa	infection,	 although	 discussion	 remains	 regarding	 which	 combination	 of	 antibiotics	 that	should	contain.	PEs	 are	 signs	 of	 symptoms	 and	 degenerating	 lung	 function;	 their	 mechanism	 is	inadequately	understood.	In	childhood,	it	is	common	for	viruses	to	be	identified	in	airway	secretions	at	the	time	of	PE	and	on	occasions,	a	new	bacterial	organism	might	be	isolated,	but	much	more	commonly,	neither	the	type	of	organism	isolated	nor	its	number	appear	to	have	altered	considerably.	This	fosters	the	probability	that	it	is	the	bacterial	behavior,	for	example	the	manufacture	of	virulence	factors,	or	the	host	response,	which	has	altered.	PEs	are	treated	with	oral	or	IV	antibiotics	varying	on	severity.	Methicillin-resistant	 S.	 aureus	 (MRSA)	 is	 on	 the	 rise	 in	 patients	 with	 CF,	 being	
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found	 in	up	to	25%	of	patients	 in	 the	USA.	MRSA	has	been	related	to	deteriorating	 lung	function	and	higher	mortality.	A	recent	research	report	 into	 the	Staphylococcal	Cassette	Chromosome	 mec	 (SCCmec)	 types	 in	 children	 with	 CF	 showed	 that	 the	 SCCmec	 type	isolated	 in	 the	 sputum	 correlated	 with	 the	 extent	 of	 exacerbation	 and	 the	 number	 of	courses	 of	 antibiotics	 administered	 by	 each	 patient.	 Those	 chronically	 infected	 with	SCCmec	II	MRSA	isolates	had	higher	exacerbation	frequencies.	The	authors	propose	that	this	points	out	 the	question	about	whether	 isolated	MRSA	 should	be	 routinely	 typed	 to	allow	 for	 direction	 of	 the	 eradication	 technique	 (Heltshe	 et	 al.,	 2015).	 STAR-TOO	 is	 a	current,	 randomized,	 controlled,	 intervention	 research	 comparing	 an	 early	 suppression	protocol	 for	MRSA	with	 the	current	standard	of	only	 treating	PEs.	The	use	of	AeroVanc,	first	 inhaled	 antibiotic,	 Savara	 USA	 to	 reduce	MRSA	 colony-forming	 units	 is	 also	 being	assessed	in	a	phase	II	randomized,	double-blind,	placebo-controlled	trial.	A	recent	phase	III,	 double	 blind,	 placebo-controlled,	 two-part	 multisite	 investigation	 confronted	aztreonam	 for	 inhalation	 solution	 (AZLI)	 with	 a	 placebo	 and	 concluded	 there	 was	 no	noteworthy	 improvement	 in	 lung	 function.	 The	 authors	 hypothesized	 that	 non-study	antibiotic	use	may	have	effected	their	results	(Tullis	et	al.,	2014).		
1.1.5.5	Non-antibiotic	agents	against	bacterial	infections	Chronic	P.	aeruginosa	produces	a	biofilm	in	the	CF	airways.	This	comprises	of	the	bacterium	itself	implanted	in	a	complex	matrix	of	neutrophil	DNA,	exopolysaccharide	and	airway	mucins,	 which	makes	 it	 extremely	 resistant	 to	 antibiotic	 therapy.	 OligoG,	 a	 dry	powder	 formulation	 of	 seaweed-derived	 alginate	 oligosaccharide,	 seems	 to	 have	 both	antibiofilm	 and	 mucolytic	 characteristics	 and	 is	 presently	 in	 phase	 II	 trials.	 A	 non-significant	 clinical	 trial	has	earlier	proposed	 that	 IgY	derived	 from	 immunized	hen	eggs	could	 be	 capable	 of	 protecting	 P.	 aeruginosa	 infection	 (Kollberg	 et	 al.,	 2003).	 A	 multi-center	 trial	 is	 currently	 investigating	 the	 benefits	 of	 this	 antibody	 directed	 as	 a	 gargle	solution.		
1.1.5.5.1	Targeting	CFTR	mutations	Drugs	 in	 treatments	 of	 CFTR	 defects	 could	 be	 classified	 in	 three	 groups:	potentiators,	correctors	or	read-through	agents.	Potentiators	 improve	the	activity	of	 the	CFTR	channel	 if	 it	 is	properly	 located.	Correctors	aim	 to	correct	defects	 such	as	protein	mis-folding	in	F508del	leading	to	easy	trafficking	to	the	cell	surface.	Read-through	agents	
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stimulate	the	ribosome	to	‘ignore’	a	premature	termination	codon	and	manufacture	a	full-length	protein.	Over	the	last	decade,	drugs	in	all	of	these	groups	have	proceeded	into,	and	in	some	cases	through,	clinical	trials	(Edmondson	&	Davies,	2016).			
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1.2	Acanthamoeba	
Acanthamoeba	 is	 a	 free-living	 protist	 which	 is	 widely	 distributed	 in	 the	environment,	 but	which	 is	 also	 an	opportunistic	 pathogen.	As	 a	 human	pathogen	 it	 can	cause	skin	lesions,	sinus	infections,	keratitis	and	an	infrequent	but	deadly	granulomatous	amoebic	encephalitis	(Marciano-Cabral	&	Cabral,	2003).		Features	of	Acanthamoeba	such	as	 being	 an	 agent	 that	 causes	 various	 illnesses,	 an	 important	 role	 in	 ecosystems;	harbouring	 endosymbionts;	 and	 a	 typical	 organism	 for	 investigations	 of	 unicellular	movement	have	led	to	notable	attention	in	recent	decades	(Figure	1.2)	(Khan,	2012).	The	term	Acanthamoeba	 is	the	combination	of	two	words,	acanth	(Greek	“acanth”	means	 “spikes”)	 and	 amoeba.	 It	 possesses	 spine-like	 structures,	 which	 are	 called			acanthopodia.	The	 function	of	contractile	vacuoles	 in	Acanthamoeba	 is	 to	secrete	excess	water	to	maintain	osmotic	pressure	in	the	cell	(Bowers	&	Korn,	1973).	In	addition	there	are	several	other	types	of	vacuoles.	These	are	 lysosomes,	digestive	vacuoles	and	a	great	quantity	 of	 glycogen-containing	 vacuoles.	 The	 constituent	 parts	 of	 the	 cell	 plasma	membrane	 are	 proteins	 (33%),	 phospholipids	 (25%),	 sterols	 (13%),	 and	lipophosphonoglycan	(29%)(Dearborn	&	Korn,	1974).		It	was	 shown	 that	 colonization	 in	 intensive	 care	 unit	 patients’	 respiratory	 tracts	with	 Acanthamoeba	 spp	 does	 occur.	 This	 fact	 may	 have	 relevance	 for	 the	 role	 of	
Acanthamoeba	 as	 a	 source	 of	 bacterial	 pathogens	 in	 CF	 patients’	 respiratory	 tracts	(Bradbury	et	al.,	2013).					
1.2.1	Classification	After	its	discovery,	Acanthamoeba	was	categorized	according	to	isolator,	source	or	other	criteria.	Pussard	and	Pons	(1977)	divided	this	genus	into	three	groups	according	to	the	characteristics	of	cysts.	So	far,	according	to	rRNA	gene	sequence,	17	diverse	types	(T1	–	 T17)	 of	Acanthamoeba	 genus	 have	 been	 found	 (Corsaro	 &	 Venditti,	 2010).	 Last	 year	T18-20	 genotypes	were	 identified	 (Corsaro	et	al.,	 2015).	 Every	 	 type	 sequence	 displays	5%	or	more	variance.	Human	infections	with	Acanthamoeba	are	mainly	related	to	the	T4	type.	For	 instance,	more	 than	90%	of	Acanthamoeba	 keratitis	 (AK)	 cases	are	associated	with	 the	 same	 type.	 Equally,	 the	 T4	 type	 has	 been	 the	 main	 type	 linked	 with		
Acanthamoeba	 granulomatous	 encephalitis	 (AGE)	 and	 skin	 infections.	 Currently,	 the		reason		for	the	T4	type	prevailing	in	human	infections	is	unclear	(Khan,	2012).	
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	Figure	 1.2	 Increasing	 scientific	 interest	 in	 the	 field	 of	 free-living	 amoebae	 as	 determined	 by	 published	articles	over	the	last	five	decades	(Khan,	2012).	
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1.2.2	Ecology	
Acanthamoeba	 has	 been	 detected	 in	 various	 natural	 surroundings,	 products	 for	daily	 use,	 hospitals,	 and	 as	 a	 human	 parasite	 	 (Castellani,	 1930).	 In	 the	 environment,	
Acanthamoeba	 has	 two	main	 impacts:	 (i)	 affecting	 the	 organization	 of	 the	 microscopic	community,	 and	 (ii)	 intensifying	nutrient	 recycling.	Free-living	amoebae	are	 the	 leading	bacterial	eaters	and	reduce	the	overall	bacterial	population	by	up	to	60%	of	(Sinclair	et	al.,	1981).	 Free-living	 amoebae	 as	 secondary	 decomposers	 devour	 bacteria,	 which	 are	primary	decomposers	and	by	expelling	waste	materials	enrich	the	soil	with	minerals	that	were	 tied	up	 in	microbes.	 It	was	shown	that	soil	containing	Acanthamoeba	and	bacteria	had	 considerably	 superior	 mineralization	 of	 carbon,	 nitrogen,	 and	 phosphorous	 to	 soil	with	bacteria	but	no	Acanthamoeba	(Ronn	et	al.,	2002).			
1.2.3	Life	cycle	The	 diameter	 of	 Acanthamoeba	 during	 the	 trophozoite	 phase	 is	 13-23	 μm	 and	during	 the	 cyst	 phase	 is	 17-33	 μm	 (Figure	 1.3).	 In	 trophozoite	 form	 (Greek	 “tropho”	means	 “to	 nourish”),	 Acanthamoeba	 is	 active,	 engulfs	 organic	 substances,	 microscopic	organisms	 and	 reproduces	 mitotically	 under	 desirable	 circumstances	 (food	 supply,	neutral	pH,	~30°C)	and	50-80mOsmol	(Band	&	Mohrlok,	1973).		During	unfavourable	conditions	Acanthamoeba	differentiates	into	a	double-walled	cyst	form	(Weisman,	1976).	The	ectocyst	consists	of	proteins	and	polysaccharides,	and	the	endocyst	 comprises	 cellulose	 (Dudley	 et	 al.,	 2009).	 Exocyst	 and	 endocyst	 are	 typically	demarcated	by	a	space,	excluding	some	points	where	they	make	opercula	in	the	midpoint	of	 ostioles	 (exit	 points	 for	 excystment).	 It	 has	 been	 shown	 that	 the	 cyst	 wall	 of	 A.	
castellanii	T4	type	is	composed	of	proteins	(33%),	 lipids	(4	-	6%),	carbohydrates	(35%)	(mostly	 cellulose),	 and	 unidentified	 and	 ash-forming	materials	 (28%)	 (Hirukawa	 et	 al.,	1998).					
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		Figure	1.3.	The	life	cycle	of	Acanthamoeba	spp.	Under	favourable	conditions,	Acanthamoeba	remains	 in	the	trophozoite	 form	 and	 divides	 mitotically	 (a)	 and	 is	 infectious,	 while	 under	 harsh	 conditions	 amoeba	transforms	 into	 a	 dormant	 cyst	 form	 (b)	 that	 is	 highly	 resistant	 to	 harsh	 conditions	 scale	 bar,	 2μm.	Micrographs	were	obtained	in	collaboration	with	Virus	Reference	Department	of	National	Infection	Service,	Public	Health	England.	
	
a)	
b)	
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1.2.4	Encystment	The	differentiation	in	response	to	undesirable	conditions	from	vegetative	form	to	resting	 form	 is	 termed	 encystment	 (Weisman,	 1976).	 Four	 morphological	 steps	 were	identified	 by	 scanning	 electron	 microscopy	 during	 encystment:	 trophozoite,	 precyst,	undeveloped	cysts,	and	developed	cysts	(Chavez-Munguia	et	al.,	2013).	Encystment	can	be	initiated	 by	 a	 number	 of	 circumstances,	 such	 as	 starvation,	 osmotic	 stress,	 and	 as	 a	reaction	to	bacteriotoxins	(Cordingley	et	al.,	1996).	Cyst	forms	are	specifically	resistant	to	treatments	 and	 therefore	 are	 crucial	 in	 the	 survival	 and	 distribution	 of	
Acanthamoeba.	 	Conversion	 of	 trophozoites	 into	 cysts	 initiates	 massive	 structural	alterations.	Cysts	are	spheroidal	with	a	rigid	cell	wall.	However,	the	structure	of	cyst	walls	is	different	among	different	genera	(Fouque	et	al.,	2012).		The	 inner	 fibrillar	 layer	 of	 the	 cyst	 -	 the	 endocyst	 -	 is	 formed	 after	 the	 ectocyst.	Both	layers	comprise	at	 least	acid-insoluble	proteins	(Neff	and	Neff,	1969)	and	cellulose	(Tomlinson	&	Jones,	1962)	but	the	exact	configuration	has	not	been	identified	yet.	One	or	more	 hole-like	 structures	 -	 ostioles	 exist	 in	 the	 exterior	 part	 of	 the	 cyst	 wall.	 Chavez-Munguia	 et	 al.	 (2005)	 suggested	 that	 excystment	 takes	 place	 over	 these	 ostioles	 after	breakdown	of	the	opercula	enclosing	the	ostioles	(Chavez-Munguia	et	al.,	2005).	Recently,	it	 has	 been	 found	 that	 the	 ectocyst	 possesses	 an	 irregular	 surface	 and	 that	 there	 are	vesicles	 inside	 its	 structure.	The	 application	of	 electron	microscopy	has	 shown	 that	 the	endocyst	is	thinner	and	more	fibrillar	than	the	ectocyst	and	is	similar	to	the	conformation	of	cellulose	in	plant	cell	walls	(Lemgruber	et	al.,	2010).		
	
1.2.5	Feeding	
Acanthamoeba	 engulfs	 microbes	 existing	 on	 surfaces,	 in	 various	 surroundings	(Brown	 &	 Barker,	 1999,	 Alsam	 et	 al.,	 2006).	 Acanthopodia	 serve	 to	 seize	 nutrient	materials,	which	generally	are	bacteria	(Weekers	et	al.,	1993),	and	in	a	minority	of	cases	algae,	 yeasts	 (Allen	 &	 Dawidowicz,	 1990)	 and	 other	 protists.	 Acanthamoeba	 feeding	 is	based	on	phagocytosis,	which	is	a	receptor-dependent	phenomenon,	and	on	pinocytosis,	a	nonspecific	process,	through	membrane	invaginations	(Bowers	&	Olszewski,	1972,	Alsam	
et	al.,	 2006,	Cardas	et	al.,	 2012).	This	 complicated	process	may	be	associated	both	with	endocytosis	and	pathogenesis	of	Acanthamoeba	(Khan,	2006).	Some	bacteria	can	survive	and	even	multiply	after	Acanthamoeba	phagocytosis.	This	can	be	followed	by	bacterial	re-
 20 
infections	occurrence.	Therefore	 treating	Acanthamoeba	 is	 essential	 to	 stop	 re-infection	processes.			
1.2.6	Pathogenesis	and	Virulence	factors	The	factors	determining	the	pathogenicity	of	Acanthamoeba	can	be	categorized	as	contact	 dependent	 and	 contact-independent	 (Martinez,	 1991).	 Contact	 dependent	pathways	 include	 binding	 to	 the	 host	 cell	 (Alsam	 et	 al.,	 2003),	 and	 phagocytosis		performed	 by	 acanthopodia	 which	 interact	 with	 microbes	 via	 calcium	 pores	 and	cytoskeletal	 particles	 (Taylor	 et	 al.,	 1995).	 Contact-independent	 pathways	 comprise	synthesis	of	extracellular	protease	as	well	as	phospholipases.	 Indirect	factors	facilitating	interaction	comprise	adequate	structure,	thermal	conditions,	proper	osmotic	medium,	no	immunological	resistance,	and	biofilm	formation	(Siddiqui	&	Khan,	2012).					
1.2.7	Acanthamoeba	Infections	There	are	different	entry	routes	for	Acanthamoeba	to	cause	this	disease	including	lower	respiratory	tract,	olfactory	neuroepithelium,	and	skin	lesions	(Figure	1.4)	(Garajová	&	Mrva,	2011).	Acanthamoeba	induces	two	well-recognized	disorders	in	human	health:	an	eye	 associated	 painful	 keratitis	 that	 may	 cause	 loss	 of	 sight	 (Khan,	 2006)	 and	 an	infrequent	 Acanthamoeba	 granulomatous	 encephalitis	 concerning	 the	 central	 nervous	system	(CNS)	that	is	associated	with	immune-compromised	patients	that	practically	at	all	times	 results	 in	 a	 fatal	 outcome.	 In	 contrast	 to	 AGE,	 keratitis	 can	 arise	 among	 healthy	people	(Clarke	et	al.,	2012).		By	restriction	fragment	length	polymorphism	analysis	or	total	sequence	analysis	of	18s	rDNA	revealed	that	practically	majority	of	clinical	isolates	of	Acanthamoeba	belonged	to	the	genotype	T4.	A	great	quantity	of	environmental	isolates	from	contact	lens	storage	cases,	tapped	water,	and	ocean	sediments	also	belonged	to	the	genotype	T4	(Kong,	2009).	So,	it	is	essential	to	look	for	T4	strain	presence	in	the	lower	respiratory	tract	and	analyse	their	interaction	with	bacteria	associated	with	CF.			 	
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	Figure	 1.4	 The	 haematogenous	 routes	 of	Acanthamoeba	 (a)	entry	 into	 the	 CNS.	Acanthamoeba	may	 pass	through	the	respiratory	tract	or	through	skin	injury	(b)	then	via	bloodstream	(3)	to	blood	brain	barrier	(4)	(Khan,	2009).				
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1.2.7.1	Acanthamoeba	Keratitis			Generally	 keratitis	 is	 identified	 in	 patients	who	 are	 contact	 lens	wearers	 (Figure	1.5).	The	reasons	leading	to	this	disorder	include:	usage	of	contact	lenses	for	long	periods,	poor	 personal	 hygiene,	 improper	 cleaning	 of	 contact	 lenses,	 biofilm	 development	 on	contact	 lenses,	 and	 exposure	 to	 infected	 water	 (Khan,	 2006).	 Reaching	 the	 cornea	
Acanthamoeba	causes	failure	of	the	epithelial	barrier,	invades	the	stroma,	drains	corneal	keratocyte	cells,	stimulates	an	extreme	inflammatory	reaction,	causes	severe	sensitivity	to	light	and	as	a	final	point	the	death	of	stromal	tissue	with	loss	of	sight	(Thebpatiphat	et	al.,	2007,	Panjwani,	2010).		
1.2.7.1.1	Pathophysiology	and	treatment		
Acanthamoeba	keratitis	requires	several	days	to	weeks	to	be	treated,	but	it	varies	on	the	route	of	amoeba’s	access.	The	emergence	of	 infection	caused	by	contact	 lenses	 is	very	slow	while,	in	the	occasion	of	corneal	trauma,	it	is	fast.	The	foremost	symptoms	of	AK	are	characterized	by	photophobia,	pain,	epithelial	defects,	and	inflammation	with	redness	and	tearing	that	result	in	epitheliopathy,	perineural	infiltrates,	ring	infiltrates,	ulceration,	abscess	 formation,	 hypopyon,	 scleritis,	 glaucoma,	 cataract,	 corneal	 perforation	 and	posterior	 segment	 inflammation	 (Alsam	 et	 al.,	 2008;	 Lorenzo-Morales	 et	 al.,	 2015).	Several	 drugs	 can	 be	 employed	 against	 AK	 comprising	 propamidine	 isothionate,	dibromopropamidine	 isothionate,	 neomycin,	 paromomycin,	 clotrimazole,	 ketoconazole,	miconazole,	 and	 itraconazole.	Debridement	 or	penetrating	keratoplasty	processed	 at	 an	initial	period	can	be	effectively	applied	 in	 treating	the	damaged	site	(Horne	et	al.,	1994;	Illingworth	et	al.,	1995;	Dudley	et	al.,	2007).										
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	 		Figure	 1.5	 Normal	 eye	 and	 ulcerated	 epithelium	 and	 corneal	 opacity	 in	 Acanthamoeba	 keratitis	 (a).	Improvement	 of	 Acanthamoeba	 keratitis	 after	 6	 months’	 treatment	 with	 polyhexamethylene	 biguanide,	propamidine-isethionate	and	neomycin	(b,c).	(Alsam	et	al.,	2008).																
a)	 b)	
c)	
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1.2.7.2	Acanthamoeba	granulomatous	encephalitis	Normally	patients	receiving	immunosuppressive	therapy	or	over-usage	of	steroids	are	 likely	 to	 be	 infected	 by	 Acanthamoeba.	 It	 is	 generally	 believed	 that	 the	 path	 of	infection	 starts	 in	 the	 respiratory	 tract	 with	 cyst	 inspiration,	 leading	 to	 amoebae	penetrating	 alveolar	 blood	 vessels,	 and	 continuing	 by	 haematogenous	 dissemination	(Figure	 1.6).	 It	 is	 proposed	 that	Acanthamoeba	 passes	 into	 the	 CNS	 through	 the	 blood-brain	barrier	(BBB)	(Martinez	&	Visvesvara,	1997).		
1.2.7.2.1	Pathophysiology	and	treatment		Known	manifestations	 of	AGE	 comprise	 confusion,	 stiff	 neck,	 headache,	 lethargy,	ataxia,	 vomiting,	 aphasia,	 nausea,	 seizures,	 cranial	 nerve	 palsies,	 increased	 intracranial	pressure,	coma	and	fatal	end	(Bloch	&	Schuster,	2005).	It	is	problematic	to	diagnose	AGE,	as	of	 the	resemblances	 in	 its	 symptoms	with	viral	encephalitis	and	bacterial	meningitis.	Though,	 scans	 by	magnetic	 resonance	 imaging	 (MRI)	 or	 cranial	 computed	 tomography	(CT)	 may	 aid	 in	 analyses	 and	 could	 reveal	 contrast	 enhancement	 sites	 demonstrating	brain	 abscess	 or	 tumors	 (Miltner	 &	 Bermudez,	 2000).	 Other	 drugs	 to	 treat	 AGE	 are	trimethoprim-sulfamethoxazole,	 ketokonazole,	 amphotericin-B,	 rifampicin,	 fluconazole,	sulfadiazine	and	albendazole	(Kaushal	et	al.,	2008;	Zamora	et	al.,	2014).														
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		Figure	1.6	Brain	cross-section	images.	(a)	Normal	brain	MRI.	(b)	MRI	of	a	patient’s	brain	with	AGE	showing	a	hemorrhagic	 lesion	 in	 the	right	 front	 lobe	(Meersseman	et	al.,	2007).	 (c)	Coronal	section	of	 the	cerebral	hemispheres	with	cortical	and	subcortical	necrosis	 from	a	 fatal	human	case	of	AGE	(Marciano-Cabral	and	Cabral,	2003).			
a)	
b)	
c)	
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1.3	Antimicrobial	Peptides	(AMPs)	Even	though	humans	historically	have	evolved	to	coexist	in	harmony	with	diverse	microorganisms,	 this	 stable	 mutual	 relationship	 can	 occasionally	 shift	 and	 allow	pathogenic	 bacteria	 to	 flourish	 and	 trigger	 infections.	 In	 the	 battle	 for	 survival,	 a	complicated	 mechanism	 including	 various	 vital	 components	 aids	 in	 the	 elimination	 of	these	 infectious	agents.	AMPs	are	well-conserved	biomolecules	among	all	 living	species,	including	 bacteria	 that	 participate	 in	 the	 struggle	 against	 the	 invading	 pathogens.	 They	are	moderately	short	(<100	amino	acid	residues),	positively	charged,	amphipathic	(have	both	hydrophobic	and	hydrophilic	domains)	and	display	diversity	in	accordance	to	their	structural	 characteristics	 (Jenssen	 et	 al.,	 2006).	 Despite	 the	 structural	 variance	 and	myriad	 of	 sequences	 integrating	 both	 natural	 and	 unnatural	 amino	 acids,	 AMPs	demonstrate	broad-spectrum	antibacterial	potencies.	The	potency	of	AMPs	to	eradicate	or	inhibit	the	growth	of	bacteria	has	attracted	the	attention	of	many	research	groups	globally	to	 investigate	 mechanisms	 of	 their	 antimicrobial	 action.	 Their	 amphipathic	 nature	 is	considered	 to	 allow	 them	 to	 interact	 with	 the	 negatively	 charged	 compartments	 and	hydrophobic	 fatty	 acid	 chains	 found	 on	 the	 target	 microbial	 cell	 envelopes,	 leading	 to	membrane	destabilization	and	evidently	 cell	 lysis	 (Wimley,	2010).	Commonly	AMPs	are	classified	 in	 four	 large	 families	 based	 on	 their	 secondary	 conformations	 in	 α-helices,	 β-sheets,	mixed	structures	and	non-	α-	or	β-structures	(Figure	1.7)	(Wang,	2013).	These	conformations	predominantly	exist	upon	interaction	with	lipid	membranes.	Most	 AMPs	 from	 both	 multi-	 and	 unicellular	 organisms	 originate	 from	 precursor	sequences.	 Successively,	 they	 exhibit	 a	 number	 of	 post-translational	 reformations	 that	basically	 modify	 their	 activity.	 These	 modifications	 involve:	 proteolytic	 processing,	glycosylation,	 amidation,	 halogenation,	 phosphorylation,	 incorporation	 of	 unnatural-amino	acids	and	cyclization	(Andreu	&	Rivas,	1998).	Particular	AMPs	are	also	synthesized	non-ribosomely	 e.g.,	 gramicidin	 S	 and	 lipopeptides.	 AMPs	 have	 also	 been	 intensively	altered	 through	 synthetic	 chemistry	 in	 order	 to	 reach	 the	 requirements	 of	 potential	therapeutic	 medications,	 therefore	 further	 increasing	 the	 structural	 diversity.	 Lately,	combinations	 of	 diverse	 structures	 such	 as	 β-peptides,	 peptoids,	 β-peptoids,	 peptide-peptoid	hybrids	and	others,	have	been	synthesized	and	 the	antimicrobial	 activity	of	 the	resulting	 peptidomimetics	 has	 been	matched	 to	 that	 of	 conventional	 AMPs.	 This	 broad	research	 holds	 immense	 potential	 in	 analysing	 the	 detailed	 mechanism	 by	 which	 both	
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innate	 and	 novel	 antimicrobial	 agents	 can	 be	 utilized,	 to	 combat	 pathogenic	 infections.	Furthermore,	 there	 is	a	significant	 interest	 in	 the	development	of	new	antimicrobials	 to	combat	 infectious	 illnesses	 in	 parallel	 with	 the	 increasing	 evidence	 of	 their	 broad-spectrum	potency.	So	 far,	more	than	2000	AMPs	have	been	 identified	 from	diverse	cells	and	tissues	of	animals,	 insects,	plants	and	bacteria	(Wang	et	al.,	2009a).	Broadly,	known	examples	of	AMPs	belong	to	the	families	of	the	cathelicidins	and	defensins	(found	in	many	insects	 and	 plants	 and	 animals,	 including	 humans),	 thionins	 (isolated	 from	 plants),	cecropins	 (found	 in	 the	hemolymph	of	 the	 cecropia	 silk	moth)	 and	magainins	 (secreted	from	frog	skin)	(Pasupuleti	et	al.,	2012).			
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 Figure	 1.7	 Protein	 models	 representing	 the	 structural	 differences	 of	 the	 four	 classes	 of	 antimicrobial	peptides,	 (A)	 a-helical	 peptides,	 (B)	 peptides	 composed	 of	 a	 series	 of	 β-sheets,	 (C)	 peptides	 that	 adopt	unconventional	structures,	such	as	extended	helices,	and	(D)	peptides	that	assemble	into	loops.(Peters	et	al.,	2010)	
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1.3.1	Structural	properties	of	AMPs	The	level	of	biological	activity	of	any	given	biomolecule	is	related	to	its	structural	properties.	Numerous	studies	have	been	performed	to	separate	 the	significant	elements	that	 define	 peptides	 as	 antimicrobial	 “armaments”.	 Extensive	 diversity	 of	 antimicrobial	peptide	sequences	occurs	in	the	environment,	which	contributes	to	the	whole	structural	variety,	however	there	are	evolutionarily	preserved	characters	that	ensure	their	activity	on	diverse	 types	of	bacteria	with	diverse	membrane	arrangement	and	different	 targets.	The	 secondary	 structure,	 cationicity,	 hydrophobicity	 and	 amphipathicity	 are	 the	 very	substantial	main	components	that	allow	characterization	of	AMPs.	Circular	 dichroism	 spectroscopy,	 X-ray	 crystallography	 and	 nuclear	 magnetic	resonance	spectroscopy	have	been	exploited	extensively	for	the	structure	identification	of	AMPs.	 For	 instance,	 the	 first	 X-ray	 crystallographic	 construction	 of	 native	 human	 α-defensin,	 the	 human	 neutrophil	 peptide	 3,	 appeared	 in	 1991,	 followed	 by	 a	 nuclear	magnetic	resonance	construction	of	human	neutrophil	peptide	1	(Pardi	et	al.,	1992).	Such	structural	 report	 was	 found	 to	 be	 valuable	 when	 studying	 the	 significance	 of	 the	secondary	structure	in	deciphering	the	antimicrobial	activity	of	AMPs.	Investigations	have	established	 that	 bacterial	 eradication	 by	 human	 neutrophil	 peptide	 1	 is	 structure-independent	 (de	 Leeuw	 et	 al.,	 2010).	 The	 most	 usual	 pattern	 noticed	 in	 numerous	proteins	 and	 peptides	with	 biological	 activities	 is	 the	 amphipathic	 α-helix,	 nonetheless,	various	AMPs	occur	as	extended	or	unstructured	conformers	and	only	adjust	to	α-helical	conformations	upon	interaction	with	phospholipid	membranes	(Yeaman	&	Yount,	2003).	Circular	 dichroism	 investigation	 has	 indicated	 that	 in	 the	 presence	 of	 unilamellar	phospholipid	 vesicles	 with	 diverse	 content	 of	 zwitterionic	 and	 negatively	 charged	phospholipids,	 numerous	 AMPs	 develop	 well	 defined	 α-helical	 and/or	 β-sheet	 like	structures	compared	to	the	buffer	condition	(Jahnsen	et	al.,	2012).	The	occurrence	of	α-helical	structures	in	AMPs	is	commonly	assumed	to	stimulate	interaction	 with	membranes	 and	 promote	membrane	 lysis	 (Epand	 &	 Vogel,	 1999)	 and	consequently	 specific	 amino	 acids	 such	 as	 alanine,	 leucine,	 arginine,	 lysine	 (Pace	 &	Scholtz,	 1998).	 From	 this	 perspective,	 Deslouches	et	 al.	revealed	 that	 normally,	 the	peptides	from	their	de	novo	library,	with	more	than	80	%	helical	content,	showed	greatest	antimicrobial	potency	against	the	examined	bacterial	strains	(Deslouches	et	al.,	2005).	In	another	 study,	 Javadpour	et	 al.	also	 designed	 a	 library	 of	 highly	 α-helical	 peptides	comprising	lysine	and	leucine/alanine/glycine	residues	in	arrangements	that	extended	up	
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to	21	residues.	In	this	library	the	predispositions	of	α-helical	conformation	was	identified	to	be	associated	with	the	toxicity	of	the	peptides	on	mammalian	model	cells.	Nevertheless,	no	exact	decision	could	be	made	 for	a	correspondence	of	 these	peptides’	 conformations	and	their	detected	antibacterial	potency	(Javadpour	et	al.,	1996).		
1.3.1.1	Cationicity	The	 universal	 characteristic	 of	 the	 most	 AMPs	 is	 the	 cationic	 property	characterised	by	 the	various	positively	 charged	 residues	 (lysine,	 arginine	and	histidine)	within	their	configuration,	which	varies	between	+1	and	+7	charges	(Wang,	2013).	Many	studies	 have	 correlated	 the	 positively	 charge	 characteristic	 in	 AMPs	 with	 the	antimicrobial	potency	detected.	The	established	prominence	lies	largely	in	the	interaction	amongst	 the	 positive	 charge	 in	 the	 peptides	 and	 the	 negatively	 charged	 bacterial	membrane	 structures	 through	 electrostatic	 interactions.	 For	 example,	 the	 antimicrobial	activity	of	the	majority	of	the	defensin	family	seems	to	be	associated	with	their	cationicity.	As	 an	 example,	 human	 defensin-5	 interacts	 with	 the	 bacterial	 membrane	 through	 its	arginine	 residues	 and	 consequently	 applies	 its	 antimicrobial	 potency.	 Substitution	 of	arginine	 residues	 at	 position	 9	 and	 28	 with	 alanine	 or	 lysine	 residues	 decreases	 the	antibacterial	properties	 and	 the	host	 cell	 interaction,	 the	 latter	 of	which	 is	 identified	as	receptor	mediated	(de	Leeuw	et	al.,	2009).	The	overall	 cationic	charge	might	not	be	 the	foremost	factor	in	the	detected	antibacterial	activity	as	in	the	case	of	human	α-defensins	which	 normally	 display	 more	 activity	 against	 Gram-positive	 bacteria	 than	 human	 β-defensins,	despite	human	β-defensins	being	more	positively	charged	(Wei	et	al.,	2009).	It	was	 shown	 that	 human	 neutrophil	 peptide-1	with	 net	 charge	 +3	 proved	more	 efficient	against	S.	 aureus	compared	 to	 human	 β-defensin-3	 with	 net	 charge	 +11	 (Schibli	 et	 al.,	2002).	Furthermore,	cationicity	encounters	a	limit,	beyond	which	raising	the	charge	does	not	 lead	 to	 boosted	 antibacterial	 activity.	 A	 study	 of	 Dathe	et	 al.	has	 established	 that	increasing	 from	 +3	 to	 +5	 in	 magainin-2	 derivatives,	 also	 boosted	 the	 peptides’	antibacterial	 potency	 against	 both	 Gram-positive	 and	 Gram-negative	 bacteria,	 but	additional	increases	to	+6	or	+7	resulted	in	loss	of	the	antibacterial	potency	and	boosted	haemolytic	 property	 (Dathe	et	al.,	 2001).	Additionally	 to	 the	net	 charge	 of	AMPs,	 it	 has	further	 been	 demonstrated	 that	 the	 location	 of	 the	 charged	 residues	 is	 likewise	 an	essential	 aspect	 that	 defines	 the	 peptides	 overall	 antibacterial	 potency.	 For	 instance,	altering	the	position	of	a	few	amino	acid	residues	inside	the	natural	structure	of	the	linear	
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bactenecin,	 ended	 up	 in	 a	 scrambled	 arrangement	 that	 exhibited	 boosted	 antibacterial	potency	 (Hilpert	 et	 al.,	 2006).	 Further	 to	 the	 prominence	 of	 charge	 in	 mediating	preliminary	 interaction	 with	 target	 membranes,	 in	 Gram-negative	 bacteria,	 the	 net	positive	 charge	 is	 essential	 for	 the	 self-promoted	 uptake	 of	 AMPs.	 Positively	 charged	AMPs	 interact	 with	 the	 bacterial	 membrane	 where	 there	 are	 divalent	 cations	 such	 as	Mg2+	or	Ca2+	cross	bridging	LPS	molecules.	Dislocation	of	these	cations	triggers	disruption	of	the	outer	membrane	and	consequently	allowing	uptake	of	molecules	(Piers	&	Hancock,	1994).	Besides,	 bacteria	have	more	negative	 trans-membrane	potential	 in	 contrary	 to	 a	normal	mammalian	cell	membrane	which	enables	introduction	of	charged	AMPs	into	the	membranes	(Matsuzaki,	2009).		
1.3.1.2	Hydrophobicity	Hydrophobicity	is	an	important	structural	characteristic	that	determines	the	total	potency	of	a	particular	antimicrobial	peptide,	and	consequently	it	is	constantly	illustrated	in	 the	 literature	 as	 a	 central	 functional	 characteristic.	 It	 impacts	 the	 potential	 of	interaction	amongst	AMPs	and	diverse	membrane	structures	and	besides	this	directs	the	degree	of	peptide	segregating	into	the	lipid	bilayer.	Boosted	hydrophobicity	is	associated	with	fading	antibacterial	specificity,	leading	to	high	toxicity	towards	mammalian	cells.	For	example,	 Yin	et	 al.	revealed	 that	 replacing	 four	 alanine	 residues	 with	 four	 hydrophobic	leucine	 residues	 produced	 higher	 haemolytic	 activity	 of	 their	 membrane	 active	 model	peptide	 (Yin	 et	 al.,	 2012).	 Magainin-2	 derivatives	 with	 varying	 hydrophobicity	 have	likewise	 been	 employed	 to	 exhibit	 that	 minimal	 alterations	 in	 the	 hydrophobicity	may	considerably	 impact	 and	 increase	 its	 membrane	 binding	 and	 permeabilization	 activity	(Wieprecht	 et	 al.,	 1997).	 The	 impact	 of	 hydrophobicity	 on	 the	 antibacterial	 and	haemolytic	 potencies	 has	 been	 further	 showed	 through	 peptide	 series	 constructed	 of	repeats	of	 lysine	and	 tryptophan	residues.	 Introduction	of	a	number	of	 repeats	of	 these	two	 residues	 led	 to	 corresponding	 increase	 of	 both	 hydrophobicity	 and	 antimicrobial	activity.	 However,	 when	 five	 repeated	 units	 were	 in	 the	 configuration,	 the	 increase	produced	 unfavourable	 variation	 in	 the	 haemolytic	 profile	 (increased	 toxicity)	 and	decrease	in	the	antimicrobial	potency	because	of	self-aggregation	(Gopal	et	al.,	2013).					
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1.3.1.3	Amphipathicity	The	 prevalence	 and	 polarization	 of	 the	 hydrophobic	 and	 hydrophilic	 domains	 is	mirrored	 by	 amphipathicity	 in	 antimicrobial	 peptide	 configurations.	 A	 majority	 of	 the	cationic	AMPs	exhibit	a	net	positive	charge	(+1	to	+7)	(Wang,	2013)	and	comprise	around	50	%	hydrophobic	 units	which	 contribute	 to	 the	 identification	 and	 interfering	with	 the	cytoplasmic	membrane	barrier	through	the	cellular	membranes.	The	cationic	charge	and	the	hydrophobic	groups	segregate	into	amphiphilic	constructions.	A	quantitative	measure	of	 amphipathicity	 is	 the	 hydrophobic	 moment,	 attributed	 to	 peptides	 in	 α-helical	confirmation	and	employed	as	a	determinant	 in	analysing	the	role	of	amphipathicity	 for	peptide	antimicrobial	potency	(Eisenberg,	1984).	The	prominence	of	amphiphilicity	in	the	identification	of	the	antimicrobial	potencies	of	AMPs	is	contentious	since	diverse	research	groups	 have	 found	 positive	 and	 adverse	 contributions	 such	 as	 increasing	 antimicrobial	and	increasing	haemolytic	activities,	respectively	(Chen	et	al.,	2005).	Amphipathicity	has	been	stated	as	a	key	structural	determinant	for	the	biological	potency	of	a	small	library	of	arginine	 and	 tryptophan	 rich	 linear	 and	 cyclic	 hexapeptides	 (Pathak	 et	 al.,	 1995).	 The	structural	 and	 conformational	 restrictions	 of	 the	 peptides	 together	 with	 the	 ultimate	locating	 of	 the	 hydrophobic	 clusters	 appeared	 to	 define	 the	 antimicrobial	 potency	 and	selectivity	of	the	peptides	(Chen	et	al.,	2005).	In	another	investigation	of	magainin-2	and	its	derivatives	it	was	revealed	that	the	antimicrobial	activity	was	directed	extensively	by	the	peptide	amphipathicity	and	not	by	hydrophobicity	or	α-helicity	(Pathak	et	al.,	1995).	Analogously,	design	of	cecropin	A	and	melittin	hybrid	constructions	has	exhibited	boosted	amphiphilicity	and	helicity	correlating	with	high	antibacterial	potency	and	lower	toxicity	against	mammalian	cells	(Andreu	et	al.,	1992).	In	contradistinction	to	these	outcomes	are	various	 other	 peptide	 studies,	 indicating	 that	 higher	 amphipathicity	 if	 measured	 as	hydrophobic	moment,	intensifies	membrane	disturbance	resulting	in	increase	in	both	the	antibacterial	 and	 haemolytic	 activity	 (Fernández-Vidal	 et	 al.,	 2007).	 Amphipathicity	 in	AMPs	 that	 occurs	 in	 β-sheet	 conformations	 is	 determined	 by	 the	 quantity	 of	 β-strands	systematized	 by	 two	 distinct	 polar	 and	 non-polar	 domains.	 β-strands	 are	 typically	stabilized	 through	 disulphide	 bonds,	 which	 deliver	 high	 conformational	 rigidity	 in	aqueous	solution.	The	polar	and	non-polar	domains	in	β-strands	enable	AMPs	to	interact	effectively	 with	 membranes	 and	 once	 linked	 with	 the	 membrane,	 the	 amphipathic	property	 triggers	 membrane	 disturbance	 through	 establishment	 of	 trans-membrane	channels	(Yeaman	&	Yount,	2003).	Modification	in	the	non-polar	domain	of	gramicidin	S	
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analogues,	which	reduced	hydrophobicity	and	the	overall	amphipathicity,	consequently	as	expected	diminished	the	peptides’	haemolytic	activity	(Kondejewski	et	al.,	1999).		
1.3.1.4	Specific	amino	acids	in	AMPs		Isolated	 AMPs	 from	 plants,	 insects,	 fish,	 frogs	 and	 mammals	 differ	 significantly	with	respect	to	their	amino	acid	configuration.	Each	of	 the	amino	acid	 individually	or	 in	cooperation	 with	 the	 adjacent	 amino	 acid	 units	 contributes	 to	 the	 experiential	antimicrobial	properties	kept	in	the	peptides.		 	The	 fundamental	 amino	 acids	 Lysine	 and	Arginine	 are	 highly	 conserved	 units	 in	antimicrobial	 peptide	 structures	 as	 they	 allow	 electrostatic	 interactions	 between	 the	peptide	 and	 the	 negatively	 charged	 surfaces	 of	 bacterial	 membranes	 (Shepherd	 et	 al.,	2001).	 These	 two	 amino	 acids	 vary	 in	 their	 side	 chain	 chemistry.	 Arginine	 has	 a	guanidinium	group	which	enables	more	distributed	positive	charge	and	suggests	greater	possibility	of	hydrogen	bonding	with	 the	 surrounding	water	molecules.	The	exceptional	features	 of	 the	 arginine	 side	 chain	 enable	 formation	of	multiple	 interactions	 contrasted	with	the	mono	charge	existing	in	lysine.		Another	 essential	 residue	 identified	 in	 the	 structure	 of	 AMPs	 is	 tryptophan.	 The	specific	side	chain	comprising	an	indole	ring	holds	hydrogen-bonding	potential	as	well	as	other	 physiochemical	 features	 such	 as	 dipole	 and	 quadrupole	 moments	 (Vogel	 et	 al.,	2002).	 Tryptophan	 amino	 acid	 displays	 strong	 membrane-disruptive	 activities	 by	 its	potential	 to	 interact	 with	 the	 interface	 of	 a	 membrane	 anchoring	 the	 peptide	 to	 the	surface	of	the	bilayer	(Khandelia	&	Kaznessis,	2007).		Another	 sulphur-containing	 amino	 acid	 residue	 is	 cysteine,	 which	 is	 strongly	reactive.	The	thiol-	group	of	it	can	be	effortlessly	oxidized	to	form	a	dimer,	consequently	generating	a	disulphide	bond	amongst	two	cysteines.	Disulphide	bridges	made	by	cysteine	residues	 are	 strongly	 hydrophobic	 (nonpolar)	 and	 play	 a	 principal	 role	 in	 the	constructions	of	many	AMPs.	Furthermore	being	critical	for	the	overall	structural	fold	of	the	 peptide,	 these	 bridges	 also	 raise	 the	 peptide’s	 stability	 towards	 proteolytic	degradation,	like	in	defensins	(Tanabe	et	al.,	2007).		Proline-rich	 AMPs	 are	 unique	 family	 of	 cationic	 peptides	 identified	 from	 both	insects	and	mammals,	with	established	antimicrobial	activities	precisely	targeted	against	Gram-negative	bacteria	(Scocchi	et	al.,	2011).			
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1.3.2	AMPs’	modes	of	actions	In	 pharmacology,	 a	 decent	 antimicrobial	 candidate	 should	 demonstrate	 highly	precise	 biological	 activity	 followed	 by	 good	 pharmacokinetic	 profile	 and	 low	immunogenicity.	 In	 order	 for	 peptides	 to	 be	 administered	 as	 antimicrobial	 agents	 of	therapeutic	relevance,	it	is	fundamental	to	separate	their	biological	activities,	particularly	their	 mode	 of	 action	 (Figure	 1.8).	 It	 is	 not	 easy	 as	 more	 than	 2000	 biological	 native	peptides	with	 broad	 spectrum	 antimicrobial	 potencies	 have	 been	 identified.	 In	 spite	 of	this	 fact,	 numerous	 scientific	 researches	 have	 provided	 structure-activity	 relationship	evidence	 that	 aids	 the	 overall	 comprehending	 of	 how	 antimicrobial	 peptide	 damage	infectious	 agents.	 For	 this	 purpose,	 investigators	 have	 employed	 numerous	 model	membranes,	 which	 AMPs	 act	 on.	 These	 comprise	 micelles,	 artificial	 liposomes	 with	variable	 lipid	 arrangements	 (Palmitoyl-oleoyl-phosphatidyl-ethanolamine	 (POPE),	Palmitoyl-oleoyl-phosphatidyl-choline	 (POPC),	 Palmitoyl-oleoyl-phosphatidyl-glycerol	(POPG),	cholesterol	etc.)	and	natural	E.	coli	polar	lipid	extracts	(Bobone	et	al.,	2012).													
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			Figure	1.8	The	proposed	diverse	mechanistic	modes	of	 actions	of	AMPs.	 (A)	Disruption	of	 cell	membrane	integrity:	 (1)	 random	 insertion	 into	 the	 membrane,	 (2)	 alignment	 of	 hydrophobic	 sequences,	 and	 (3)	removal	of	membrane	sections	and	formation	of	pores.	(B)	Inhibition	of	DNA	synthesis.	(C)	Blocking	of	RNA	synthesis.	 (D)	 Inhibition	of	enzymes	necessary	 for	 linking	of	cell	wall	structural	proteins.	 (E)	 Inhibition	of	ribosomal	function	and	protein	synthesis.	(F)	Blocking	of	chaperone	proteins	necessary	for	proper	folding	of	proteins.	(G)	Targeting	of	mitochondria:	(1)	inhibition	of	cellular	respiration	and	induction	of	ROS	formation	and	 (2)	 disruption	 of	mitochondrial	 cell	 membrane	 integrity	 and	 efflux	 of	 ATP	 and	 NADH	 (Peters	 et	 al.,	2010).		 									
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1.3.2.1	AMP	disruption	activities	on	membrane		It	 is	 well	 known	 that	 after	 membrane	 binding,	 AMPs	 contribute	 to	 potential	interchanges	 of	 the	membrane	 structure	 such	 as	 thinning,	 pore	 formation,	 and	 altered	curvature.	Then	 loss	 of	 membrane	 potential	 eventually	 halts	 ATP	 manufacture	 and	cellular	metabolism	and	results	in	cell	death	(Bobone	et	al.,	2013).		One	 of	 the	 earliest	models	 for	 pore	 formation	 suggested	 for	 AMPs	 is	 the	 barrel-stave	 model	 (Ehrenstein	 &	 Lecar,	 1977)	 (Figure	 1.9a).	 This	 model	 has	 been	 widely	investigated	and	illustrates	a	process	where	following	initial	binding	of	the	peptides	to	the	membrane.	 They	 align	 perpendicularly	 to	 the	membrane	 and	 aggregate	 on	 the	 surface	resulting	 in	 formation	 of	 pores.	 It	 has	 been	 shown	 that	 AMPs	 with	 distinct	 secondary	structures	exploit	this	mode	as	their	hydrophobic	fragments	interact	with	the	lipids	of	the	membrane	 and	 the	 hydrophilic	 part	 line	 the	 lumen	 of	 the	 pore	 (Brogden,	 2005).	Alamethicin	 (Ac-Aib-Pro-Aib-Ala-Aib-Ala-Gln-Aib-Val-Aib-Gly-Leu-Aib-Pro-Val-Aib-Aib-Glu-Gln-Phl)	 (Wang	 et	 al.,	 2014)	 is	 an	 antimicrobial	 peptide	 that	 has	 been	 widely	investigated	for	its	capacity	to	disrupt	membranes	using	this	model	(Laver,	1994).	Lately,	Bobone	et	 al.	identified	 and	 suggested	 that	 trichogin	 GA	 IV	 (n-Oct-Aib-Gly-Leu-Aib-Gly-Gly-Leu-Aib-Gly-Ile-Lol)	 (De	 Zotti	 et	 al.,	 2012)	 and	 analogously	 short	 peptaibols	 act	through	the	barrel-stave	model	to	employ	their	membrane	disruption	powers	(Bobone	et	
al.,	2013).		 	The	 second	 hypothesis	 of	 membrane	 interaction	 by	 AMPs	 supports	 the	 toroidal	pore	model	 (Figure	 1.9b)	where	 the	 peptides	 trigger	 the	membrane	 to	 fold	 inwards	 so	that	the	channels	made	comprise	peptides	and	hydrophilic	lipid	head	groups	(Yang	et	al.,	2001).	 Chaotic	 toroidal	 pore	 models	 have	 been	 detected	 by	 Sengupta	et	 al.	exploiting	molecular	dynamics	simulations	for	melittin	and	DPPC	membranes	where	peptides	were	found	to	position	close	to	the	pore	centre,	while	other	molecules	were	located	near	to	the	pore	edge	(Sengupta	et	al.,	2008).		The	 third	model	which	 suggests	 further	 vigorous	 disruption	 of	 the	membrane	 is	the	carpet	model	(Figure	1.9c).	In	this	model	the	peptides	align	parallel	to	the	membrane	and	when	 they	 reach	 a	 particular	 concentration	 they	 turn	 the	membrane	 into	micelles,	similar	 to	 a	 detergent–like	 mode	 of	 membrane	 permeabilisation	 (Bechinger,	 2009).	Recently,	this	model	has	been	suggested	for	a	derivative	of	PMAP-23	peptide	(cathelicidin;	RIIDLLWRVRRPQKPKFVTVWV)	 focussing	on	 its	potency	on	E.	coli	(Roversi	et	al.,	 2014).	Bacterial	 death	 had	 only	 occurred	 when	 a	 complete	 saturation	 of	 the	 membrane	 with	
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PMAP-23	 molecules	 happened,	 demonstrating	 the	 suitability	 of	 the	 carpet	 model	mechanism	of	membrane	disruption	as	it	has	been	defined	exploiting	artificial	membrane	systems	(Roversi	et	al.,	2014).	Five	other	models	are	proposed	by	various	research	groups	comprising	interfacial	activity	 (Orioni	 et	 al.,	 2009),	 sinking	 raft	 (Pokorny	 et	 al.,	 2002),	 leaky	 slit	 (Zhao	 et	 al.,	2006),	 lipid	 clustering	 (Epand	&	Epand,	 2011)	 and	 sand	 in	 a	 gearbox	 (Pag	et	al.,	 2008)	models.	Looking	through	these	differing	models,	it	is	clear	that	the	challenge	is	to	deliver	commonly	 recognisable	 explanations	 of	 mechanisms	 of	 action	 from	 the	 diverse	techniques	that	are	employed	to	study	their	complexity.	
	
1.3.2.2	Nonspecific	killing	properties	of	AMPs	It	 is	 generally	 accepted	 that	 cationic	AMPs	 interact	with	membranes	where	 they	disrupt	 the	 amphipathic	 lipid	 bilayer,	 which	 consequently	 results	 in	 disruption	 of	fundamental	 bacterial	 metabolic	 activities	 and	 eventually	 bacterial	 killing.	 Bacterial	membranes	hold	a	large	portion	of	negatively	charged	lipids	and	conserve	high	electrical	potential	 gradients,	 therefore	 attracting	 positively	 charged	 compounds	 such	 as	 cationic	AMPs.	An	outcome	of	 the	 electrostatic	 interaction	of	positively	 charged	peptides	on	 the	negatively	 charged	 bacterial	 composition,	 is	 deterioration	 and	 discharge	 of	 built-in	divalent	cations	from	the	membrane.	This	transposition	results	in	disturbance	of	the	outer	membrane	barrier	in	Gram-negative	bacteria.	In	contrast	to	bacterial	membranes,	plant	and	animal	cell	membranes	are	concentrated	in	cholesterol	 and	 lipids,	 have	 no	 net	 charge,	 and	 keep	 weak	 trans-membrane	 potential	(Zasloff,	 2002a).	 Researches	 that	 mention	 the	 electrostatic	 interactions	 amongst	 the	positively	charged	amino	acids	and	 the	negatively	charged	phospholipid	head	groups	 in	the	 membranes	 have	 shown	 that	 by	 rising	 the	 buffer	 salt	 concentrations	 the	 peptide	potency	on	the	negatively	charged	membranes	is	weakened	(Kagan	et	al.,	1990).								
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              			Figure	 1.9	 Three	 types	 of	 AMP	 insertion	 into	 cell	 membrane.	 The	 barrel-stave	 model	 of	 antimicrobial-peptide-induced	killing.	Hydrophilic	regions	of	the	peptide	are	shown	coloured	red,	hydrophobic	regions	of	the	 peptide	 are	 shown	 coloured	 blue	 (a).	 The toroidal model of antimicrobial peptide induced killing. 
Hydrophilic regions of the peptide are shown coloured red, hydrophobic regions of the peptide are shown coloured 
blue (b). The carpet model of antimicrobial-induced killing. Hydrophilic regions of the peptide are shown coloured 
red, hydrophobic regions of the peptide are shown coloured blue (c) (Brogden, 2005). 								
a)	
c)	
b)	
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1.3.2.3	AMP	binding	affinity	to	membranes	Isothermal	 titration	 calorimetry	 is	 one	 of	 the	 procedures	 exploited	 to	 obtain	knowledge	 about	 the	 antimicrobial	 peptide	 binding	 affinity	 to	 model	 membranes.	Andrushchenko	et	al.	(Andrushchenko	et	al.,	2008)	examined	the	thermodynamics	of	the	interaction	 of	 tryptophan-rich	 AMPs	 with	 large	 uni-lamellar	 vesicles	 (LUVs).	 They	achieved	binding	 isotherms	 that	might	 illustrate	 the	potency	 of	 binding	 of	 the	 peptides	with	model	membranes.	All	peptides	employed	in	that	study	showed	selectively	stronger	binding	 to	 anionic	 and	E.	 coli	membranes	 in	 contrast	 to	 zwitterionic	 membranes	(Andrushchenko	et	al.,	2008).	Fluorescence	 spectroscopy	 is	 another	 procedure	 employed	 for	 investigations	 of	peptide	interaction	with	model	membranes,	which	yields	valuable	but	partial	information	concerning	 the	 affinity	 of	 the	 peptide	 for	 lipid	 bilayers.	 It	 could	 likewise	 be	 useful	 on	peptide	 accumulation,	 localisation	 in	 the	 membrane	 and	 the	 influences	 on	 membrane	integrity.	Whilst	using	fluorescence	spectroscopy	on	tryptophan-rich	peptides,	deviations	of	 blue	 shifts	 in	 tryptophan	 fluorescence	 can	 be	 calculated,	 and	 related	 to	 binding	 to	model	membranes.	Several	tryptophan-containing	β-hairpin	peptides	have	been	tested	for	their	 binding	 to	 phosphatidyl-ethanolamines	 (PhE)/phosphatidyl-glycerol	 (PG)	 and	phosphatidyl-cholines	 (PC)/cholesterol-containing	 vesicles	 and	 their	 binding	 features	specifically	to	PE/PG	related	to	their	antimicrobial	activity	(Dong	et	al.,	2012).		Lipopolysaccharide	 (LPS)	 is	 the	 endotoxin	 identifiable	 on	 the	 external	 surface	 of	the	 outer	 membrane	 envelope	 of	 Gram-negative	 bacteria,	 which	 aids	 cell	 health	 by	increasing	 the	 overall	 negative	 charge.	 It	 is	 associated	 with	 systemic	 inflammatory	reaction	in	mammals,	occasionally	resulting	in	septic	shock.	The	charge	distribution	in	the	majority	 of	 cationic	 AMPs	 is	 reported	 to	 demonstrate	 high	 affinity	 to	 LPS.	 Peptide	interaction	 with	 LPS	 is	 enhanced	 by	 dislocation	 of	 Mg2+	which	 typically	 stabilizes	 and	cross-bridges	joining	LPS	molecules	in	the	external	membrane	(Sawyer	et	al.,	1988).	This	interaction	 additionally	 supports	 the	 peptides	 in	 self-stimulated	 uptake	 providing	 them	entry	 to	 the	 inner	membrane	where	 they	can	extend	bacterial	destruction.	Nonetheless,	when	LPS	are	detected	as	endotoxins,	the	binding	of	a	majority	of	cationic	AMPs	has	the	capacity	of	counteracting	the	toxin,	therefore	they	hold	potential	as	novel	candidates	for	elaboration	of	better	approaches	for	clinical	treatment	of	sepsis	(Andrä	et	al.,	2006).			
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1.3.2.4	AMP	and	bacterial	biofilm	interactions		Prolonged	 cultivation	 of	 bacterial	 organisms	 lead	 to	 adherence	 to	 animal	 tissues	and	inorganic	materials	(Costerton	et	al.,	1981).	And	it,	in	turn,	enables	the	establishment	of	 a	 biofilm,	 which	 is	 a	 multi-layered	 population	 of	 sessile	 bacterial	 microorganisms.	Biofilms	allow	an	advantage	in	persistence	compared	to	planktonic	bacteria	by	boosting	nutrient	trapping	and	colonization	(Costerton,	1999).	Presently,	biofilms	are	an	extensive	medical	 issue	 in	 clinics	 and	 healthcare	 facilities.	 Certainly,	 the	 United	 States	 National	Institutes	 of	 Health	 found	 that	 80	%	 of	 chronic	 infections	 are	 associated	with	 biofilms	(Monroe,	 2007).	 Furthermore,	 many	 investigations	 have	 identified	 that	 biofilms	 are	related	 to	 dental	 plaque	 (Hojo	 et	al.,	 2009),	 endocarditis	 (Palmer,	 2006),	 lung	 infection	(Wagner	&	Iglewski,	2008a),	and	infection	through	medical	devices	(Khardori	&	Yassien,	1995).	Biofilm-formation	 by	 bacteria	 is	 accomplished	 through	 responses	 to	 numerous	factors,	 such	 as	 nutritional	 signals,	 cellular	 recognition	 of	 binding	 sites	 on	 the	 surface,	exposure	 to	 sub-lethal	dosages	of	 antibiotics,	 and	environment	 stresses	 (Hoffman	et	al.,	2005).	 Biofilm-formation	 is	 commonly	 initiated	 with	 the	 attachment	 of	 planktonic	bacteria	to	a	surface	via	weak	van	der	Waals	forces,	and	the	colonies	are	anchored	firmly	using	pili.	 To	 enable	 the	 accumulation	 and	 attachment	 of	 other	planktonic	 bacteria,	 the	primary	 attached	 bacteria	 build	 numerous	 adhesion	 sites	 and	 the	 matrix.	 Bacteria	 are	positioned	within	this	matrix	of	extracellular	polymeric	substance	(EPS),	which	comprises	extracellular	 DNA,	 proteins,	 lipids,	 and	 polysaccharides	 with	 numerous	 conformations	(Hall-Stoodley	&	Stoodley,	2009).	These	constituents	are	very	key	targets	for	controlling	both	biofilms	and	drug-resistant	bacteria	(Landini	et	al.,	2010).	Throughout	colonization,	particular	 bacteria	 are	 able	 to	 communicate	 exploiting	 a	 quorum	 sensing	 (QS)	 system	(Horswill	 et	 al.,	 2007)	 through	 tiny	 molecules	 named	 auto-inducers	 and	 governors	 of	overall	 behaviours,	 like	 bioluminescence,	 virulence	 factor	 manufacture,	 and	 biofilm	formation	(Waters	&	Bassler,	2005a).	Auto-inducers	in	Gram-negative	and	Gram-positive	bacteria	 are	 reported	 to	 be	 acyl-homoserine	 lactone	 molecules	 and	 oligopeptides,	respectively.	 These	 are	presently	 accepted	 as	 key	 target	 for	 inhibiting	biofilm	 infection.	The	 mature	 biofilm	 demonstrates	 boosted	 antibiotic-resistance	 compared	 to	 bacterial	colonies,	with	 increased	cell	division	and	recruitment.	Following	establishment,	biofilms	are	distributed	 and	 the	bacteria	 translocate	 to	 further	 surfaces,	 such	 as	 organs,	 tissues,	and	medical	devices,	where	the	biofilm	formation	progression	appears	again.	
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Two	leading	models	in	the	inhibition	of	biofilms	are	dispersion	of	the	biofilm	EPS	and	disrupting	of	the	bacteria	embedded	in	the	EPS.	Naturally,	lethal	or	inhibiting	dosages	of	 antibiotics	 are	 considerably	 increased	 by	 up	 to	 1000-fold	 against	 biofilm	 of	 bacteria	since	 they	 are	 incapable	 of	 trans-locating	 into	 EPS	 and	 consequently	 do	 not	 reach	 the	bacterial	 populations.	 AMPs	 are	 considered	 to	 possess	 the	 potential	 for	 employment	 as	anti-biofilm	 drugs	 owing	 to	 their	 specific	 mechanisms,	 which	 comprise	 membrane-disrupting	 potencies,	 functional	 inhibition	 of	 proteins,	 binding	 with	 DNA,	 and	detoxification	 of	 polysaccharides.	 The	 EPSs	 of	 biofilms	 include	 significant	 quantities	 of	polysaccharides,	 proteins,	 nucleic	 acids	 and	 lipids	 (Sutherland,	 2001).	 For	 instance,	particular	AMPs	can	be	relocated	in	biofilm	EPS	via	channels	or	pores	formed	in	the	lipid	constituent	of	the	EPS,	while	others	can	disperse	biofilms.	
P.	 aeruginosa	is	 the	 notorious	 pulmonary	 pathogen	 affecting	 patients	 with	 CF	(Moreau-Marquis	et	al.,	2008a),	and	this	bacterium	develops	a	biofilm	on	medical	devices	and	 tissues.	 LL-37,	 a	 human	 origin	 cationic	 host	 defence	 peptide,	 displayed	 an	 active	inhibitory	 activity	 in	 biofilm	 development	 at	 a	 dosage	 of	 0.5	 μg/mL	 against	P.	
aeruginosa	biofilm	 and	 diminished	 pre-grown	 biofilms	 (Overhage	 et	 al.,	 2008a).	 It	 was	also	revealed	that	these	effects	were	reached	by	reducing	the	attachment	of	bacteria	onto	the	 surface,	 triggering	 twitching	 motility	 mediated	 by	 type	 IV	 pili,	 and	 supressed	 the	genes	associated	with	the	QS	system	(Overhage	et	al.,	2008a).			
1.3.2.5	AMP	intracellular	antibacterial	targets	Other	 than	 the	 capacity	 to	 effectively	 lyse	 bacterial	membranes,	 there	 are	 AMPs	that	can	successfully	cross	the	membrane	barrier	without	disturbing	it	and	display	their	antimicrobial	 potency	 through	 intracellular	 targeting.	 There	 is	 a	 collective	 suggestion	stated	in	the	literature	for	such	AMPs.	Human	neutrophil	peptide	1	(HNP1)	and	human-β	defensin	3	(HBD3)	have	been	stated	to	attach	to	 lipid	 II,	a	bacterial	cell	wall	 foundation	(Sass	 et	 al.,	 2010).	 Human	 β-defensin	 3	 also	 influences	 electron	 transport	 in	S.	 aureus	(Sass	 et	 al.,	 2008).	 Numerous	 AMPs	 possess	 immune-modulatory	 roles.	 For	 instance,	human	 neutrophil	 peptides	 1-3	 that	 once	 released	 by	 invading	 granulocytes	 induce	discharge	 of	 tumour	necrosis	 factor	 (TNF-α)	 and	 interferon-gamma	 (IFN-γ)	 from	 tissue	macrophages.	 This	 increases	 the	 eradication	 of	 bacteria	 as	 examined	 in	 a	 murine	in	
vivo	model	 (Soehnlein	et	al.,	 2008).	Human	β-defensin	3	 also	 triggers	particular	 antigen	carrying	 cells	 such	 as	 monocytes	 therefore	 inducing	 the	 adaptive	 immune	 system	
 42 
(Funderburg	 et	 al.,	 2007).	 Buforin	 II,	 a	 21-amino	 acid	 peptide	(TRSSRAGLQFPVGRVHRLLRK)	 (Park	 et	 al.,	 1996)	 with	 active	 wide	 spectrum	antimicrobial	potency,	is	also	capable	of	crossing	the	cell	membrane	and	reducing	cellular	metabolism	by	attaching	to	DNA	and	RNA	of	the	cells,	leading	to	prompt	cell	death	(Park	
et	al.,	1996).	Lately,	it	has	been	shown	that	indolicidin	attaches	DNA,	thus	reducing	DNA	replication	 and	 transcription	 (Ghosh	 et	 al.,	 2014)in	 addition	 to	 bind	 to	 DnaK	 (Li	 et	 al.,	2006).		
1.3.3	Bacterial	Resistance	to	AMPs	Applying	 antibiotic	 treatments	 to	 fight	 numerous	 infections	 has	 significantly	contributed	to	improve	human	life	expectancy	through	the	decades.	Nevertheless,	only	a	year	after	the	discovery	and	the	global	use	of	penicillin,	resistant	strains	of	bacteria	were	already	identified	owing	to	the	extreme	selection	pressure	and	fast	progress	of	resistance.	It	 is	 a	 similar	 picture	 with	 other	 antibiotics	 against	 which	 numerous	 bacteria	 have	advanced	 resistance;	 therefore	 there	 are	 numerous	 infections	 currently,	 which	 do	 not	have	treatment	options.	AMPs	are	possible	good	candidates	for	being	part	of	novel	anti-infective	strategies.	The	predominant	part	of	the	peptides	act	on	the	microbial	membrane	and	not	on	particular	 intracellular	targets,	with	a	mode	less	 inclined	to	the	formation	of	resistance.	Nevertheless,	to	resist	the	effect	of	AMPs,	bacteria	have	developed	numerous	strategies.	 These	 comprise,	 proteolytic	 degradation,	 shielding	 bacterial	 cell	 surface,	alteration	 of	 superficial	 membrane	 structures,	 dynamic	 efflux	 and	 suppression	 of	 AMP	expression	 (Gruenheid	&	Le	Moual,	 2012).	 Proteolytic	 denaturation	has	 been	described	for	 LL-37	 and	 β-defensin	 2,	 by	 proteases	 from	P.	mirabilis	(Belas	 et	al.,	 2004)	 on	 top	 of	numerous	proteases	discharged	by	bacteria	 that	 slice	peptides	on	particular	amino	acid	units.	 Amongst	 Gram-negative	 bacteria,	 particularly,	 various	 proteases	 that	 deactivate	AMPs	 are	 identified	 at	 the	 outer	 membrane	 (Hritonenko	 &	 Stathopoulos,	 2007).	Extracellular	constituents	such	as	capsule	polysaccharides,	 fimbriae,	exopolysaccharides	and	O-polysaccharide	 of	 LPS	 (Figure1.10)	 assist	 bacteria	 by	 attaching	 AMPs	 and	 thus	diminishing	 the	 quantity	 of	 peptide	 reaching	 the	 bacterial	membrane	 (Ilg	 et	 al.,	 2009).	Reduced	overall	 negative	 charge	has	 also	been	documented	 as	 a	 resistance	 strategy	 for	cationic	 peptides	 (Hein-Kristensen	 et	 al.,	 2013).	 Gram-positive	 bacteria	 also	 resist	 the	AMPs	by	enzymatic	mechanism	of	their	extracellular	proteases	(Nawrocki	et	al.,	2014)	as	well	as	cell	wall	and	membrane	modifications.	The	last	is	predominantly	by	deacetylation	
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of	N-acetylglucosamine	 or	O-acetylation	 of	N-acetylmuramyl	 units	 in	 the	 cell	 wall	 and	modification	of	charge	by	d-analynation	of	the	lipoteichoic	acids	(Bernard	et	al.,	2011).	An	alternative	tactic	to	resist	AMP	activity	is	to	pump	these	antimicrobials	out	of	the	bacterial	cytoplasm.	Bacteria	utilize	membrane	pumps	for	the	transportation	of	diverse	molecules	through	the	bacterial	membrane.	When	bacterial	strains	with	deleted	or	 inactive	pumps	were	tested,	it	was	shown	that	these	mutant	strains	were	much	more	susceptible	to	AMP	action	 (Shafer	 et	 al.,	 1998).	 At	 the	 same	 time	 as	 regulation	 of	 their	 defence	 system,	numerous	bacteria	also	generate	toxins	that	influence	host	identification	of	bacteria.	For	instance,	 the	 exotoxins	 of	Vibrio	 cholerae	and	 enterotoxigenic	E.	 coli	were	 found	 to	 be	involved	in	down-regulation	of	expression	of	AMP	such	as	LL-37	and	hBD1,	by	host	cells	(Chakraborty	et	al.,	2008).															
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										Figure	 1.10	 Depiction	 of	 Gram-positive	 and	 Gram-negative	 cell	 envelopes:	 CAP	 =	 covalently	 attached	protein;	 IMP,	 integral	membrane	 protein;	 LP,	 lipoprotein;	 LPS,	 lipopolysaccharide;	 LTA,	 lipoteichoic	 acid;	OMP,	outer	membrane	protein;	WTA,	wall	teichoic	acid	(Silhavy	et	al.,	2010).	
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1.3.4	Mammals	as	a	source	of	AMPs	Amongst	 mammals,	 AMPs	 have	 been	 found	 from	 diverse	 sources	 such	 as	 the	granules	 of	 neutrophils,	 Paneth	 cells,	 mucosal	 secretions	 from	 epithelial	 cells	 and	 as	protein	 degradation	 products	 (Boman,	 1995).	 Three	 classes	 of	 AMPs,	 identified	 in	abundance	 in	 neutrophils,	 defensins,	 cathelicidins	 and	 histatins	 (Selsted	 &	 Ouellette,	2005)	have	been	researched	comprehensively.		Defensins,	discovered	 in	human	neutrophils,	 are	18-45	amino	acids	 long	cationic	molecules	which	were	identified	from	mast	cells	and	tissues	encompassed	in	host	defence	(Ganz,	2003).	They	have	been	categorised	as	α-,	β	and	θ-defensins	according	to	structural	variances.	 All	 three	 categories	 are	 rich	 in	 cysteine	 and	 arginine	 residues.	 The	 variance	amongst	the	classes	lies	in	the	site	of	disulphide	linked	cysteine	residues.	Herein,	the	first	class	of	defensins	 (α-defensins),	have	disulphide	connections	between	cysteine	residues	1-6,	 2-	 and	 3-5,	 while	 β-defensins	 disulphide	 bridges	 are	 situated	 between	 cysteine	residues	1-5,	2-4	and	3-6	(Bowdish	et	al.,	2006).	Furthermore,	human	α-defensins	are	less	cationic,	 shorter	 and	more	 hydrophobic	 than	 human	 β-defensins	 (Pazgier	 et	 al.,	 2006).	Human	neutrophil	peptides	(HNP1-HNP4)	and	human	defensins	(HD-5	and	HD-6)	are	six	diverse	human	α-defensins	 identified	 in	monocytes,	NK	 cells,	 B	 and	T	 cells,	 neutrophils	and	 Paneth	 cells,	 respectively	 (Ouellette	 &	 Selsted,	 1996).	 Findings	 demonstrate	 that	HNPs	 display	 antimicrobial	 activity	 against	 both	 Gram-negative	 and	 Gram-positive	bacteria	 (Ericksen	 et	 al.,	 2005).	 Human	 defensin	 5	 expresses	 its	 antimicrobial	 potency	against	 numerous	 bacteria	 such	 as	E.	 coli,	Listeria	 monocytogenes,	Salmonella	
typhimurium,	S.	aureus	and	Vibrio	cholerae	(Porter	et	al.,	1997).	Dissimilar	to	α-defensins,	four	 human	 β-defensins	 (HBD	 1-4)	 have	 been	 identified	 from	 leukocytes	 and	 epithelial	cells.	The	β-defensins	also	demonstrate	microbicidal	potency	against	a	range	of	bacteria,	with	 HBD-4	 being	 the	 most	 active	 against	P.	 aeruginosa	 (Xu	 et	 al.,	 2006).	 It	 has	 been	shown	 that	 epithelial	 human	 β-defensins	 are	 over-expressed	 in	 patients	 suffering	 from	psoriasis,	 a	 chronic	 skin	 inflammation,	 with	 specific	 skin	 lesions	 cleared	 of	 infection.	Contrariwise	 in	atopic	dermatitis	where	 the	expression	of	HBDs	 is	 inhibited,	 the	 lesions	are	infection-prone	(Nomura	et	al.,	2003),	clarifying	the	significance	of	these	AMPs	in	host	defence.	The	 cathelicidins	 are	 another	 class	 of	AMPs	which	have	been	 isolated	 in	 various	vertebrates	such	as	 fish,	bird,	cow,	pig,	rabbit,	sheep,	mouse,	monkey,	horse	and	human	(Scocchi	 et	 al.,	 2009).	 They	 are	 predominantly	 manufactured	 in	 epithelial	 cells,	
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neutrophils	 and	macrophages.	 Indolicidin	 and	 human	 cathelicidin	 LL-37	 are	 two	 of	 the	most	investigated	members	of	this	category	of	peptides.	LL-37	is	the	only	member	of	this	category	of	peptides	 identified	 in	man.	The	prominence	of	 these	peptides	 is	 revealed	 in	findings	 where	 increased	 susceptibility	 to	 infections	 is	 observed	 in	 patients	 with	deficiencies	 in	 neutrophil	 manufacture	 of	 LL-37,	 the	 foremost	 source	 of	 human	 AMPs	(Pütsep	et	al.,	2002).	Indolicidin	 is	 a	 short	 antimicrobial	 peptide	with	 13	 amino	 acids	 identified	 from	bovine	neutrophils.	It	 is	rich	in	tryptophan	(39%)	and	arginine	(23%)	residues,	and	it	is	amidated	 at	 the	C-terminal	 arginine	 (Falla	 et	 al.,	 1996).	 The	 antimicrobial	 potency	towards	 both	 Gram-negative	 and	 Gram-positive	 bacteria,	 fungi	 and	 protozoa	 is	 most	possibly	 not	 an	 outcome	 of	 any	 confined	 secondary	 structure,	 as	 nuclear	 magnetic	resonance	spectroscopy	investigations	failed	to	report	distinct	secondary	or	amphipathic	structure	which	is	specific	for	the	majority	of	AMPs	(Hsu	et	al.,	2005).	Human	 cathelicidin	 LL-37	 is	 a	 broadly	 researched	 representative	 of	 the	cathelicidin	 family	 of	 AMPs,	 and	 is	 also	 the	 only	 cathelicidin	 identified	 in	 humans.	 It	 is	most	identifiable	in	the	granules	of	neutrophils.	Upon	infection	and	inflammation,	LL-37	is	discharged	in	high	intensities	at	neutrophil	accumulation	sites.	Human	cathelicidin	LL-37	is	also	manufactured	by	lymphocytes	and	macrophages	as	well	as	diverse	epithelial	cells,	and	 hence	 found	 in	 plasma,	 sweat	 and	 other	 body	 fluids	 (Zanetti,	 2004).	 The	 family	 of	cathelicidins	are	categorised	in	accordance	to	their	highly	conserved	cathelicidin	domain,	which	 is	 lined	 by	 an	N-terminal	 signal	 peptide	 and	 a	C-terminal	 segment	 related	 to	 the	active	antimicrobial	peptide.		Bacterial	 constituents	 are	 another	 mode	 of	 LL-37/hCAP-18	 gene	 expression	inducers.	For	instance,	it	has	been	shown	that	expression	of	LL-37/hCAP-18	considerably	boosted	 in	Helicobacter	 pylori-infected	 patients	 compared	 to	 patients	 with	 non-
Helicobacter	 pylori	induced	 inflammation	 (Hase	 et	 al.,	 2003).	 Once	 expressed,	 LL-37	applies	diverse	biological	activities;	direct	bactericidal	activity	against	Gram-positive	and	Gram-negative	 bacteria	 detected	in	 vitro	(Travis	 et	 al.,	 2000)	 and	 modulation	 of	inflammation	and	 immune	response	 in	host	 cells	 against	various	 infections	 (Bowdish	et	
al.,	2005).				
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1.3.5	AMPs	isolated	from	Insects	Insects	 form	 the	 largest	 group	 of	 multicellular	 organisms	 in	 nature.	 Lacking	 an	apparent	 adaptive	 immune	 system,	 they	 combat	 numerous	 pathogens	 by	 rapid	 innate	cellular	 and	 humoral	 reactions.	 Therefore,	 AMPs	 play	 a	 significant	 role	 in	 the	 insect’s	defence	 system	 as	 they	 are	 discharged	 in	 the	 haemolymph	 as	 a	 consequence	 of	 the	humoral	defense	mechanism	upon	microbial	infections.	AMPs	isolated	from	diverse	insect	species	 are	 classified	 as	 cecropins,	 attacins,	 lysozymes,	 defensins	 and	 dipteracins.	Moreover,	 in	Drosophila	two	 groups,	 drosomycin	 and	 the	 metchikowins,	 have	 been	isolated	and	characterized	(Bulet	et	al.,	1999).	Cecropins	 are	 the	 most	 widespread	 group	 of	 linear	 AMPs	 in	 insects.	 They	 lack	cysteine	 residues	 and	 adopt	 most	 regularly	 an	 α-helical	 conformation	 in	 membrane	mimetic	 environments.	 To	 demonstrate,	 cecropin	 A	(KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK-NH2)	 is	one	of	 the	 first	 cecropins	 for	which	 a	 solution	 confirmation	 for	 adaptation	 of	 a	 stable	 α-helix	 in	 hydrophobic	environments	 has	 been	 established	 exploiting	 circular	 dichroism	 spectroscopy	 (Steiner,	1982).	Melittin	 is	 the	most	 investigated	 α-helical,	 cationic	 and	 haemolytic	 antimicrobial	peptide	in	the	field,	which	comprises	50	%	of	the	dry	mass	of	bee	venom	(Raghuraman	&	Chattopadhyay,	 2007).	 It	 is	 a	 26-amino	 acids	 amphiphilic	 peptide	(GIGAVLKVLTTGLPALISWIKRKRQQ),	 described	 by	 a	 hydrophilic	C-terminal	 and	 mainly	hydrophobic	N-terminal	 region,	 and	 performs	 as	 a	 model	 peptide	 in	 many	 membrane-peptide	interaction	studies	(Dempsey,	1990).	Furthermore,	structure-activity	relationship	investigations	 where	 diverse	 segments	 of	 melittin	 have	 undergone	 substitution	 or	deletion,	have	established	the	fundamental	elements	required	for	the	high	haemolytic	and	antimicrobial	potency	of	this	peptide	(Mojsoska	&	Jenssen,	2015).			
1.3.6.	AMPs	isolated	from	Plants	Representatives	 of	 plants	 have	 also	 developed	 defence	 molecules	 to	 combat	undesirable	 infections.	 AMPs	 identified	 in	 plants	 are	 positively	 charged	 and	 exhibit	 the	characteristic	 structural	 patterns	 such	 as	 α-helices,	 β-sheets	 and	 loops.	 They	 are	separated	 into	 five	 categories:	 lipid	 transfer	 proteins	 (Marion	 et	 al.,	 2007),	 thionins,	defensins	 (Stotz	 et	 al.,	 2009),	 chitin-binding	 proteins	 (Beintema,	 1994)	 and	 cyclotides	(Burman	et	al.,	2014).	Thionins	and	defensins	were	the	first	AMPs	identified	in	plants.	
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Thionins	 comprise	 up	 to	 48	 amino	 acids,	 mainly	 arginine,	 lysine	 and	 cystein	residues	 and	 include	 a	 few	 conserved	 disulphide	 bonds.	 As	 a	 constituent	 of	 the	 plant	defence	 system,	 thionins	 act	 on	 diverse	 pathogens	 and	 apply	 toxic	 effects	 on	 bacteria,	fungi,	yeast	and	mammalian	cells	(Stec,	2006).	A	subgroup	of	the	thionins	group	is	the	β-purothionins,	which	interact	intensely	with	lipid	bilayer,	then	insert	into	the	hydrophobic	core,	causing	cell	lysis	(Clifton	et	al.,	2011).		Viscotoxins,	another	class	of	plant	thionins,	were	identified	in	the	leaves	and	stems	of	 the	 European	mistletoe	 (Viscum	album)	 in	 1973	 (Samuelsson	&	 Jayawardene,	 1974).	Reports	 have	 shown	 their	 high	 conformational	 stability	 and	 their	 ability	 to	 disturb	bacterial	membranes	(Giudici	et	al.,	2003).			
1.3.7	Bacteria	as	a	source	of	AMPs	AMPs	 manufactured	 by	 bacteria,	 initially	 referred	 to	 as	 colicins,	 are	 known	currently	 as	 bacteriocins.	 Bacteriocins	 manufactured	 by	 the	 host	 bacteria	 have	 the	property	 to	 selectively	 act	 against	 a	 broad	 spectrum	 of	 bacterial	 species	 without	destroying	the	producer	itself.	This	group	of	AMPs	finds	extensive	application	in	the	food	industry	to	keep	food	safe	and	prevent	contamination.	Some	bacteriocins	are	synthesized	by	lactic	acid	bacteria.	Moreover,	bacteriocins	draw	exceptional	attention	for	their	clinical	potential	 for	 treatments	 of	 MRSA,	 enterococci,	 including	 Vancomycin-resistant	enterococci	(VRE),	streptococci,	Clostridium	botulinum	and	Propionibacterium	acnes.	As	an	outcome	of	 intensive	 studies	over	 the	 last	years	 there	have	 lately	been	requests	 for	 the	classification	 of	 bacteriocins	 to	 be	 modified,	 and	 the	 current	 grouping	 proposed	 by	Cotter	et	al.	includes	Class	I	(lanthionine-containing),	Class	II	(non-lanthionine	containing)	and	bacteriolysins	(non-bacteriocin	lytic	proteins)	(Cotter	et	al.,	2005).	Nisin	is	a	conventional	exemplar	of	a	Class	I	bacteriocin	that	has	been	successfully	approved	as	an	antimicrobial	with	marketable	applicability	in	over	50	countries	globally	since	its	discovery	in	1927	(Rogers,	1928).	Found	from	Lactoccocus	lactis	it	was	not	until	1971	that	its	multipart	structure,	comprising	34	amino	acids	containing	some	uncommon	lanthionine	 residues,	 four	 β-methyllanthionines,	 didehydroalanine	 and	didehydroaminobutyric	 acid	 was	 fully	 designated	 (Gross	 &	 Morell,	 1971).	 Its	 potency	against	Gram-positive	pathogenic	bacteria	 is	 related	 to	 its	 interaction	with	 the	bacterial	membrane-occasioning	 disturbance	 of	 the	membrane’s	 integrity.	 This	 happens	 through	pore	 formation	and	so	 far	 two	mechanisms	are	suggested.	The	 first	one	depends	on	 the	
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low-affinity	pore	construction	of	nisin	alone,	while	the	second	one	suggests	nisin	and	lipid	II	 interaction	consequently	contributing	to	the	pore	formation	by	this	complex	(Lipid	II-dependent	 pathway)	 (Hasper	 et	 al.,	 2006).	 Some	 structure-activity	 relationship	 (SAR)	investigations	 have	 been	 described	 where	 the	 significance	 of	 diverse	 segments,	particularly	those	comprising	lanthionine	rings,	have	been	emphasised	to	be	fundamental	for	the	observed	antimicrobial	activity	(Chan	et	al.,	1996).	Mutacin	1140	(Strother	et	al.,	2000)	 is	another	representative	of	 the	 lanthionine-comprising	 bacteriocins	which	 has	 been	widely	 investigated.	 It	 is	 a	 22	 amino	 acid	 long	peptide	manufactured	by	Streptococcus	mutans	(Hillman	et	al.,	1998)	with	a	type	of	action	analogous	 to	 that	 of	 nisin,	 which	 associates	 with	 the	 capacity	 to	 inhibit	 peptidoglycan	synthesis	by	binding	to	lipid	II	(Hasper	et	al.,	2006).	Mutacin	1440	has	a	broad	spectrum	of	 potency	 against	 clinically	 significant	 bacteria	 with	 time	 of	 eradication	 profiles	comparable	 with	 that	 of	 vancomycin,	 an	 antibiotic	 licensed	 for	 treatment	 of	 severe	infections	induced	by	Gram-positive	bacteria.	This	peptide	is	presently	under	examination	for	 its	 pharmacological	 application	 and	 has	 been	 submitted	 for	 preclinical	 trials	 (Fox,	2013).	Lysostaphin	 is	 a	 bacteriolysin.	 It	 hydrolyses	 the	 cell	 wall	 of	 the	 target	 bacteria.	Currently,	it	is	being	examined	for	its	potency	in	food	and	nutritional	microbiology.	Even	though	 bacteriolysins	 are	 structurally	much	 greater	 than	 the	 conventional	 bacteriocins	and	AMPs,	their	application	as	peptide	antibiotics	possess	massive	potential.	Lysostaphin	(27	kDa)	 for	 instance,	 is	capable	of	splitting	 the	pentaglycine	cross-links	 in	 the	cell	wall	of	Staphylococci	and	 consequently	 lyse	 the	 pathogenic	 bacteria	 in	 entirely	 metabolic	conditions.	The	therapeutic	effectiveness	of	this	bacteriolysin	against	clinical	methicillin-resistant	S.	 aureus	 isolate	 has	 been	 stated	 in	 animal	 models	 and	 matched	 to	 that	 of	vancomycin.	The	recombinant	lysostaphin,	showed	better	in	vitro	and	in	vivo	antibacterial	potency	against	methicillin-resistant	S.	aureus	compared	to	vancomycin,	as	well	as	having	low	 toxicity,	 thus	 it	 is	 a	 possible	 main	 candidate	 for	 advanced	 structural	 optimization	investigations	(Chen	et	al.,	2014).		
1.3.8	AMPs	from	Frog	Skin	Amphibian	 genomes	 have	 developed	 the	 ability	 to	 respond	 to	 environmental	challenges	with	the	vastly	concentrated	genetic	alterations	(Caporale,	1999).	The	dermal	glands	 of	 anuran	 frogs	 not	 only	 manufacture	 colossal	 quantities	 of	 biologically	 active	
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peptides	 which	 are	 very	 like	 mammalian	 neuropeptides	 as	 hormones	 (Severini	 et	 al.,	2002),	 but	 they	 also	 comprise	 a	 rich	 resource	 for	 broad	 spectrum,	 cytosolic	 AMPs	(Simmaco	et	al.,	1998).	Many	of	these	peptides	display	antibiotic,	fungicidal,	anti-viral	and	anti-tumour	 potencies	 with	 a	 low	 cytotoxicity	 on	mammalian	 cells.	 These	 peptides	 are	synthesized	as	prepropeptides	that	are	managed	by	the	elimination	of	the	signal	peptide	to	 proform	 and	 they	 are	 deposited	 in	 the	 large	 granules	 of	 the	 glands	 (Lacombe	 et	al.,	2000).	 Glands	 may	 discharge	 their	 peptide	 content	 onto	 the	 skin	 surface	 by	 holocrine	mechanisms	 to	 deliver	 an	 efficient	 and	 rapid-acting	 defence	 against	 pernicious	microorganisms	(Lacombe	et	al.,	2000).	The	AMPs	are	short,	10–50	amino	acid	residues	long,	cationic	and	function	in	a	range	of	modes,	though	permeabilising	and	disturbing	the	target	cell	membrane	is	the	most	common	mechanism	(Reddy	et	al.,	2004).		The	sequences	of	these	AMPs	diverge	significantly	from	one	amphibian	to	another.	The	 skin	 of	 a	 frog	 may	 have	 10–20	 AMPs	 with	 diverse	 size,	 sequences,	 charges,	hydrophobicity,	tri-dimensional	constructions	and	spectrum	of	potential,	and	this	arsenal	differs	 amongst	 frogs	 belonging	 to	 diverse	 families,	 genera,	 species	 or	 even	 subspecies,	consequently,	 no	 two	 species	 with	 the	 similar	 arsenal	 of	 peptide	 antibiotics	 has	 been	discovered	(Ong	et	al.,	2002).	This	remarkable	variance	amongst	and	within	species	means	that	there	may	be	as	many	as	100	000	various	peptides	manufactured	by	the	skin	glands	of	 the	5000	anuran	amphibians	(Jacob	&	Zasloff,	1994).	The	outstanding	variants	in	the	peptide	sequence	of	frog	skin	AMPs	may	be	manipulated	 for	 finding	novel	molecules	and	structural	patterns	targeting	precise	microorganisms	for	which	the	therapeutic	armamentarium	is	limited.		Magainins,	also	identified	as	peptide	glycine	serine	(PGS)	(Giovannini	et	al.,	1987),	are	23	amino	acid	long	peptides	isolated	from	the	skin	of	the	African	clawed	frog	Xenopus	
laevis	(Zasloff,	 1987a).	 Magainins	 are	 representatives	 of	 a	 large	 family	 of	 amphibian	amphipathic	α-helical	 AMPs.	 These	 peptides	 have	 been	 stated	 to	 have	 an	 extensive	spectrum	 of	 antimicrobial	 potencies	 against	 Gram-positive	 and	 Gram-negative	 bacteria	and	 fungi.	 They	 are	 also	 acknowledged	 to	 accelerate	 wound	 closure	 and	 decrease	inflammation	 (Sai	 et	 al.,	 1995).	 Analogs	 of	 the	 peptide	 representing	 increased	antimicrobial	potency	have	been	synthesized	(Zasloff,	1987a).	Arhana	et	al.	revealed	that	magainin-A	reduces	the	development	of	various	strains	of	STI-causing	pathogens,	and	the	effects	were	 established	 to	 be	dose-dependant.	 The	minimum	 inhibitory	 concentrations	(MICs)	 for	 typical	 strains	 of	E.	 coli,	 S.	 aureus,	Candida	 albicans	 and	P.	 aeruginosa	were	
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fluctuating	from	50	μg/mL	to	150	μg/mL.	It	is	important	to	underline	that	this	peptide	did	not	 induce	 red	 blood	 cells	 (RBC)	 haemolysis	 up	 to	 300	μg/mL	 (Clara	 et	al.,	 2004).	 The	antimicrobial	 efficacy	 might	 be	 related	 to	 the	 disturbance	 of	 the	 bacterial	 membrane.	Because	 of	 the	 somewhat	 non-specific	 mechanism	 on	 the	 bacterial	 membrane	 (Albiol	Matanic	&	Castilla,	2004),	magainin-A	is	potent	against	a	broad	spectrum	of	microbes.			
1.3.9	Developing	novel	AMPs		The	foremost	goal	of	all	research	studies	in	the	area	of	AMPs	is	to	contribute	to	the	AMP	 range	 with	 novel	 strategies	 for	 the	 advancement	 of	 pharmacologically	 applicable	AMP	configurations.	The	production	of	de	novo	constructions	is	not	typically	precise	and	it	requires	 broad	 experimental	 investigation.	 To	 achieve	 this	 objective	 and	 assist	 the	discovery	of	de	novo	peptides,	numerous	computer-based	approaches	have	been	engaged.	Most	 include	 constructing	 quantitative	 structure-activity	 relationship	 parameters	 for	computer-assisted	design	of	AMPs.	The	overall	concept	is	to	relate	chemical	sequence	and	configuration	of	AMPs,	defined	with	physiochemical	parameters	and	associate	them	with	their	 corresponding	 biological	 activities	 exploiting	 mathematical	 models	 (Juretić	 et	 al.,	2009).	 One	 of	 the	 mathematical	 models	 exploited	 for	 prediction	 of	 novel	 polypeptide	sequences	with	potentially	upgraded	biological	potencies	is	the	Designer	algorithm	(Ilić	et	
al.,	 2013).	 Operating	 the	 Designer	 algorithm	 the	 latest	 study	 of	 Ilic	et	 al.	reveals	 on	 a	number	 of	 peptide	 sequences	 with	 high	 antibacterial	 potency	 against	 Gram-negative	bacteria	 (0.5–4	 µM)	 and	 low	 hemolytic	 properties	 (HC50	>	 400	 µM)	 (Fjell	 et	 al.,	 2009).	Fjell	et	 al.	have	 also	 generated	 a	 software	 system	 that	 could	 predict	 peptides	 with	antibacterial	potency	with	up	to	94%	accuracy	(Fjell	et	al.,	2011).		AMPs	can	be	the	next	generation	cohort	of	antimicrobial	agents	for	struggling	with	multi-drug	 resistant	 and	 biofilm	 forming	 bacterial	 infections.	 These	 cationic	 peptides	possess	 a	 prospective	 for	 employment	 as	 Nano-films	 or	 other	 coating	 constituents	 for	surgical	 devices,	 involving	 catheters.	 Despite	 obstacles	 in	 AMP	 properties	 to	 the	exploitation	of	peptides	as	therapeutics,	such	as	low	bioavailability	and	great	cost,	these	difficulties	 may	 be	 overcome.	 	 There	 is	 enormous	 effort	 to	 avoid	 the	 complications	associated	with	diverse	approaches	comprising	the	utilizing	of	d-	or	unnatural	amino	acid,	formulation,	and	recombinant	DNA	expression	of	peptides,	binding	of	fatty	acyl	chains	to	short	peptides.	Consequently,	it	is	probable	that	AMPs	will	become	the	optimal	drugs	for	emerging	bacterial	infections	in	the	following	decades.	
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1.4	Aim	and	objectives		Bacterial	pathogens	are	 the	main	 causes	of	morbidity	and	mortality	among	CF	patients.	The	 thick	mucus	and	 impaired	mucociliary	clearance	result	 in	accumulation	of	bacterial	pathogens,	 the	 formation	 of	 biofilms,	 and	 compromised	 immunity.	 Treatment	 is	prolonged,	problematic	and	 re-infection	 is	quite	 common.	Along	with	bacteria,	CF	 lungs	can	be	 colonized	with	protozoan	microorganisms	 such	as	Acanthamoeba,	which	 feed	on	bacteria.	The	widespread	distribution	of	Acanthamoeba	in	the	environment	and	its	role	as	a	 “Trojan	 horse”	 for	 various	 bacterial	 strains	 suggest	 that	 these	 organisms	may	 play	 a	critical	 role	 in	 CF	 lung	 infections.	 Acanthamoeba	 could	 be	 acting	 as	 a	 protector	 of	intracellular	 bacteria	 against	 drug	 treatment	 (Figure	 1.11).	 Moreover,	 occurrences	 of	bacterial	re-infections	and	longer	therapeutic	periods	could	be	related	to	the	presence	of	
Acanthamoeba	in	 lower	respiratory	airways.	However,	there	is	no	single	report	showing	the	presence	of	Acanthamoeba	in	human	lower	respiratory	tract.	Despite	all	the	attempts	to	get	clinical	sputum	samples,	it	was	problematic	to	acquire	Ethical	approval	within	time	of	 study.	 The	 major	 questions	 of	 the	 current	 thesis	 are:	 is	 the	 antimicrobial	 peptide	magainin	II	effective	against	bacterial	pathogens	associated	with	CF	and	if	Acanthamoeba	occurs	in	human	lower	respiratory	airways,	does	it	have	any	role	in	bacterial	infections	in	CF	lung?			To	this	end,	several	aspects	and	objectives	have	been	examined.	First,	can	bacteria	interact	with	and	survive	inside	a	lung	adenocarcinoma	cell	line	and	in	an	Acanthamoeba	strain.	 Secondly,	 to	 investigate	new	alternative	 therapies	 to	 combat	pathogenic	bacteria	associated	with	CF	pulmonary	 infections.	Thirdly,	 to	 study	 the	effect	of	 an	environment	resembling	CF	conditions	on	the	growth	of	bacteria	and	on	the	effectiveness	of	alternative	therapy.	Finally,	to	investigate	if	magainin	II	has	the	ability	to	prevent	bacterial	pathogens	forming	biofilms	(Figure	1.12).			 					
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		Figure	1.11	Using	antimicrobial	peptides	in	treatment	of	bacteria	that	are	protected	inside	Acanthamoeba.	1-Lung	of	CF	patient	containing	pathogenic	bacteria.	2-	Acanthamoeba	 engulfs	bacteria.	Some	of	 them	are	digested	 and	 some	 of	 them	 survive.	 3-Antibiotic	 treatment	 kills	 extracellular	 bacteria.	 4-Intracellular	bacteria	remain	intact.	These	bacteria	survive,	multiply	and	burst	Acanthamoeba,	causing	reinfections	in	CF	lung.	5-	Antimicrobial	peptides	are	used	 to	 target	 intracellular	pathogenic	bacteria	along	with	eradicating	
Acanthamoeba.																				
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		Figure	 1.12	 Antibiofilm	 activity	 of	 antimicrobial	 peptides.	 1-Lung	 of	 CF	 patient	 with	 bacteria	 that	 are	capable	of	forming	biofilms.	2a-Pathogenic	bacteria	accumulation.	3a-Biofilm	formation.	2b-Treatment	with	antimicrobial	peptide.	3b-No	biofilm	formation.					
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Chapter	2	
	
“The	interactions	of	bacteria	related	to	Cystic	Fibrosis	with	
Acanthamoeba	castellanii	and	Human	epithelial	lung	carcinoma	(A549)	
cell	line”	
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2.1	Background	CF	is	a	recessive	genetic	disorder	characterized	by	thickening	of	the	airway	mucus	and	weakened	 self-clearing	mechanism	of	 the	 bronchi.	 As	 a	 consequence,	 patients	with	the	disease	have	 a	difficulty	 clearing	pathogens	 from	 the	 respiratory	 tract	 and	undergo	chronic	 respiratory	 infections	 and	 inflammation.	 Generally	 respiratory	 insufficiency	eventually	results	in	death	(Emerson	et	al.,	2002).			Recently	 introduced	 therapies	 and	 continuous	 management	 of	 the	 lung	 disease	have	resulted	in	great	enhancements	 in	 length	and	quality	of	 life,	with	the	outcome	that	the	average	estimated	survival	age	has	risen	to	36	years.	Yet,	as	the	number	of	treatments	broadens,	 the	medical	regimen	is	getting	even	more	onerous	 in	time,	money,	and	health	resources.	Therefore,	it	is	important	that	treatments	should	be	recommended	on	the	basis	of	available	proof	of	effectiveness	and	safety	(Flume	et	al.,	2007).		CF	 is	 believed	 to	 be	 inherited	 as	 an	 autosomal	 recessive	 trait,	 and	 to	 be	 highly	inconstant	 in	 its	 severity,	duration,	 and	 range	of	 symptoms	 (Minear	et	al.,	 2013).	There	are	about	70,000	people	suffering	from	CF	worldwide	(http://www.cff.org,	2012).	About	1	in	every	2,500	children	born	in	the	UK	is	born	with	CF	and	there	are	more	than	9,000	people	living	with	the	condition	in	this	country	(NHS,	2012).		CF	 is	 a	 result	 of	 mutations	 in	 the	 cystic	 fibrosis	 trans-membrane	 conductance	regulator	 (CFTR)	 gene	 on	 chromosome	 7,	 which	 encodes	 a	 chloride	 ion	 channel.	 Such	mutations	influence	a	huge	protein	pore	functioning	as	a	conductor	of	negatively	charged	chloride	atoms	through	the	plasma	membrane.	Genetically	changed	CFTR	protein	results	in	an	accumulation	of	dense,	 gluey	mucus	 in	 the	 lungs,	digestive	 tract	and	 reproductive	system.	 This	 kind	 of	 mucus	 makes	 it	 problematic	 for	 patients	 to	 clear	 lung	 infections,	which	 are	 the	 prominent	 reason	 of	 death	 in	 CF	 (http://www.lung.org,	 2012).	Compromised	 mucociliary	 clearance	 in	 lung	 makes	 CF	 patients	 susceptible	 to	opportunistic	infections	(De	Soyza	et	al.,	2013).		Recent	 records	 from	 nonculture-based	 techniques	 put	 forward	 that	 the	 airway	microbiome	 in	 CF	 is	 polymicrobial	 with	 numerous	 organisms	 existent	 (Blainey	 et	 al.,	2012).	The	pathogens	isolated	by	culture	are	mainly	Staphylococcus	aureus,	Haemophilus	
influenzae,	 and	 Pseudomonas	 aeruginosa.	 Fewer	 microorganisms	 from	 the	 Burkholderia	
cepacia	complex	(Bcc)	and	other	pathogens	are	also	found	(Davies	&	Rubin,	2007).			
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2.1.1	Acanthamoeba	Parts	of	the	human	respiratory	tract	also	can	be	infected	with	protozoans	such	as	
Acanthamoeba	 castellanii	 (A.	 castellanii),	 which	 cause	 eye	 and	 central	 nervous	 system	diseases.	 Acanthamoeba	 are	 abundant	 in	 surroundings	 and	 identified	 in	 nasal	 cavity	(Cerva	et	al.,	1973),	and	pharynx	of	healthy	individuals	(Wang,	1961).	The	Acanthamoeba	cysts	are	able	 to	stand	drying,	which	allows	 them	to	be	airborne.	 (Im	&	Kim,	1998).	On	average,	 each	 human	 breathes	 in	 two	 cysts	 of	 Acanthamoeba	 per	 day	 (Kingston	 &	Warhurst,	 1969).	 Moreover,	 it	 is	 largely	 accepted	 that	 the	 routes	 of	 entrance	 for	
Acanthamoeba	 include	 the	 respiratory	 tract,	 enabling	 amoebic	 invasion	 of	 the	 alveolar	capillaries,	followed	by	distribution	in	the	blood	(Marciano-Cabral	&	Cabral,	2003).			
2.1.2	Acanthamoeba-bacteria	interactions		
Acanthamoeba	 is	 the	 opportunistic	 representative	 of	 protists	 group	 which	 has	been	 distinguished	 from	 various	 environments	 (De	 Jonckheere,	 1991).	 Acanthamoeba	living	in	water	and	soil	feeds	on	bacteria	living	in	the	same	ecosystem	by	engulfing	and	at	the	same	 time	has	essential	ecological	 role,	which	 is	maintaining	of	number	of	bacterial	populations	(Khan,	2012).		Some	 bacterial	 strains	 have	 evolved	 strategies	 to	 defend	 themselves	 from	
Acanthamoeba	 phagocytosis	 by	 secreting	 soluble	 anti-Acanthamoebic	 materials	 in	 the	medium	(Jousset	et	al.,	2010),	or	straight	inserting	such	materials	into	the	protoplasm	of	
Acanthamoeba	 via	 the	 type	 III	 secretory	 system	 (Matz	 et	 al.,	 2008).	 Moreover,	 some	bacteria	mainly	pathogenic	ones,	have	evolved	approaches	to	slip	away	the	microbicidal	strategies	 of	 Acanthamoeba	 and	 furthermore	 exploit	 the	 amoeba	 as	 a	 “Trojan	 horse”	(Greub	&	 Raoult,	 2004).	Burkholderia	 cepacia	 was	 shown	 to	 be	 able	 to	 survive	 in	 free-living	amebae	(Marolda	et	al.,	1999),	as	well	as	 in	Acanthamoeba	polyphaga	(Landers	et	
al.,	 2000).	 In	 another	 study	 it	 was	 revealed	 that	 Burkholderia	 cepacia	 survive	intracellularly	 without	 replication	 within	 acidic	 vacuoles	 of	 Acanthamoeba	 polyphaga	(Lamothe	et	al.,	2004).	P.	aeruginosa	is	another	bacteria	to	demonstrate	ability	to	survive	within	Acanthamoeba	(José	Maschio	et	al.,	2015).	These	 facts	 propose	 that	 Acanthamoeba	 and	 bacteria	 interact	 in	 the	 ecosystem	constantly.	However,	what	are	the	strategies	and	mechanisms	of	Acanthamoeba	survival	among	 overcrowded	 bacterial	 population	 keeps	 staying	 insufficiently	 conceived.	
 58 
Accordingly,	 it	 is	 rational	 to	 assume	 that,	 bacteria	 are	 not	 only	 organisms	 to	 have	antibiotics,	Acanthamoeba	also	holds	antibiotics	to	fight	bacterial	onslaught.	The	majority	of	antibiotics	used	nowadays	have	been	developed	according	to	these	targeting	strategies	of	 microorganisms	 (Iqbal	 et	 al.,	 2014).	 The	 attacking	 of	 each	 other	 of	 these	microorganisms	 is	 of	 great	 importance	 in	 finding	 new	 antibiotics	 where	 identification	experiments	 of	 antibacterial	 potency	 of	 Acanthamoeba	 and	 anti-Acanthamoebic	properties	of	employed	bacteria	were	carried	out.		In	this	project,	 the	 interaction	patterns	of	bacteria	such	as	MSSA,	H.	influenzae,	P.	
aeuriginosa,	Str.	pneumoniae,	E.	coli	and	Staphylococcus	epidermidis	with	human	epithelial	adenocarcinoma	 cell	 line	 (A549)	 and	 Acanthamoeba	 trophozoites	 have	 been	 studied.	Furthermore,	conditioned	medium	of	Acanthamoeba	was	tested	for	its	bacteriostatic	and	bactericidal	 potency;	 and	 conditioned	media	 of	 employed	 bacteria	were	 investigated	 to	possess	amoebistatic	and	amoebicidal	activities.				
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2.2	Materials	and	Methods	All	chemicals	were	purchased	from	Sigma-Aldrich	(UK),	unless	otherwise	stated.	
2.2.1	Acanthamoeba	culture	and	conditioned	medium	A	 clinical	 isolate	 of	 A.	 castellanii	 (ATCC	 50492)	 belonging	 to	 the	 T4	 genotype,	isolated	 from	 a	 keratitis	 patient,	 was	 kindly	 provided	 by	 Dr	 S.	 Maciver	 (University	 of	Edinburgh,	UK).	Acanthamoeba	was	grown	axenically	without	shaking	in	10	mL	of	sterile	PYG	medium	[proteose	peptone	0.75	%	(w/v),	yeast	extract	0.75	%	(w/v)	and	glucose	1.5	%	(w/v)]	in	T-75	culture	flasks	at	30	°C	and	medium	refreshed	17-20	h	prior	experiments	(Alsam	 et	 al.,	 2003).	 Acanthamoeba	 was	 maintained	 by	 weekly	 sub-culturing	 5	 ×105	amoebae	 into	 10	 mL	 of	 PYG	 medium	 in	 T-75	 tissue	 culture	 flasks.	 A.	 castellanii	conditioned	 medium	 (ACM)	 was	 prepared	 by	 incubating	 confluent	 cultures	(~2×106	trophozoites/mL)	 for	 48	 h	 in	 PYG.	 Given	 confluent	 cultures,	 amoebae	 number	increased	 slightly	 to	 ~3×106	trophozoites/mL.	 Following	 this,	 cell-free	 medium	 was	collected	 by	 centrifugation	 (1000	 ×	 g	 for	 5	min)	 and	 filtered	 using	 0.22	μM	 pore	 size	filters.	
2.2.2	Bacterial	cultures	and	conditioned	media	Clinical	bacterial	strains	such	as	MSSA,	Str.	pneumoniae,	P.	aeruginosa,	H.	influenzae	
E.	coli	and	S.	epidermidis	were	used	in	this	study.	All	strains	were	kindly	provided	by	Dr.	Tony	 Elston	 from	 Colchester	 General	 Hospital.	 MSSA,	 P.	 aeruginosa,	 E.	 coli	 and	 S.	
epidermidis	strains	were	streaked	onto	Cysteine	Lactose-Electrolyte-Deficient	(CLED)	agar	and	 incubated	 in	 37	 °C	 in	 air,	 and	 refreshed	 every	week.	One	 or	 two	 single	 colonies	 of	MSSA,	P.	aeruginosa,	E.	coli	and	S.	epidermidis	were	grown	in	Luria-Bertani	broth	(LB)	and	incubated	overnight	at	37	°C.	The	MSSA,	P.	aeruginosa,	and	E.	coli	optical	densities	(OD)	were	measured	 by	 spectrophotometer	 with	 wavelength	 595	 nM	 and	 optical	 density	 of	0.22	 (OD595	 0.22=	 ~	 108	 CFU/ml),	 S.	 epidermidis	 with	 OD	 0.35	 (OD595	 0.35=	 ~108	CFU/ml).	 Str.	 pneumoniae	 strains	 were	 streaked	 onto	 Blood	 agar,	 H.	 influenzae	 onto	Chocolate	agar	and	incubated	in	37	°C	in	a	5	%	CO2-enriched	incubator.	One	or	two	single	colonies	of	Str.	pneumoniae	were	grown	 in	Brain	Heart	 Infusion	 (BHI)	and	H.	influenzae	were	grown	in	BHI	Broth	with	Fildes	Enrichment	and	incubated	overnight	at	37	°C	in	CO2	incubator.	OD	of	Str.	pneumoniae	and	H.	influenzae	were	measured	by	spectrophotometer	with	wavelength	595	 and	optical	 density	 of	 1.06	 (OD595	1.06=	~	108	 CFU/ml)	 and	OD	0.22	(OD595	0.22=	~108	CFU/ml)	respectively.	Bacterial	conditioned	media	(BCM)	were	
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prepared	 by	 culturing	 single	 colonies	 (grown	 on	 nutrient	 agar	 plates)	 in	 100	mL	 PYG	medium	 and	 incubating	 for	 24h	 at	 37	 °C	 aerobically,	 with	 shaking.	 These	 conditions	resulted	 in	 growth	 of	 all	 bacterial	 cultures	 to	 stationary	 phase	 of	 their	 growth.	 The	bacterial	cultures	were	centrifuged	at	4000	×	g	at	4	°C	for	20	min.	The	supernatants	were	collected	and	filter	sterilized	using	0.22	μM	pore	size	membrane	filters.	
2.2.3	Cell	line	and	cell	culture	Human	 epithelial	 lung	 carcinoma	 (A549)	 cell	 line	 was	maintained	 in	 Dulbecco’s	modified	Eagle’s	medium	(DMEM)	supplemented	with	10	%	fetal	bovine	serum	(FCS),	1	%	nonessential	amino	acids.	A549	cell	line	was	provided	as	proliferating	cells	in	T-75	flask.	Cells	were	passaged	into	three	T-75	flasks	and	incubated	at	37	°C	in	humidified	95	%	air,	5	%	CO2.	Theoretically,	cells	become	confluent	within	2	days	(~3x106	cells).	All	passages	which	used	in	experiments	were	between	passage	numbers	7	to	13.		
2.2.3.1	Passage	cells	into	T-75	flasks	The	growth	medium	was	aspirated	off	from	the	confluent	flask.	Growing	cells	were	washed	off	with	phosphate-buffered	 saline	 (PBS)	once,	 and	 followed	by	adding	 into	 the	tissue	culture	 flask	1	mL	of	accutase	 to	detach	cells.	They	were	rocked	 for	1-2	minutes,	and	 then	 the	 flask	 was	 tapped.	 Once	 the	 cells	 detached	 from	 the	 tissue	 culture	 flask,	accutase	 was	 immediately	 inactivated	 by	 adding	 9	 mL	 of	 growth	 medium.	 The	 flask	contents	were	transferred	to	15	mL	centrifuge	tube.	The	sample	was	centrifuged	for	5	min	at	 300	 ×	 g.	 The	 supernatant	 was	 discarded	 and	 the	 pellet	 was	 re-suspended	 in	 warm	growth	 medium.	 In	 turn,	 suspended	 cells	 were	 passaged	 to	 three	 other	 flasks	 and	incubated	at	37	°C	in	humidified	95	%	air,	5	%	CO2	incubator.		
2.2.4	Association	assays	To	 determine	 the	 interaction	 of	 bacterial	 strains	 with	 the	 A549	 cell	 line	 and	
Acanthamoeba	 association	 assays	 were	 performed	 (Figure	 2.1).	 In	 brief,	 A549	 cells	 or	
Acanthamoeba	were	cultured	and	grown	in	96-well	plates	in	growth	medium	[DMEM	for	cell	 line	 and	PYG	 for	Acanthamoeba](~2×105	cells	 per	0.2	mL	 in	 each	well).	 Plates	were	incubated	 till	 confluence.	 Growth	 medium	 was	 discarded,	 and	 Roswell	 Park	 Memorial	Institute	medium	1640	(RPMI	1640)	(with	Stable	Glutamine	and	Phenol	Red)	was	added	for	 Acanthamoeba,	 DMEM	 for	 A549	 cell	 line.	 Bacterial	 strains	 (~2×106	CFU/well)	 were	
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added	onto	cells	with	medium	and	 incubated	 for	1h	at	room	temperature.	Supernatants	were	discarded	and	washed	with	PBS	once	to	remove	non-adherent	bacteria.	A549	cells	and	 Acanthamoeba	 were	 lysed	 by	 adding	 0.2	 mL	 Cell	 Lytic	 M	 for	 10	 and	 5	 min,	respectively.	 Finally,	 20	 µL	 of	 lysed	 solution	were	 cultured	 onto	 agar	 (CLED,	 blood	 and	chocolate),	and	incubated	overnight	at	37	°C	O2	incubator.		
2.2.5	Invasion	assays	Invasion	assays	were	performed	to	determine	the	ability	of	bacteria	to	invade	or	be	taken	 up	 by	 A549	 cell	 line	 or	 A.	 castellanii	 (Figure	 2.1).	 Briefly,	 A549	 cells	 or	
Acanthamoeba	were	grown	until	confluent	in	96-well	plates	as	described	above.	After	1h	of	 incubation,	 wells	 were	 washed	 with	 PBS,	 and	 then	 antibiotics	 were	 added	 to	 kill	extracellular	 bacteria	 (Vancomycin	 with	 final	 concentration	 of	 100	 µg/mL	 for	 45	 min	against	 MSSA,	 Str.	 pneumoniae	 and	 S.	 epidermidis	 and	 Ciprofloxacin	 with	 final	concentration	of	75	µg/mL	against	E.	coli,	P.	aeruginosa	and	H.	 influenzae	strains	 for	45	min).	Finally,	cells	were	lysed	and	bacteria	cultured	onto	agar.		
2.2.6	Intracellular	survival	assays	To	 determine	 the	 long-term	 fate	 of	 bacteria	 inside	 A549	 cells	 or	Acanthamoeba,	intracellular	 survival	 assays	 were	 performed	 (Figure	 2.1).	 Briefly,	 A549	 cells	 or	
Acanthamoeba	were	incubated	with	bacteria,	followed	by	the	addition	of	antibiotic	for	45	min,	as	described	above.	After	incubation,	wells	were	washed	with	PBS.	A549	cells	were	incubated	in	0.2	mL	of	DMEM,	while	Acanthamoeba	were	incubated	in	0.2	mL	RPMI	1640	for	24h	at	30	°C.	Finally,	cells	were	lysed	and	cultured	onto	agar	and	counted	the	number	of	bacteria	survived	inside	cells.		
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	Figure	2.1	Steps	of	bacterial	interaction	assays	(association,	invasion	and	survival)	with	host	cells	(A549	cell	line	and	Acanthamoeba).	
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2.2.7	Intracellular	localization	of	MSSA	and	P.	aeruginosa		To	visualize	MSSA	and	P.	aeruginosa	 inside	A.	castellanii	 and	A549	cell	 line,	Rose	Bengal	stain	was	used.	Briefly,	a	few	colonies	of	each	bacterium	were	inoculated	into	10	mL	LB	medium	and	incubated	at	37	°C	overnight.	Next	day,	bacteria	were	centrifuged	at	300	x	g	for	10	min	and	the	pellets	were	washed	twice	with	PBS.	Following	centrifugation	and	washing,	 the	 pellets	 were	 suspended	 in	 Rose	 Bengal	 (1	mM	 final	 concentration	 in	PBS)	and	incubated	at	37	°C	for	20	min.	After	incubation,	the	pellets	were	washed	three	times	with	PBS	and	bacterial	fluorescence	and	viability	were	verified	every	30	min	for	up	to	3	h.	The	bacterial	viability	was	determined	by	inoculation	onto	nutrient	agar	plates	and	examined	 under	 Nikon	 Optiphot	 fluorescence	 microscope.	 Next,	 106	 cells/mL	
Acanthamoeba	trophozoites	or	A549	cells	were	detached,	centrifuged	(300	x	g	for	3	min)	and	washed	twice	with	PBS.	Then,	10	000	bacteria	per	cell	were	added	in	a	final	volume	of	500	μL	RPMI-1640	medium	and	incubated	for	1h	at	30	°C	for	amoebae	and	37	°C	in	5	%	CO2	for	A549	cells.	Following	1h	of	co-culture,	cells	were	harvested	by	centrifugation	(300	x	g	 for	3	min)	and	pellets	were	re-suspended	in	100	nM	Lyso	Tracker	Green	(Molecular	Probes)	 for	 20	 min	 at	 30	 °C.	 Lyso	 Tracker	 Green	 stains	 acidic	 organelles	 green.	 Cell	suspensions	 with	 intracellular	 bacteria	 were	 pipetted	 on	 slides	 followed	 by	 coverslip	application	for	5	min	at	room	temperature	to	allow	the	infected	cells	to	settle	and	form	a	monolayer.	The	intracellular	localization	of	bacteria	was	assessed	using	the	fluorescence	microscope.		
2.2.8	Transmission	electron	microscopy	Images	were	 obtained	 in	 collaboration	with	 Dr.	Matthew	Hannah,	 Lead	 Electron	Microscopist	 in	 the	 Virus	 Reference	 Department	 of	 National	 Infection	 Service,	 Public	Health	England	in	London.	All	samples	were	prepared	in	Medical	Microbiology	laboratory,	School	 of	 Biological	 Sciences,	 Essex	 University.	 Afterwards,	 samples	 were	 taken	 to	 Dr.	Matthew	Hannah	for	getting	micrographs	using	Electron	Microscope.		Bacteria	were	centrifuged	(10	min	at	300	x	g)	and	washed	three	times.	The	pellets	obtained	were	fixed	in	2.5	%	glutaraldehyde	(v/v)	(in	0.1	M	sodium	cacodylate	buffer,	pH	=	7.2)	and	incubated	for	60	min	at	room	temperature.	Next,	the	samples	were	centrifuged	(10	min	at	300	x	g)	and	re-suspended	 in	0.1	M	sodium	cacodylate	buffer.	This	step	was	repeated	twice	to	remove	the	fixative	agent.	Then,	the	pellets	were	washed	again	in	0.1	M	sodium	cacodylate	buffer	as	mentioned	above	and	embedded	in	3	%	Nobel	agar	prior	to	
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being	cut	into	section	of	1-2	mm	cubes.	Bacteria	were	dehydrated	using	graded	series	of	ethanol.	Afterwards,	the	pellets	were	infiltrated	with	London	Resin	(LR)	white	resin	and	polymerized	 at	 67	 °C	 for	 24	 h.	 Sections	 of	 80-100	 nm	 were	 cut	 using	 a	 NOVA	ultramicrotone,	 stained	 with	 lead	 citrate	 for	 20	 min,	 rinsed	 with	 distilled	 water	 and	stained	with	uranyl	acetate	for	5	min.	After	drying,	the	grids	were	imaged	in	a	JEOL	JEM-1400	TEM	operating	at	120	kV.	Images	were	acquired	using	an	AMT	XR60	digital	camera.	
	
2.2.9	PCR-based	studies	for	capsular	gene	identification	
	
2.2.9.1	Identification	of	capsular	gene	bexB	in	H.	influenzae	The	 design	 of	 PCR	 primers	 (Table	 2.1)	 targeting	 a	 567-	 or	 760-bp	 region	 of	H.	
influenzae	bexB	was	based	on	sequence	data	available	in	GenBank.	Primers	targeting	bexA,	
pepN	(which	served	as	a	DNA	positive	control),	and	serotype-specific	capsule	genes	have	been	 described	 (McCrea	 et	al.,	 2010).	Whole-cell	 lysate,	 i.e.,	 crude	 lysate,	 served	 as	 the	DNA	template	source	for	PCRs.	It	was	prepared	by	suspending	several	bacterial	colonies,	from	a	 fresh	plate	 into	Tris-EDTA	 (TE;	pH	7.5),	 heating	 them	 for	10	min	at	100	 °C	 in	 a	thermocycler,	centrifuging	them	for	10	min.	Next,	the	supernatant	was	removed	and	the	rest	 was	 stored	 at	 −20	 °C	 until	 it	 was	 used	 for	 PCR.	 PCR	 was	 performed	 with	 Taq	polymerase.	Each	20	μL	PCR	mixture	consisted	of	1×	ThermoPol	reaction	buffer,	a	0.2	mM	concentration	 of	 each	 deoxynucleoside	 triphosphate	 (dNTP),	 a	 0.2	 μM	 concentration	 of	each	 primer,	 2.0	 U	 Taq,	 and	 1	 μL	 crude	 lysate	 (template).	 Reaction	 mixtures	 were	subjected	 to	an	 initial	denaturation	 step	of	2	min	at	95	 °C	 followed	by	30	amplification	cycles	of	95	°C	for	30	s,	54	°C	for	30	s,	and	72	°C	for	45	s.	Amplicons	were	separated	in	2	%	agarose	gels	in	1×	Tris-acetate-EDTA	(TAE)	buffer.	Gels	were	stained	with	Safeview	dye	(5	μL),	 and	 gel	 images	were	 recorded.	 The	 sizes	 of	 the	 PCR	products	were	 determined	by	comparison	with	the	molecular	size	standard	(1	Kb	DNA	ladder).	
2.2.9.2	Identification	of	capsular	gene	cpsA	in	Str.	pneumoniae	Pneumococcal	 isolates	were	 retrieved	 from	 storage	 by	 subculture	 on	 blood	 agar	plates	(blood	agar	base	supplement	with	5	%	sheep	blood)	and	incubated	overnight	at	37	°C	in	5	%	CO2.	Bacterial	cells	were	suspended	in	250	μL	of	TE	buffer	(10	mM	Tris-HCl,	1	mM	EDTA,	pH	8.0).	The	suspension	was	heated	at	100	°C	for	5	min	(Lawrence	et	al.,	2003)	
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and	 immediately	 frozen	 at	 −20	 °C	 for	 5	min.	 These	 lysates	were	 stored	 at	 −20	 °C	 until	further	 use.	 The	 PCRs	 were	 performed	 in	 25	 μL	 volumes,	 with	 each	 reaction	 mixture	containing	the	following:	1×	PCR	buffer	(Solution,	100	mM	Tris-HCl,	500	mM	KCl),	200	μM	of	each	deoxynucleoside	triphosphate,	2.5	mM	of	MgCl2,	2.0	U	of	Taq	DNA	polymerase,	and	primers	(Table	2.2).	Crude	extract	(2.5	μL)	was	used	as	the	DNA	template	for	each	PCR.	Thermal	cycling	was	performed	under	the	following	conditions:	94	°C	for	4	min	followed	by	30	amplification	cycles	of	94	°C	for	45	s,	54	°C	for	45	s,	and	65	°C	for	2	min	30	s. The	PCR	products	were	analyzed	by	gel	electrophoresis	on	2	%	agarose	gels	in	1×	TAE	buffer	(40	mM	Tris,	20	mM	of	glacial	acetic	acid,	1	mM	EDTA,	pH	8.0)	at	120	V	for	45	min.	Gels	were	stained	with	Safeview	dye	(5	μL),	and	gel	 images	were	taken.	The	sizes	of	the	PCR	products	were	determined	by	 comparison	with	 the	molecular	 size	 standard	 (1	Kb	DNA	ladder).	
2.2.10	Inhibition	of	Acanthamoeba	growth	by	bacterial	conditioned	media		To	 determine	 amoebistatic	 activity	 of	 BCM,	 A.	 castellanii	 trophozoites	 (105	amoebae/0.2	mL/well)	were	incubated	in	PYG	with	different	amounts	of	BCM	(in	96	well	plates	 at	 30	 °C	 for	 48	 h).	 After	 this	 incubation,	 amoebae	 were	 counted	 using	 a	haemocytometer.	In	controls,	A.	castellanii	trophozoites	were	incubated	in	PBS	and	in	PYG	.	
2.2.11	Amoebicidal	effects	of	bacterial	conditioned	media	For	 amoebicidal	 activity	 of	 BCM,	 A.	 castellanii	 trophozoites	 (106	 amoebae/0.2	mL/well)	were	incubated	in	PYG	with	different	amounts	of	BCM	in	96	well	plates	at	30	°C	for	48	h.	Amoebae	viability	was	determined	by	adding	0.1	%	Trypan	blue	and	number	of	live	 (non-stained)	 and	 dead	 (stained)	 A.	 castellanii	 were	 enumerated	 using	 a	haemocytometer.							
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Table	2.1	PCR	primers	used	for	H.	influenzae	capsule	identification	
Target	 Primer	 Primer	sequence	(5’	to	3’)	 Expected	
size	(bp)	
Reference	
bexB	 bexB.1F	 GGTGATTAACGCGTTGCTTATGCG	 567	 (Davis	et	al.,	2011)		 bexB.1R	 TTGTGCCTGTGCTGGAAGGTTATG	 	 		 bexB.FLF	 TCATTGTGGCTCAACTCCTTTACT	 760	 (Davis	et	al.,	2011)		 bexB.FLR	 AGCTATTCAAGGACGGGTGATTAACGC	 	 	
pepN	 pepN_F	 GATGGTCGCCATTGGGTGG	 918	 (Ecevit	et	al.,	2004)		 pepN_R	 GATCTGCGGTTGGCGGTGTGG	 	 	
	
	Table	2.2	PCR	primers	used	for	Str.	pneumoniae	capsule	identification	
Target	 Primer	 Primer	sequence	(5’	to	3’)	 Expected	
size	(bp)	
Reference	
cpsA	 cpsA-f	 GCAGTACAGCAGTTTGTTGGACTGACC	 160	 (Pai	et	al.,	2006)		 cpsA-r	 GAATATTTTCATTATCAGTCCCAGTC	 	 			
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2.2.12	Cytotoxic	effects	of	ACM	and	BCM	on	A549	cells.	The	 conditioned	media	 (100	μL)	or	PYG	medium	 (100	μL)	were	 added	 in	100	μL	RPMI-1640.	 Plates	 were	 incubated	 at	 37	 °C	 in	 a	 5	%	 CO2	incubator	 and	monitored	 for	monolayer	 disruptions	 over	 the	 period	 of	 24	h.	 After	 this	 incubation,	 the	 supernatants	were	 collected	 from	each	well,	 centrifuged	 to	 remove	cellular	debris	and	 then	cytotoxic	effects	 were	 determined	 by	 estimating	 the	 amount	 of	 lactate	 dehydrogenase	 released	from	 A549	 cells	 using	 a	 Cytotoxicity	 Detection	 kit	 (Roche	 Applied	 Sciences).	 The	cytotoxicity	percentage	was	calculated	as	follows:	%	cytotoxicity = (sample	value	–	control	value)	 /	 (total	 LDH	 release	 –	 control	 value)	 ×	 100	 (Khan,	 2007).	 Control	 values	 were	determined	 by	 incubating	 A549	 cells	 in	 RPMI	 1640	 alone	 and	 total	 LDH	 release	 was	obtained	by	completely	lysing	the	A549	cells	using	1	%	Triton	X-100.		
2.2.13	Bactericidal	effects	of	Acanthamoebic	conditioned	media	To	 determine	 the	 effects	 of	 ACM	 on	 bacteria,	 clinical	 isolates	 of	bacteria	were	 used.	Approximately	 106	colony	 forming	 units	 (suspended	 in	 20	 μL)	 were	 incubated	 with	180	μL	of	ACM	at	37	°C	for	18	h.	After	incubation,	cultures	were	serially	diluted	in	PBS	and	plated	 onto	 agar	 plates.	 Plates	 were	 incubated	 at	 37	 °C,	 overnight	 and	 bacterial	 C.F.U.	were	enumerated	 (Lee	et	al.,	 2011).	For	 controls,	bacteria	were	 incubated	 in	PYG	alone	and	PBS	alone.		
3.2.14	Presentation	of	results	and	statistical	analysis.	The	 results	 shown	 in	 this	 work	 are	 representative	 of	 three	 independent	experiments	 performed	 in	 triplicate	 by	 identical	methods.	 The	 results	 are	 expressed	 as	means	±	1	standard	deviation.	Differences	were	considered	statistically	significant	if	the	P	value	was	<0.05	by	Student's	t	test.	
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2.3.	Results	
2.3.1	Interaction	assays	Association	assays	were	performed	to	determine	the	ability	of	bacteria	employed	in	 these	experiments	 to	associate	with	 the	A549	cell	 line	and	A.	castellanii.	Our	 findings	show	that	H.	influenzae	strains	exhibited	the	least	association	with	both	A549	cells	and	A.	
castellanii,	(0,4	and	0,3	bacteria	per	host	cell,	respectively).	A	significant	association	with	
Acanthamoeba	was	 with	 MSSA,	 and	 for	 A549	 cell	 line	 with	 E.	 coli	 (control	 for	 Gram-negative	 bacteria)	 with	 indices	 of	 7	 and	 2.5	 bacteria	 per	 cell	 respectively.	 However	 S.	
epidermidis	(control	 for	Gram-positive	bacteria)	showed	a	similar	association	with	A549	cells,	 compared	 to	 pathogenic	Gram-positive	 bacteria	 (Figure	2.2).	 Association	 of	E.	coli	with	Acanthamoeba	was	significantly	higher	than	other	pathogenic	Gram-positive	bacteria	(one	 tail	 t-test	P<0.05).	 The	 number	 of	 associated	 bacteria	 per	Acanthamoeba	 was:	 1.5;	0.5;	2.9;	and	1.5	for	P.	aeruginosa;	Str.	pneumoniae;	E.	coli;	and	S.	epidermidis,	respectively.	And	associated	bacteria	per	A549	cell	was:	MSSA	1.2;	P.	aeruginosa	1.1;	Str.	pneumoniae	1.1;	and	S.	epidermidis	1.1.								
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	Figure	2.2	The	number	of	bacteria	associated	per	A549	cell	(a)	and	A.	castellanii.	(b).	Results	are	the	mean	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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To	define	whether	bacteria	entered	A549	cells	and	Acanthamoeba,	invasion	assays	were	 carried	 out.	 All	 bacterial	 strains	 could	 be	 recovered	 from	Acanthamoeba,	but	 not	from	 A549	 cells.	 From	 Acanthamoeba,	 MSSA,	 S.	 epidermidis,	 E.	 coli	 and	 P.	 aeruginosa	showed	 the	 highest	 recovery	 (1.99;	 1.43;	 1.18;	 and	 0.82	 bacteria	 per	 Acanthamoeba,	respectively)	compared	with	H.	influenzae	and	Str.	pneumoniae.	The	number	of	invaded	H.	
influenzae	 and	 Str.	 pneumoniae	 were	 0.02	 and	 0.01	 per	 Acanthamoeba.	 The	 highest	number	 of	 bacteria	 invading	 each	 A549	 cell	 was	 exhibited	 by	 E.	 coli	 1.84.	 MSSA,	 H.	
influenzae,	Str.	pneumoniae	and	S.	epidermidis	had	 lower	ability	of	recovery	with	 indices	0.409;	0.029;	0.002;	and	0.166	per	cell	(Figure	2.3).										
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 Figure	2.3	The	number	of	bacteria	invading	each	A549	cell	(a)	and	A.	castellanii.	(b).	Results	are	the	mean	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.			
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To	visualize	MSSA	and	P.	aeruginosa	inside	Acanthamoeba	and	A549	cells,	bacteria	were	 stained	 with	 Rose	 Bengal	 and	 Acanthamoeba	 with	 lysotracker.	 Following	 1h	 co-culture	at	a	multiplicity	of	infection	of	one	cell:	10	000	bacteria,	fluorescence	microscopy	showed	 that	 amoebae	 and	 A549	 cells	 were	 infected	 with	 MSSA	 or	 P.	 aeruginosa.	Microscopy	 showed	 that	 most	 of	 host	 cells	 contained	 bacteria	 within	 phagolysosomes.	Bacteria	 were	 able	 to	 invade	 or	 be	 engulfed	 by	 amoebae	 and	 A549	 cells	 (Figure	 2.4)	within	 1h	 of	 incubation	 and	 withstand	 acidic	 conditions.	 The	 infected	 A549	 cells	 and	amoebae	 also	 stain	 green	 throughout	 the	 cell	 suggesting	 that	 perhaps	 phagolysosomal	fusion	does	occur	before	the	bacterium	escapes	the	phagolysosome.																
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	 	 	 	Figure	 2.4	 Localization	 of	 bacteria	 within	 A549	 cell,	 and	 Acanthamoeba	 trophozoite.	 Fluorescence	microscopy	images	of	MSSA	in	A549	cell	(A-D);	MSSA	in	A.	castellanii	(E-H);	P.	aeruginosa	in	A549	cell	(I-L);	and	P.	aeruginosa	 in	A.	castellanii.	MSSA	(B,	F),	P.	aeruginosa	(J,	N)	are	stained	red,	and	acidic	vacuoles	are	stained	green	(C,	G,	K	&	O)	with	the	corresponding	overlay,	which	is	yellow/orange	(D,	H,	L	&	P).	Bar	=	10	μm.						
A	 B	 C	 D	
E	 F	 G	 H	
I	 J	 K	 L	
M	 N	 O	 P	
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To	determine	the	number	of	bacteria	inside	A549	cells	and	Acanthamoeba,	survival	assays	 were	 carried	 out,	 by	 incubating	 A549	 cells	 or	 Acanthamoeba,	 with	 internalized	bacteria,	 for	24	h.	Our	results	 indicated	 that	H.	influenzae	 and	Str.	pneumoniae	were	not	able	to	survive	and	multiply	 in	A549	cells	or	Acanthamoeba,	while	P.	aeruginosa	did	not	survive	 in	A549	cells.	The	number	of	MSSA,	E.	coli	 and	S.	epidermidis	per	A549	cell	was	3.7;	 2.9;	 and	 3.9	 respectively.	 Interestingly,	 the	 number	 of	 bacteria	 inside	 each	
Acanthamoeba	for	MSSA,	P.	aeruginosa,	E.	coli	and	S.	epidermidis	was	967,	1390,	753	and	1553	respectively	(Figure	2.5).				
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 Figure	 2.5	 The	 number	 of	 bacteria	 surviving	 inside	 A549	 cells	 (a)	 and	 A.	 castellanii	 (b)	 after	 24	 h	 of	incubation.	 	 Results	 are	 the	mean	 of	 three	 autonomous	 experiments	 carried	 out	 in	 duplicate.	 Error	 bars	symbolize	standard	error.	
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To	 determine	 if	 low	 survival	 of	 Str.	 pneumoniae	 and	H.	 influenzae	 was	 due	 to	 capsule	presence,	 Electron	 Microscopy	 studies	 were	 carried	 out.	 Electron	 micrographs	demonstrated	capsular	polysaccharides	(Figure	2.6).	
 
 
 Figure	 2.6	 Identification	 of	 bacterial	 capsules	 by	 Electron	 Microscopy.	 Electron	 micrographs	 of	 Str.	
pneumoniae	(a);	and	H.	influenzae	(b).	Black	arrows	indicate	polysaccharide	capsules.	Bars,	200	nm.	
 
a)	
				b)	
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To	 further	 analyse	 if	 Str.	pneumoniae	 and	H.	 influenzae	 are	 encapsulated	 PCR-based	studies	were	 carried	 out.	 Capsular	 gene	 loci	were	 targeted	 in	 both	 bacterial	 genotypes.	Results	 revealed	 the	presence	of	 capsular	genes	 (Figure	2.7	 for	Str.	pneumoniae	 and	2.8	for	H.	influenzae).	
	
	
	
	
	
	
	
	
	
Figure	 2.7	Molecular	 identification	 of	 Str.	pneumoniae	 capsules	 by	 detection	 of	 cpsA	 gene.	 Lane	M,	 1	 kbp	ladder;	 Lane	 1,	 Control	 strain	 (Str.	 pneumoniae	 ATCC6305);	 Lane	 2,	 alpha-hemolytic	 isolate	 detected	 as	encapsulated	S.pneumoniae.	
	
	
	
	
	
	
	
	
Figure	2.8	Molecular	 identification	of	H.	influenzae	 capsules	by	detection	of	bexB	 gene.	Lane	M,	1	kbp	ladder;	Lane	1,	Primer	(pep_N)	targeting	pepN	gene	(which	served	as	a	DNA	positive	control);	Lane	2,	Primer	(bexB.1)	targeting	bexB	gene;	Lane	3,	Primer	(bexB.FL)	targeting	bexB	gene.	
						M	 												1													2	
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2.3.2	Inhibition	of	Acanthamoeba	growth	by	bacterial	conditioned	media	Among	the	various	bacterial	 isolates	 investigated,	Str.	pneumoniae,	P.	aeruginosa	and	
H.	 influenzae	BCM	 inhibited	Acanthamoeba	 growth	 (75	%,	82	%	and	80	%	amoebistatic	effects	 respectively).	 To	 identify	 whether	 amoebistatic	 effects	 of	 BCM	were	 because	 of	nutrient-depletion,	 A.	 castellanii	 trophozoites	 (105	 amoebae	 in	 100	 μL	 PYG)	 were	incubated	with	100	μL	of	PBS	in	a	1:1	ratio.	The	results	showed	amoebae	growth	profiles,	in	50	%	PBS,	similar	to	amoebae	incubated	in	neat	PYG	(Figure	2.9).										
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	Figure	 2.9	 Amoebastatic	 activities	 of	 bacterial	 conditioned	 media.	 Results	 are	 the	 mean	 of	 three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
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Among	 other	 bacteria,	 BCM	 of	 MSSA,	 S.	 epidermidis	 and	 E.	 coli	 also	 inhibited	 A.	
castellanii	 growth	 (35	%,	16	%	and	18	%	amoebistatic	effects	 respectively).	 In	order	 to	address	the	possibility	of	conversion	of	Acanthamoeba	trophozoites	into	cysts	after	BCM	treatment,	BCM-treated	Acanthamoeba	 trophozoites	were	 incubated	with	0.5	%	SDS	 for	10	min,	which	is	known	to	selectively	lyse	trophozoites.	Post-SDS	treatment,	none	of	the	BCM-treated	Acanthamoeba	exhibited	 cyst	 presence.	 To	 identify	 the	 activity	 of	 BCM	of	bacteria	employed	in	this	study,	additionally	25	%	diluted	BCM	was	prepared	and	used	against	A.	castellanii.	The	results	demonstrated	that	BCM	of	Str.	pneumoniae,	P.	aeruginosa	and	 H.	 influenzae	 exhibited	 amoebistatic	 effects	 in	 a	 concentration-dependent	 manner	(Figure	2.10).		
2.3.3	Amoebicidal	effects	of	bacterial	conditioned	media	Diluted	 at	 1/2	 (50	 %	 concentration),	 Str.	 pneumoniae,	 P.	 aeruginosa	 and	 H.	
influenzae	 BCM	 were	 ineffective	 against	 A.	 castellanii	 viability	 (0.3	 %,	 0.8	 and	 0.7	 %	amoebicidal	 effect	 respectively),	while	 undiluted	 (at	 100	%	 concentration),	 BCM	 of	 Str.	
pneumoniae,	 P.	 aeruginosa	 and	 H.	 influenzae	 displayed	 more	 than	 90	 %	 amoebicidal	effects	(Figure	2.11).								
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	Figure	 2.10	 Amoebastatic	 activities	 of	 bacterial	 conditioned	 media.	 Results	 are	 the	 mean	 of	 three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.			
	Figure	2.11	Amoebicidal	activities	of	bacterial	conditioned	media.	Green	bars	indicate	the	total	number	of	Acanthamoeba	in	PYG	only.	The	orange	bars	represent	the	number	of	dead	Acanthamoeba	in	various	dilutions	of	BCM	(50	%	diluted	and	non-diluted	BCM)	with	either	PYG	or	PBS.	Results	are	the	mean	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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2.3.4	Cytotoxic	effects	of	Acanthamoebic	and	bacterial	conditioned	media	on	A549	
cells.	Cytotoxicity	assays	were	performed	to	define	the	activities	of	the	Acanthamoebic	and	bacterial	 (MSSA,	 S.	 epidermidis,	 Str.	 pneumoniae,	E.	 coli,	P.	 aeruginosa	and	H.	 influenzae)	conditioned	 media	 on	 A549	 cells.	 Neither	ACM	 nor	BCM	 exhibited	 significant	 host	 cell	cytotoxicity	(9.3	%,	5.3	%,	4.5	%,	6.2	%,	9	%,	6.5	%	and	7.1	%	host	cell	death	respectively).	As	BCM	was	prepared	using	PYG,	similar	volumes	of	PYG	alone	(100	μL)	were	 tested	as	controls.	The	results	showed	that	PYG	alone	exhibited	no	cytotoxicity	on	A549	cells	(	1.2	%)	(Figure	2.12).	
2.3.5	Bactericidal	effects	of	Acanthamoebic	conditioned	media	Among	the	various	bacterial	strains	investigated,	ACM	inhibited	100	%	growth	of	Str.	
pneumoniae	 and	 slight	 bactericidal	 effects	 against	 MSSA,	 S.	 epidermidis,	 E.	 coli,	 P.	
aeruginosa	 and	 H.	 influenzae	 (10.6	 %,	 3.4	 %,	 6.1	 %,	 11.1	 %	 and	 2.5	 %,	 respectively)	(Figure	2.13).										
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 Figure	2.12	Cytotoxic	effects	of	Acanthamoebic	and	bacterial	conditioned	media	on	A549	cells.	Results	are	the	mean	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
 Figure	2.13	Bactericidal	activities	of	Acanthamoebic	 conditioned	media.	Results	are	 the	mean	of	 three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
	
	
	
0.0	1.0	
2.0	3.0	
4.0	5.0	
6.0	7.0	
8.0	9.0	
10.0	
A.castellanii	 S.epidermidis	 Str.pneumoniae	 E.coli	 P.aeruginosa	 H.in7luenzae	 MSSA	
Cy
to
to
xi
ci
ty
	p
er
ce
nt
ag
e	
(%
)	
Conditioned	media		
Cytotoxic	effects	of	Acanthamoebic	and	Bacterial	conditioned	media		
on	A549	cells	
0.0	10.0	
20.0	30.0	
40.0	50.0	
60.0	70.0	
80.0	90.0	
100.0	
MSSA	 S.epidermidis	 Str.pneumoniae	 E.coli	 P.aeruginosae	 H.	in8luenzae	
Ba
ct
er
ia
l	k
ill
	p
er
ce
nt
ag
e	
(%
)	
Bacterial	strains	
Bactericidal	activities	of	Acanthamoebic	conditioned	media	
 84 
2.4.	Discussion	It	is	well	known	that	several	species	of	bacterial	pathogens	are	associated	with	CF	and	 that	 they	 are	 major	 causes	 of	 morbidity	 and	 mortality	 among	 patients.	 However,	knowledge	of	pathogenesis	and	pathophysiology	of	these	infections	as	well	as	the	number	of	 effective	 treatments	 remain	 insufficient.	 A	 fundamental	 question	 is	 how	 bacteria	interact	with	epithelial	cells	of	the	respiratory	tract,	causing	at	the	same	time	infections.	Moreover,	 the	 presence	 of	 Acanthamoeba	 in	 the	 respiratory	 tract	 could	 contribute	 in	exacerbation	 of	 pulmonary	 infections.	 For	 this	 reason,	 in	 this	 project,	 human	 epithelial	lung	 carcinoma	 (A549)	 cell	 line,	 Acanthamoeba	 trophozoites	 and	 six	 types	 of	 bacteria	(pathogenic	 MSSA,	 H.	 influenzae,	 Str.	 pneumoniae,	 P.	 aeruginosa,	 nonpathogenic	 S.	
epidermidis	 and	 E.	 coli)	 isolated	 from	 CF	 patients	 were	 studied.	 To	 identify	 if	 bacteria	interact	with	A549	cells	or	Acanthamoeba,	interaction	assays	were	carried	out.	The	results	clearly	showed	that	all	bacteria	used	have	the	ability	to	associate	with	host	cells.	However,	
H.	 influenzae	and	Str.	pneumoniae	exhibited	 very	 low	 ability	 to	 invade	 and	 no	 ability	 to	survive	within	A549	cells	and	Acanthamoeba	trophozoites.		
In	 vitro	 interaction	 assays	 showed	 that,	 S.	 aureus	 and	 P.	 aeruginosa	possess	 the	capability	 to	 adhere,	 invade	 and	 survive	 within	 epithelial	 cells	 (Ichikawa	 et	 al.,	 2000).	Virulence	factors	of	S.	aureus,	such	as	protein	A,	elastin-binding	protein,	collagen-binding	protein,	 fibronectin-binding	protein	and	 clumping	 factor,	are	associated	with	adherence	and	invasion	of	epithelial	cells	(Gordon	&	Lowy,	2008).	Pili	and	LPS	of	P.	aeruginosa	have	a	role	 in	binding	 to	and	 invading	epithelial	 cells	 (Ben	Haj	Khalifa	et	al.).	Several	 lines	of	evidence	have	 indicated	 that	amoeba	 serve	as	 a	host	 to	 a	number	of	human	pathogens,	including	Mycobacterium	avium	(Steinert	et	al.,	1998),	Legionella	pneumophila	(Kilvington	&	Price,	 1990),	Escherichia	coli	(Alsam	 et	al.,	 2006),	Enterobacter	aerogenes,	Aeromonas	
hydrophila	 (Yousuf	et	al.,	2013),	P.	aeruginosa	(Michel	et	al.,	1995)	and	MRSA	(Cardas	et	
al.,	2012a)	and	are	able	 to	accommodate	bacterial	 intracellular	replication	and	augment	their	virulence	properties	pertinent	to	susceptible	hosts	(Abd	et	al.,	2010).		Although	 a	 lot	 is	 known	 about	 bacterial	 strains	 employed	 in	 this	 project,	performing	further	characterization	assays	could	help	to	conduct	broader	investigations.		As	 it	 has	 been	 shown	 in	 this	 project,	 Acanthamoeba	 takes	 up	 bacteria	 through	phagocytosis,	and	employs	phagolysosomes	 for	 lysing.	Although	Acanthamoeba	feeds	on	
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both	 Gram-positive	 and	 Gram-negative	 bacteria,	 they	 prefer	 Gram-negative	 bacteria,	which	are	widely	used	as	a	food	source	to	isolate	Acanthamoeba	(Khan,	2006).	Proteases	produced	 by	 Acanthamoeba	 are	 used	 as	 significant	 markers	 to	 differentiate	 between	pathogenic	 and	non-pathogenic	Acanthamoeba	species	 (Khan	et	al.,	 2000;	 Sissons	et	al.,	2006;	 Dudley	 et	 al.,	 2008).	 Acanthamoeba	proteases	 have	 antimicrobial	 effects	 against	different	 types	 of	 bacteria	 including	 MRSA	 and	 P.	 aeruginosa	 (Iqbal	 et	 al.,	 2014).	 Our	findings	indicate	that	Acanthamoeba	(genotype	T4),	was	able	to	host	S.	epidermidis,	MSSA,	
E.	coli	and	P.	aeruginosa.	This	is	interesting	as	this	could	play	role	in	infections	associated	with	CF.	Moreover,	bacteria	can	remain	and	multiply	inside	Acanthamoeba	within	a	harsh	environment,	where	they	can	turn	to	cysts	that	may	help	transmit	bacterial	pathogens	to	susceptible	hosts	and	also	to	cause	reinfection.		Using	PCR	method	in	present	study	it	was	demonstrated	that	Str.	pneumoniae	and	
H.	 influenzae	 are	 encapsulated.	 Bacterial	 capsules	 play	 important	 roles	 in	 virulence,	including	preventing	phagocytosis	 (Merino	&	Tomás,	 2015).	Thus,	H.	 influenzae	 capsule	inhibits	ingestion	by	macrophages	(Noel	et	al.,	1992).	Encapsulated	H.	influenzae	are	more	virulent	than	non-encapsulated	H.	influenzae	(NTHi)	strains	(Hallström	&	Riesbeck,	2010).		Data	 obtained	 in	 a	 recent	 study	 have	 shown	 that	 non-encapsulated	 Str.	 pneumoniae	 is	susceptible	to	phagocytosis	by	neutrophils,	whereas	polysaccharide	capsules	were	able	to	inhibit	 complement	 activity,	which	 resulted	 in	 resistance	 to	 phagocytosis	 (Hyams	et	al.,	2010).	 Current	 project	 demonstrated	 that	 the	 outcome	 of	 bacteria	 interactions	 with	A.	
castellanii	and	an	epithelial	cell	line,	are	related	to	the	virulence	of	bacteria.		The	existence	of	antimicrobial	substances	in	microorganisms	is	not	an	unusual	fact	and	 they	 are	 accepted	 to	 be	 an	 ancient	 defence	 system	 contrary	 to	 the	 progression	 of	other	microorganisms.	From	the	time	when	penicillin	was	discovered	in	nature	produced	by	mould,	Penicillium	in	1928	(Fleming,	1946),	a	great	quantity	of	microorganisms	have	been	checked	for	the	isolation	of	hypothetically	advantageous	antimicrobials,	while	there	has	 been	 effort	 in	 searching	 for	 new	antibiotics	 from	other	 sources	 like	Actinomycetes,	cyanobacteria	 and	 uncultivable	 bacteria,	 in	 addition	 to	 acknowledged	 sources	 like	Streptomycetes	 (Iqbal	 et	 al.,	 2014).	 The	 capability	 of	 bacteria	 to	 prosper	 at	 high	population	masses	and	the	predatory	role	of	Acanthamoeba	in	the	regulation	of	bacterial	populations	 in	 the	 ecosystem	 as	 well	 as	 the	 capability	 of	 the	 amoeba	 to	 perform	 as	 a	“Trojan	 horse”	 of	 the	 microbial	 world	 suggests	 that	 bacteria-amoeba	 are	 involved	 in	
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complex	 communications	 (Jousset	 et	 al.,	 2010).	 The	 exact	 nature	 of	 such	 complicated	interactions	 remains	 unclear,	 but	 it	 is	 identified	 in	 this	 project	 that	 both	 bacteria	 and	amoebae	 are	 competent	 to	 counter-attack	 one	 another	 and	 the	 overwhelming	 micro	organismal	 populations	 by	 discharging	 antimicrobial	 substances.	 Among	 six	 bacteria	tested,	it	is	attention-grabbing	that	ACM	exhibited	selective	and	effective	activity	against	
Str.	 pneumoniae,	 which	 is	 a	 pathogen	 of	 acute	 infections,	 many	 of	 which	 may	 possess	strong	 epidemiological	 consequences,	 such	 as	meningitis,	 otitis	media,	 pneumonia,	 and	sinusitis.	 Simultaneously,	 some	 clones	 of	 Str.	 pneumoniae	may	 be	 implicated	 in	 initial	stages	 of	 lung	 inflammation	 in	 CF	 patients	 (Rosenfeld	 et	 al.,	 2003).	 It	 is	 possible	that	bacteria	 resistant	 to	 ACM	and	 Acanthamoeba	are	 involved	 in	 multipart	communications	 where	 the	 bacteria	 develop	mechanisms	 to	 safeguard	 themselves	 and	stand	amoebic	attack	(Pantosti	&	Venditti,	2009).	Yet	to	come	are	projects	where	ACM	will	be	 investigated	 against	 a	 great	 panel	 of	 various	 bacterial	 pathogens	 to	 define	 broad-spectrum	 or	 species-specific	 antibacterial	 characteristics.	 The	 detection	 of	 antibacterial	compounds	 from	Acanthamoeba	will	 perhaps	 lead	 to	 ideas	 for	 future	 investigations	 in	other	 free-living	 protists	 as	 a	 prospective	 source	 of	 antibiotics	 for	 the	 treatment	 of	bacterial	 pathogens.	 Due	 to	 emerging	 tendencies	 in	 antibiotic	 resistance	 in	 various	pathogenic	bacteria	(Alanis,	2005),	the	current	findings	in	this	study	show	some	promise	in	our	future	ability	to	fight	infections	caused	by	bacteria.		Among	various	bacterial	strains	studied,	BCM	of	Str.	pneumoniae,	P.	aeruginosa	and	
H.	 influenzae	 displayed	 quantifiable	 amoebistatic	 and	 amoebicidal	 activities.	 Future	investigations	 will	 determine	 the	 fact	 of	 whether	 these	 BCM	 possess	 selective	 effects	on	Acanthamoeba	or	 possess	 broad-spectrum	 activities	 on	 diverse	 protist	 pathogens.	Amazingly,	neither	ACM	nor	BCM	were	significantly	cytotoxic	to	adenocarcinomic	human	alveolar	basal	epithelial	cells	in	vitro.		The	current	findings	are	encouraging	in	our	pursuit	to	find	complementary	sources	of	 antimicrobials	 with	 novel	 modes	 of	 action	 to	 challenge	 this	 threat.	 As	 antimicrobial	resistance	of	pathogens	 rises,	discovery	of	novel	non-toxic	 to	human	cells	 antimicrobial	substances	from	a	range	of	pathogens	ubiquitous	in	clinical	settings	is	fundamental.	It	 is	expected	 that	 these	 molecules	 will	 sooner	 or	 later	 be	 technologically	 advanced	 into	treatments	 for	 bacterial	 and	 amoebic	 infections,	 which	 are	 progressively	 resistant	 to	presently	existing	drugs.	
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“Effects	of	magainin	II	on	Acanthamoeba	and	bacteria		
in	both	extracellular	and	intracellular	conditions”	
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3.1	Background	Despite	 aggressive	 antimicrobial	 therapies,	 respiratory	 pathogens	 such	 as	 S.	
aureus,	 H.	 influenzae	 and	 P.	 aeruginosa	 persist	 in	 the	 lung,	 underpinning	 the	 chronic	inflammation	 and	 eventual	 lung	 decline	 that	 are	 characteristics	 of	 respiratory	 disease	among	 CF	 patients	 (Reen	 et	 al.,	 2016).	 Moreover,	 emerging	 multidrug-resistant	 CF	pathogens	contribute	to	this	concerning	scenario	(López-Causapé	et	al.,	2015).	Therefore,	there	 is	 an	urgent	 need	 to	 develop	new	 therapies	 to	 overcome	 the	drug	 resistance	 and	eradicate	pathogenic	bacteria.	Drug	combinations	have	been	broadly	used	to	overcome	drug	resistance	and	treat	complicated	 infectious	diseases	(Chen	et	al.,	2016).	Drug	combinational	 treatment	could	inhibit	new	multiple	 targets	and	consequently	provide	 the	opportunity	 for	surmounting	drug	 resistance	 of	 infectious	 bacteria	 (Zimmermann	 et	 al.,	 2007).	 The	 prospective	molecular	 mechanism	 underlying	 this	 is	 that	 biological	 systems	 are	 less	 capable	 of	compensating	for	the	simultaneous	activity	of	two	or	more	drugs	(Levy	&	Marshall,	2004).	There	 is	 growing	 interest	 over	 the	 development	 of	 synergistic	 drug	 combinations	 in	academia	and	the	pharmaceutical	industry	(Iwata	et	al.,	2015).	The	use	of	synergistic	drug	combinations	 can	 increase	 treatment	 efficacy	 and	 decrease	 drug	 dosage	 to	 prevent	toxicity.	Additionally,	“off-target”	effects	could	be	overcome	by	drug	combinations	(Lehár	
et	 al.,	 2009).	 These	 advantages	 have	 progressively	 attracted	 researchers	 towards	 the	search	for	safe	and	effective	combinatorial	drugs	(Jansen	et	al.,	2009).		
3.1.1	Cationic	antimicrobial	peptides	(AMPs)	Cationic	antimicrobial	peptides	which	target	the	microbial	membrane	directly	have	long	been	a	favorable	treatment	alternative	(Easton	et	al.,	2009)	for	direct	use,	or	for	use	in	 combination	 with	 other	 antimicrobial	 agents.	 However,	 their	 potential	 is	 still	predominantly	 not	 understood.	 The	 potential	 advantages	 of	 membrane	 permeabilizing	antimicrobial	 peptides	 are	 important.	 It	 was	 demonstrated	 that	 antimicrobial	 peptide,	pleurocidin	 (Mason	et	al.,	 2006a),	 and	designed	 cationic	 helical	 peptides	 (Mason,	 2005;	Mason	et	al.,	2006b)	cause	strong	reductions	 in	 lipid	acyl	chain	order	 in	 the	anionic	but	not	the	zwitterionic	lipid	component	in	mixed	membranes,	specifying	that	the	peptide	has	a	 strong	effect	on	 the	 lipids	 related	 to	 it	but	not	on	other	 lipids	 in	 the	membrane.	They	have	broad-spectrum	antibacterial	potency	against	number	of	Gram-negative	and	Gram-
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positive	 bacteria,	 in	 vitro,	 including	 drug-resistant	 strains	 (Huang	 et	 al.,	2012)	and	(Wiradharma	 et	 al.,	 2011).	 Moreover,	 resistance	 to	 AMPs	 is	 rare	 and	 is	 not	easily	selectable	or	inducible	(Pollard	et	al.,	2012)	and	(Daniels,	2011),	unlike	the	case	for	majority	 of	 chemical	 antibiotics.	 It	 could	 be	 because	AMPs	 act	 on	 bacterial	membranes	comprehensively,	 and	not	with	 a	 particular	macromolecular	 component	 of	 the	 cell.	 The	necessity	 for	 bacteria	 to	 adjust	 the	 architecture	 of	 the	 entire	 membrane	 to	 achieve	resistance	likely	increases	the	overall	fitness	cost.		At	 present	 multidrug	 combinations	 are	 occasionally	 used	 for	 the	 treatment	 of	routine	bacterial	 infections	(Tängdén,	2014)	as	well	as	tuberculosis	(Zumla	et	al.,	2014).	Therefore	 it	 is	 rational	 to	 propose	 a	 combination	 therapy	 utilizing	 AMPs	 and	 chemical	antibiotics	since	the	mechanism	of	action	of	membrane	permeabilising	cationic	peptides	is	 dramatically	 different	 from	 the	 chemical	 antibiotics.	 It	 has	 been	 documented	 in	 the	literature	 that	 AMPs	 could	 synergise	 with	 antibiotics	 increasing	 the	 permeability	 of	bacterial	membranes	 (Giacometti	et	al.,	2000a).	According	 to	another	study	AMPs	could	enhance	the	activity	of	bacterial	murein	hydrolases	(LeBel	et	al.,	2013)	or	other	enzymes	which	decrease	the	 integrity	of	 the	peptidoglycan	 layer,	allowing	antibiotics	to	act	more	effectively.			
3.1.1.1	Magainin	II	Magainin	 II	 is	 an	 antimicrobial	 cationic	 peptide	 glycine	 serine	 (Giovannini	 et	al.,	1987),	which	consists	of	23	amino	acids	(GIGKFLHSAKKFGKAFVGEIMNS).	It	was	isolated	from	the	skin	of	the	African	clawed	frog	Xenopus	laevis	(Zasloff,	1987).	It	is	believed	that	peptides	are	secreted	 into	the	skin	mucus	 following	discharge	of	 the	contents	of	dermal	granular	glands,	where	it	serves	as	a	first	line	of	defense	against	potential	pathogens	that	may	 be	 present	 at	 the	 skin	 surface	 of	 amphibia	 (Rollins-Smith,	 2009).	 Magainin	 II	 is	representative	 of	 a	 large	 family	 of	 amphibian	 amphipathic	 α-helical	 antimicrobial	peptides.	Magainin	was	reported	to	possess	antimicrobial	potency	against	Gram-positive	and	Gram-negative	bacteria	(Sai	et	al.,	1995).	The	in	vitro	activity	of	magainin	II	alone	and	in	 combination	 with	 clinically	 used	 antibiotics	 was	 investigated	 against	 multidrug-resistant	 bacterial	 strains.	 Synergy	 occurred	 when	 magainin	 II	 was	 combined	 with	 β-lactam	antibiotics	 (Giacometti	et	al.,	 2000b).	 In	 another	 study,	magainin	 in	 combination	with	silver	nitrate	showed	synergistic	effects	against	Acanthamoeba	polyphaga	(Schuster	&	Jacob,	1992a).		
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In	AMP	databases,	more	than	100	AMPs	have	been	described	as	having	prospective	anti-tumor	activity	(Wang	&	Wang,	2004).	AMPs	are	able	to	provoke	death	in	cancer	cells	through	two	common	mechanisms:	apoptosis	or	necrosis.	A	necrotic	death	pathway	could	be	the	outcome	of	AMPs	targeting	negatively	charged	molecules	on	the	cell	membrane	of	cancerous	 cells,	 resulting	 in	 cell	 lysis,	 whereas	 apoptosis	 could	 be	 the	 consequence	 of	mitochondrial	membrane	disarrangement	(Boohaker	et	al.,	2012).		In	this	study	the	in	vitro	activity	of	magainin	II	alone	and	in	combination	with	three	clinically	 used	 antimicrobial	 agents	 against	 bacteria	 (MSSA,	 S.	 epidermidis,	 E.	 coli,	 P.	
aeruginosa	and	H.	influenzae),	A.	castellanii	trophozoites	and	human	lung	adenocarcinoma	cell	line	was	investigated.																								
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3.2	Materials	and	Methods	All	chemicals	were	purchased	from	Sigma-Aldrich	(UK),	unless	otherwise	stated.	
	
3.2.1	Acanthamoeba	culture	
Acanthamoeba	(T4	genotype)	were	grown	and	cultured	as	described	in	section	2.2.1.		
	
3.2.2	Bacterial	cultures		Six	clinical	bacterial	strains	were	employed	(MSSA,	Str.	pneuminae,	S.	epidermidis,	
P.	aeruginosa,	H.	influenzae	and	E.	coli).	All	 strains	were	cultured,	 inoculated	and	optical	densities	(OD)	were	measured	by	spectrophotometer	as	described	in	section	2.2.2.		
	
3.2.3	Cell	line	and	cell	culture	Human	 epithelial	 lung	 carcinoma	 (A549)	 cell	 line	 was	 grown	 and	 cultured	 as	described	in	section	2.2.3.			
3.2.4	Preparation	of	antimicrobial	agents	Antimicrobial	agents	such	as	magainin	 II,	 silver	nitrate	 (AgNO3),	vancomycin	and	ciprofloxacin	were	utilized	in	this	study.		Magainin	 II	 with	 95	%	 purity	 and	molecular	mass	 of	 2.467	 kDa,	 was	 purchased	from	Cambridge	Bioscience	as	a	powder.	The	solutions	for	this	peptide	were	prepared	by	dissolving	powder	in	distilled	water.	Antimicrobial	activities	of	magainin	II	(with	different	concentrations	 and	 time	 intervals)	 were	 tested	 against	 Acanthamoeba	 trophozoites,	bacteria	outside	and	inside	Acanthamoeba	and	A549	cells.	In	parallel,	cytotoxic	effects	on	the	A549	cell	line	were	studied.	Silver	nitrate	(AgNO3)	is	0.170	kDa	in	mass	and	with	≥	99	%	purity,	was	dissolved	in	 distilled	 water.	 Tested	 against	 Acanthamoeba	 trophozoites,	 A549	 cell	 line	 and	intracellular	 bacteria	 (alone	 and	 in	 combination	 with	 magainin	 II,	 vancomycin	 and	ciprofloxacin).	Vancomycin	molecular	mass	is	1.486	kDa.	The	solution	was	prepared	by	dissolving	in	 sterile	 distilled	 water	 (100	 μg/mL).	 It	 was	 used	 in	 drug	 combination	 experiments	against	Gram-positive	bacteria	inside	Acanthamoeba	trophozoites	and	A549	cells.		
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Ciprofloxacin	antibiotic	is	0.331	kDa	compound.	Stock	solutions	were	prepared	by	dissolving	 antibiotic	 powder	 in	 distilled	 water	 (75	 μg/mL).	 It	 was	 utilized	 in	combinatorial	drug	experiments	with	magainin	II	and	AgNO3	against	 intracellular	Gram-negative	bacteria.	All	solutions	were	filter	sterilized	using	a	0.2	µm	filter.	Stocks	were	kept	in	-20	°C.	The	chemical	structures	of	compounds	are	shown	(Figure	3.1).																
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	Figure	3.1	Chemical	structure	of	vancomycin	(a);	ciprofloxacin	(b);	silver	nitrate	(c);	and	magainin	II	(d).												
	
a)	
	b)	 c)	
d)	
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3.2.5	Antimicrobial	assays	
3.2.5.1	Antibacterial	assays	To	determine	the	antimicrobial	activity	of	magainin	II	 to	 inhibit	bacterial	growth,	antimicrobial	 assays	 were	 performed.	 Bacterial	 strains	 were	 grown	 in	 their	 media	(LB/BHI/BHI+FE)	overnight	at	37	°C.	Then	ODs	were	measured	by	spectrophotometer	as	described	 above.	 96-well	 plates	 were	 used	 to	 perform	 these	 assays.	 Bacteria	 (~1x106	CFU/well)	were	incubated	with	different	concentrations	of	magainin	II	for	2,	4,	6	and	24	h	at	 37	 °C.	 Wells	 with	 untreated	 bacteria	 were	 used	 as	 controls.	 The	 number	 of	 viable	bacteria	 in	each	well	was	determined	by	plating	onto	CLED/Blood/Chocolate	agar	using	20	μL	volumes	in	duplicate.	The	percentage	of	bacterial	killing	was	calculated	as	follows:		
	where	R	is	the	bactericidal	rate,	X0	the	number	of	bacteria	without	magainin	II	(control),	and	Xt	the	number	of	bacteria	after	the	treatment	with	magainin	II	(Qiu	et	al.,	2011).		
3.2.5.2	Antiamoebic	assays	To	 determine	 the	 antimicrobial	 activity	 of	 the	 magainin	 II	 on	 Acanthamoeba,	antiamoebic	assays	were	performed.	Acanthamoeba	were	cultured	and	grown	in	96-well	plates	in	PYG	(~1x105	cells	per	0.150	ml	in	each	well);	next,	plates	were	incubated	until	confluent.	Then,	 the	growth	medium	was	discarded	and	wells	washed	with	PBS	once	 to	remove	non-adherent	Acanthamoeba.	Four	different	final	concentrations	of	magainin	II	(3,	10,	 20	 and	 30	 μM)	 were	 added	 to	 different	 wells.	 All	 wells	 contained	 150	 μL	 of	antimicrobial	agent	in	RPMI,	except	wells	of	controls	that	contained	only	150	μL	of	RPMI.	Then	Acanthamoeba	with	magainin	 II	were	 incubated	at	30	 °C	 for	2,	4,	6	and	24	h.	The	number	of	viable	and	dead	Acanthamoeba	in	each	well	was	determined	by	adding	150	μL	of	 0.4%	 Trypan	 blue	 in	 each	well	 on	 top	 of	media	 and	 incubating	 for	 15	min	 at	 room	temperature.	The	numbers	of	viable	and	dead	Acanthamoeba,	as	judged	by	dye	exclusion	or	staining,	were	counted	by	a	haemocytometer.				
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3.2.5.3	Cytotoxicity	assays		To	 determine	 the	 cytotoxic	 activity	 of	 the	 magainin	 II	 on	 A549	 cells,	 cytotoxic	assays	were	performed.	A549	cells	were	cultured	and	grown	in	96-well	plates	 in	DMEM	(~1	x105	cells	per	0.150	milliliter	in	each	well);	and	plates	were	incubated	till	confluent.	Then,	the	growth	medium	was	discarded	and	wells	washed	with	PBS	once	to	remove	non-	adherent	 cells.	Four	different	 concentrations	of	magainin	 II	 (3,	10,	20	and	30	μM)	were	added	to	different	wells.	All	wells	contained	150	μL	of	peptide	in	DMEM,	except	wells	of	controls	 that	 contained	 only	 150	 μL	 of	 DMEM.	 Then	 A549	 cells	with	magainin	 II	 were	incubated	for	2,	4,	6	and	24	h	in	CO2	incubator	(37	°C	in	humidified	95	%	air,	5	%	CO2).	The	number	of	viable	and	dead	A549	cells	in	each	well	was	determined	by	adding	150	μL	of	 0.4%	Trypan	blue	 in	 each	well	 and	 incubating	 for	 15	min	 at	 room	 temperature.	 The	number	 of	 viable	 and	 dead	 A549	 cells,	 as	 judged	 by	 dye	 exclusion	 or	 staining,	 were	counted	by	a	haemocytometer.	
3.2.6	Intracellular	antimicrobial	assays			
3.2.6.1	Acanthamoeba	intracellular	uptake		Drugs	 in	 combinations	 were	 used	 in	 this	 assay.	 Two	 combinations	 such	 as	magainin	II	with	silver	nitrate	and	magainin	II	with	antibiotic	(vancomycin/ciprofloxacin)	were	 applied	 against	 intracellular	 bacteria	 inside	 Acanthamoeba.	 Non-lethal	concentration	of	magainin	II	(3	μM)	to	Acanthamoeba	 trophozoites	was	used	along	with	silver	 nitrate	 (12.5	 μM).	 Second	 combination	 is	 magainin	 II	 (3	 μM)	 with	 vancomycin	against	Gram-positive	intracellular	bacteria	(5	μM	for	S.	epidermidis	and	10	μM	for	MSSA).	Or	magainin	 II	 (3	 μM)	 combined	with	 ciprofloxacin	 against	 Gram-negative	 intracellular	bacteria	(7	μM	for	E.	coli	and	13	μM	for	P.	aeruginosa).				 Acanthamoeba	were	 cultured	 in	 96-well	 plates	 in	 PYG	 (~1x105	 cells	 per	 0.150	milliliter	 in	 each	 well);	 and	 plates	 were	 incubated	 until	 confluent.	 Then,	 the	 growth	medium	 was	 discarded	 and	 wells	 washed	 with	 PBS	 once	 to	 remove	 non-adherent	
Acanthamoeba.	 Next,	 bacterial	 strains	 (~1.2x106	 CFU/well)	 were	 added	 onto	
Acanthamoeba	with	 RPMI	 medium	 and	 incubated	 for	 1	 h	 at	 room	 temperature.	 After	incubation,	supernatants	were	discarded	and	wells	washed	by	PBS	once	to	remove	non-	adherent	bacteria.	Next,	the	wells	were	washed	once	again	with	PBS,	and	then	antibiotics	were	 added	 to	 kill	 extracellular	 bacteria	 (vancomycin	 against	MSSA	 and	 S.	 epidermidis;	
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ciprofloxacin	against	P.	aeruginosa	and	E.	coli;	100	μg/ml	final	concentration,	for	45	min).	Then	the	supernatants	were	discarded	and	wells	washed	once	with	PBS.	Drugs	alone	and	in	 two	 combinations	 were	 added.	 All	 wells	 contained	 150	 μL	 of	 antimicrobial	 agent	combinations	in	RPMI,	except	wells	of	controls	that	contained	only	150	μL	of	RPMI.	Next,	
Acanthamoeba	with	bacteria	inside	and	drugs	were	incubated	at	30	°C	for	2,	4,	6	and	24	h.	After	 each	 incubation	 interval	 Acanthamoeba	 were	 lysed	 by	 adding	 Sodium	 Dodecyl	Sulphate	(0.5	%	final	concentration)	(SDS)	for	10	min.	Finally,	20	μL	of	lysate	was	cultured	onto	CLED/Blood/Chocolate	agar,	and	incubated	overnight	at	37	°C	in	CO2	incubator.	The	bactericidal	 rates	 of	 drugs	 alone	 and	 in	 combinations	 on	 intracellular	 bacteria	 within	
Acanthamoeba	were	calculated	as	follows:		
	where	R	is	the	bactericidal	rate,	X0	the	number	of	bacteria	without	drugs	(control),	and	Xt	the	number	of	bacteria	after	the	treatment	with	drugs	(Qiu	et	al.,	2011).		
3.2.6.2	A549	cell	line	intracellular	uptake		To	 investigate	 the	 effects	 of	 drugs	 in	 combinations	 (peptide	 +	 silver	 nitrate;	peptide	 +	 antibiotic)	 on	 the	 intracellular	 bacteria	 within	 A549	 cell	 line,	 antimicrobial	assays	were	performed.	In	brief,	A549	cells	were	cultured	and	grown	in	96-well	plates	in	DMEM	 (~1x105	 cells	 per	 0.150	milliliter	 in	 each	 well);	 then	 plates	 were	 incubated	 till	confluent.	When	confluent,	the	growth	medium	was	discarded	and	wells	washed	with	PBS	once	 to	 remove	 non-adherent	 cell.	 Next,	 bacterial	 strains	 (~1.2x106	 CFU/well)	 were	added	onto	cells	with	DMEM	medium	and	incubated	for	1	h	(37	°C	in	humidified	95%	air,	5%	 CO2).	 Then,	 supernatants	were	 discarded	 and	 cells	were	washed	with	 PBS	 once	 to	remove	non-adherent	bacteria.	Next,	antibiotics	were	added	to	kill	extracellular	bacteria	(vancomycin	against	MSSA,	S.	epidermidis;	and	ciprofloxacin	against	P.	aeruginosa,	E.	coli;	100	 μg/ml	 final	 concentration,	 for	 45	min).	 Then	 the	 supernatants	were	 discarded	 and	wells	 washed	 once	 with	 PBS.	 Following	 this,	 drugs	 alone	 and	 in	 combinations	 (as	mentioned	above	in	section	3.2.6.1.)	were	used	in	this	assay.	All	wells	contained	150	μL	of	antimicrobial	agents	in	DMEM	medium,	except	wells	of	controls	that	contained	only	150	μL	of	DMEM	medium.	The	A549	cell	 line	with	bacteria	inside	and	drugs	in	combinations	were	incubated	in	CO2	incubator	(37	°C	in	humidified	95	%	air,	5	%	CO2)	for	2,	4,	6	and	24	
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h.	Then,	A549	cells	were	lysed	by	adding	150	μl	of	CelLytic	M®	 for	10	min.	In	the	end,	20	μL	 of	 lysed	 solution	 was	 cultured	 onto	 CLED/Blood/Chocolate	 agar,	 and	 incubated	 for	overnight	 at	 37	 °C	 in	 O2	 incubator.	 The	 bactericidal	 rates	 of	 drugs	 alone	 and	 in	combinations	on	intracellular	bacteria	within	A549	cells	were	calculated	as	described	in	section	3.2.6.1.	
3.2.6	Flow	cytometry	assays	(Apoptosis)		To	study	 the	ability	of	magainin	 II	to	 induce	programmed	cell	death	 in	A549	cell	line	and	Acanthamoeba	 trophozoites,	 a	 fluorescence	 technique	 (flow	cytometry	assay	 to	measure	 externalized	 plasma	 membranephosphatidyl	 serine)	 was	 performed.	 In	 brief,	cells	were	seeded	and	grown	in	24	well	plates	until	confluent.	Then,	the	growth	medium	was	discarded,	and	cells	were	washed	once	with	PBS.	Various	concentrations	of	magainin	II	(3,	10,	20	and	30	μM)	were	added	to	different	wells	to	induce	cell	death.	Control	wells	were	devoid	of	peptides.	Plates	were	incubated	for	24	h	at	37	°C	in	an	incubator.	After	cell	death	 induction,	 cells	 were	 harvested	 and	 collected	 with	 the	 supernatants	 in	 1.5	 mL	eppendorf	 tubes	 for	 flow	cytometry	assays.	 Samples	were	centrifuged	at	1500	x	g	for	5	min.	 The	 pellets	 of	 cells	 were	 washed	 twice	 with	 200	 μL	 of	 cold	 cell	 staining	 buffer	(BioLegend).	 Then,	 cells	 (1	 x	 105)	 were	 resuspended	 in	 100	 μL	 of	 Annexin	 V	 binding	buffer	 (BioLegend)	 containing	 5	 μL	 of	 Annexin	 V	 Fluorescein	 isothiocyanate	 (FITC)	(BioLegend)	 and	 1	 μL	 of	 Zombie	 NIR	 (BioLegend).	 Samples	 were	 gently	 vortexed	 and	incubated	at	room	temperature	for	20	min	in	the	dark.	Next,	samples	were	washed	once	with	cell	 staining	buffer	and	 fixed	with	4	%	paraformaldehyde	 (PFA)	on	 ice	 for	20	min.	Samples	were	 centrifuged	 and	 supernatants	were	 discarded.	 Pellets	were	washed	 once	with	 cell	 staining	 buffer	 and	 then	 re-suspended	 in	 400	 μL	 of	Annexin	V	 binding	 buffer.	Next,	 cells	 were	 analysed	 by	 flow	 cytometry	 [The	 BD	 AccuriTM	 C6]	 and	 each	 run	was	restricted	to	10000	moments.		
3.2.7	Transmission	electron	microscopy	(TEM)	Images	were	 obtained	 in	 collaboration	with	 Dr.	Matthew	Hannah,	 Lead	 Electron	Microscopist	 in	 the	 Virus	 Reference	 Department	 of	 National	 Infection	 Service,	 Public	Health	England	in	London.	All	samples	were	prepared	in	Medical	Microbiology	laboratory,	School	of	Biological	Sciences,	Essex	University.		
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The	 antimicrobial	 effects	 of	 magainin	 II	 on	 bacteria	 (MSSA,	 Str.	 pneumoniae,	 P.	
aeruginosa	 and	 H.	 influenzae)	 and	 A.	 castellanii	 were	 observed	 by	 TEM.	Bacteria/Acanthamoeba	 were	 co-incubated	 with	 either	 peptide-treated	 or	 peptide-untreated	media	 (RPMI)	 in	 36	 °C	 incubator.	Next	 day,	microorganisms	were	 harvested,	centrifuged	 and	 washed	 three	 times.	 The	 pellets	 obtained	 were	 fixed	 in	 2.5	 %	glutaraldehyde	(v/v)	(in	0.1	M	sodium	cacodylate	buffer,	pH	=	7.2)	and	incubated	for	60	min	at	RT.	Next,	the	samples	were	centrifuged	(10	min	at	300	x	g)	and	re-suspended	in	0.1	M	sodium	cacodylate	buffer.	This	 step	was	 repeated	 twice	 to	 remove	 the	 fixative	agent.	Then,	the	pellets	were	washed	again	with	0.1	M	sodium	cacodylate	buffer	as	mentioned	in	section	2.2.8	and	embedded	in	3	%	Nobel	agar	prior	to	being	cut	into	section	of	1-2	mm	cubes.	 Acanthamoeba	 trophozoites/bacteria	 were	 dehydrated	 using	 graded	 series	 of	ethanol.	Afterwards,	 the	pellets	were	 infiltrated	with	LR	white	resin	and	polymerized	at	67	 °C	 for	 24	 h.	 Sections	 of	 80-100	 nm	were	 cut	 using	 a	NOVA	ultra-microtone,	 stained	with	lead	citrate	for	20	min,	rinsed	with	distilled	water	and	stained	with	uranyl	acetate	for	5	min.	After	drying,	the	grids	were	imaged	in	a	JEOL	JEM-1400	TEM	operating	at	120	kV.	Images	were	acquired	using	an	AMT	XR60	digital	camera.	
3.2.8	Presentation	of	results	and	statistical	analysis.	The	 results	 shown	 in	 this	 work	 are	 representative	 of	 three	 independent	experiments	 performed	 in	 triplicate	 by	 identical	methods.	 The	 results	 are	 expressed	 as	means	±	1	standard	deviation.	Differences	were	considered	statistically	significant	if	the	P	value	was	<0.05	by	Student's	t	test.	
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3.3	Results		
3.3.1	Peptides	as	biocidal	agents	To	determine	the	effects	of	magainin	II,	cytotoxicity	assays	on	A549	cell	 line,	and	the	 antimicrobial	 assays	 on	 Acanthamoeba	 were	 carried	 out.	 Four	 different	concentrations	of	magainin	II	(3,	10,	20	and	30	µM)	at	different	time	intervals	(2,	4,	6	and	24	 h)	 were	 applied.	 The	 antimicrobial	 effect	 of	 magainin	 II	 on	 the	 survival	 of	 both	
Acanthamoeba	and	A549	cell	were	dose	and	time	dependent.	The	lowest	concentration,	3	µM,	did	not	demonstrate	significant	cytotoxicity	on	A549,	resulting	in	3	%	dead	cells	when	incubated	 for	 24	 h.	 The	 same	 concentration	 on	 Acanthamoeba	 trophozoite	 was	 more	cytotoxic,	resulting	in	9	%	killing.	The	greatest	concentration,	30	µM,	was	100	%	fatal	for	both	A549	cells	 and	Acanthamoeba	when	 incubated	 for	24	h.	20	µM	of	magainin	 II	was	able	to	decrease	the	number	of	A549	cells	by	70	%	and	Acanthamoeba	trophozoites	by	51	%	in	24	h	of	 incubation.	At	2	h	 incubation	with	30	µM	peptide,	both	Acanthamoeba	and	A549	cells	viability	decrease	by	60	%.	It	was	important	to	determine	the	effects	of	various	concentrations	at	different	 time	 intervals	 since	one	of	 the	aims	of	 the	 study	 is	 to	 target	intracellular	 pathogenic	 bacteria	 inside	Acanthamoeba	 and	 A549	 cells	without	 harming	host	cells	(Figure	3.2).					
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 Figure	 3.2	 Cytotoxic	 effects	 of	 magainin	 II	 on	 a)	 A549	 cells	 and	 b)	 Acanthamoeba	 trophozoites.	
Acanthamoeba/A549	 cells	 were	 cultured	 and	 grown	 until	 confluent.	 Then,	 the	 growth	 medium	 was	discarded	and	wells	washed.	Four	different	concentrations	of	magainin	II	were	added	to	different	wells	and	incubated.	The	number	of	viable	and	dead	Acanthamoeba/A549	cells	in	each	well	was	determined	by	adding	0.4%	Trypan	blue	using	haemocytometer.	Results	are	the	average	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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3.3.2	Induction	of	Acanthamoeba	trophozoite	and	A549	cell	death	by	magainin	II	at	
different	concentrations		To	 study	 the	 antimicrobial/cytotoxic	 effects	 of	 cationic	 peptide	 magainin	 II,	 cell	death	 induction	was	 determined.	 Cell	 death	 induced	 by	magainin	 II	was	 determined	 at	different	 concentrations	 (3,	 10,	 20	 and	 30	 µM)	 to	 investigate	 the	 induction	 of	 different	points	 of	 apoptosis	 and	 then	necrosis.	A549	 cells	 and	Acanthamoeba	 trophozoites	were	treated	with	various	concentrations	of	cationic	peptide	for	24	h.	Cells	were	stained	with	annexin	 V-FITC	 and	 Zombie	 NIR	 and	 analyzed	 by	 flow	 cytometry.	 Cells	 with	 double	positive	 for	 both	 annexin	 V-FITC	 and	 Zombie	 NIR	were	 dead	 cells,	 while	 cells	 staining	positive	 for	annexin	V-FITC	and	negative	for	Zombie	NIR	were	apoptotic	cells.	Live	cells	are	those	cells	with	low	Zombie	NIR	and	negative	for	annexin	V-FITC.		Percentages	of	apoptotic	and	necrotic	cells	of	both	A549	cells	and	Acanthamoeba	trophozoites	were	slightly	and	gradually	increased	after	being	treated	with	antimicrobial	peptide,	while	they	increased	in	A549	cell	line	(14	±2	%)	and	Acanthamoeba	trophozoites	(7	±2	%)	for	necrotic	cells,	and	54	±11	%	and	26	±4	%,	respectively,	for	apoptotic	cells	at	24	h	post-treatment.	Cell	death	induced	by	magainin	II	in	A549	cell	line	was	higher	than	death	 induced	 by	 peptide	 on	Acanthamoeba.	 The	 percentage	 of	 apoptotic	 and	 necrotic	A549	cells	induced	by	magainin	II	was	different	when	exposed	to	different	concentrations.	The	percentage	of	apoptosis	for	0	(control),	3,	10,	20	and	30	µM	were	19	±7	%,	23	±6	%,	25	±9	%,	37	±7	%	and	54	±11	%,	respectively.	While,	the	percentage	of	necrosis	were	3	±1	%,	5	±3	%,	6	±1	%,	10	±4	%and	14	±2	%,	respectively.	Acquired	results	showed	that	the	percentage	 of	 apoptosis	 and	 necrosis	 of	 Acanthamoeba	 was	 dose	 dependent.	 For	apoptosis,	results	were	12	±2%,	15	±1%,	13	±2%,	26	±3%	and	19	±4%,	respectively.	And	for	 necrosis,	 they	were	 1	 ±0.5	%,	 2	 ±0.5	%,	 3	 ±1	%,	 4	 ±2	%	 and	 7	 ±1	%,	 respectively.		(Figure	3.3	and	3.4).		
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	Figure	3.3	Evaluation	of	apoptosis	 in	A549	(a)	cells	and	Acanthamoeba	 (b)	 trophozoites	after	exposure	 to	magainin	II.	Both	Acanthamoeba	and	A549	cells	were	treated	with	3	µM	(c),	10	µM	(d),	20	µM	(e)	and	30	µM	(f)	concentrations	of	peptide	and	incubated	for	24	h.	Cells	were	stained	with	annexin	V-FITC,	Zombie	NIR	and	analyzed	by	flow	cytometry.	Cells	double	positive	for	both	annexin	V-FITC	and	Zombie	NIR	were	dead	cells,	while	 cells	positive	 for	 annexin	V-FITC	and	negative	 for	Zombie	NIR	were	apoptotic	 cells.	 Live	 cells	were	those	cells	with	low	Zombie	NIR	and	negative	for	annexin	V-FITC.	The	data	shown	are	representative	of	three	experiments.		
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	Figure	 3.4	 Evaluation	 of	 apoptosis	 and	 necrosis	 in	 A549	 cells	 and	 Acanthamoeba	 trophozoites	 after	exposure	 to	 magainin	 II.	 Both	 Acanthamoeba	 and	 A549	 cells	 were	 treated	 with	 3,	 10,	 20	 and	 30	 µM	concentrations	of	peptide	and	incubated	for	24	h.	Cells	were	stained	with	annexin	V-FITC	and	Zombie	NIR	and	 analyzed	 by	 flow	 cytometry.	 Controls	 (cells	 only)	 are	 untreated	 cells.	 Results	 are	 the	mean	 of	 three	independent	experiments	performed	in	duplicate.	Error	bars	represent	standard	error.		
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The	effects	of	cationic	peptide	on	the	viability	of	bacterial	strains	were	studied	at	similar	concentrations	and	incubation	timings	to	those	used	above.	Three	strains	of	Gram-positive	 and	 three	 strains	 of	 Gram-negative	 bacteria	 were	 studied.	 100	 %	 killing	 of	bacteria	in	24	h	was	achieved	by	different	concentrations	of	the	antimicrobial	agent.	For	instance	a	50	µM	concentration	eradicated	S.	epidermidis	and	MSSA	by	100	%,	whereas	for	
Str.	pneumoniae	40	µM	was	sufficient	 to	kill	all	bacteria.	The	50	µM	peptide	 for	6	h	was	able	 to	 decrease	 the	 number	 of	 bacteria	 (S.	 epidermidis	 and	 MSSA)	 by	 91	 %.	 	 Str.	
pneumoniae	was	decreased	by	93	%	when	exposed	to	40	µM	peptides	for	6	h.	3	µM	dosage	was	ineffective	against	all	Gram-positive	bacteria	in	all	time	intervals	(2,	4,	6	and	24	h).	25	µM	concentration	of	peptide	was	able	to	kill	 less	than	50	%	of	S.	epidermidis	(44	%)	but	more	 than	 50	 %	 of	 MSSA	 (65	 %)	 (Figure	 3.5).	 Gram-negative	 bacteria	 were	 more	susceptible	to	magainin	II.	For	instance	a	30	µM	peptide	concentrations	was	sufficient	to	kill	100	%	of	bacteria	such	as	E.	coli	and	H.	influenzae,	whereas	 for	P.	aeruginosa	40	µM	was	required.	Similar	concentrations	demonstrated	more	than	68	%	and	61	%	reduction	for	E.	coli	and	P.	aeruginosa,	respectively.	Interestingly,	a	30	µM	concentration	was	not	as	effective	 against	H.	 influenzae	 as	 against	 other	 strains	 in	 2	 h,	 decreasing	 the	 number	 of	bacteria	by	29	%.	The	ineffective	dosage	for	Gram-negative	bacteria	was	found	to	be	3	µM,	where	98	%	of	all	bacteria	remained	viable.	 	So,	magainin	II	had	greater	effect	on	Gram-negative	bacteria	when	compared	to	Gram-positive	ones	(Figure	3.6).			
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		Figure	 3.5	 Antibacterial	 effects	 of	magainin	 II	 on	 Gram-positive	 bacteria	 a)	 S.epidermidis	b)	MSSA	 c)	 Str.	
pneumoniae,	 for	 various	 incubation	 timings.	 Results	 are	 the	 average	 of	 three	 autonomous	 experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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	Figure	 3.6	 Antibacterial	 effects	 of	magainin	 II	 on	 Gram-negative	 bacteria	 a)	E.	 coli	b)	P.	 aeruginosa	 c)	H.	
influenzae,	for	various	 incubation	timings	(2,	4,	6	and	24	h).	Results	are	 the	average	of	 three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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To	 investigate	 the	 ultrastructural	 alterations	 caused	 by	 magainin	 II	 in	 the	
Acanthamoeba	 trophozoites	 and	 bacteria	 such	 as	 MSSA,	 Str.	 pneumoniae,	 P.	 aeruginosa	and	H.	influenzae,	TEM	studies	were	performed.	Microorganisms	were	grown	as	described	previously	 and	 treated	with	 antimicrobial	peptide	 for	24	h.	Acanthamoeba	 trophozoites	were	exposed	to	20	µM,	MSSA	to	25	µM,	Str.	pneumoniae	to	20	µM,	P.	aeruginosa	to	20	µM	and	 H.	 influenzae	 to	 15	 µM.	 	 Control	 strains	 for	 all	 microorganisms	 were	 free	 of	antimicrobial	 peptides.	 Acquired	 micrographs	 revealed	 significant	 cytotoxic	 effects	 of	peptide	on	microorganism	cellular	structures.	It	was	observed	that	24	h	incubation	with	magainin	II	resulted	in	Acanthamoeba/bacterial	cell	envelopes	disorganization	with	a	loss	of	 plasma	membrane	 regions	 compared	 to	 control	microorganisms	 exposed	 to	medium	alone	(Figure	3.7	and	3.8).	
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	Figure	 3.7	 Transmission	 electron	 microscopy	 of	 Acanthamoeba	 trophozoites	 untreated	 and	 treated	 with	magainin	II.	a)	control,	without	peptide;	b)	with	magainin	II	(20	μM).	Trophozoites	were	co-incubated	with	either	peptide-treated	or	peptide-untreated	media	for	overnight.	Next	day,	microorganisms	were	harvested,	centrifuged,	 washed	 and	 fixed.	 Images	 were	 acquired	 using	 an	 AMT	 XR60	 digital	 camera. bar	 =	 2	 μm.	Electron	micrographs	revealed	the	disruption	of	cell	membrane	integrity	of	trophozoites.	Swelling	of	the	cell	by	becoming	larger	in	size	compared	with	control.	
a)	
b)	
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	Figure	3.8	Transmission	electron	microscopy	of	bacteria	untreated	and	treated	with	magainin	II.		
MSSA:	a)	control,	without	peptide;	b)	with	peptide	(25	μM);	Str.	pneumoniae:	c)	control;	d)	with	peptide	(20	μM);	P.	aeruginosa	 e)	 control;	 f)	with	peptide	 (20	μM);	H.	influenzae:	 g)	 control;	h)	with	peptide	 (15	μM).	Bacteria	were	co-incubated	with	either	peptide-treated	or	peptide-untreated	media	for	overnight.	Next	day,	microorganisms	were	harvested,	centrifuged,	washed	and	fixed.	Images	were	acquired	using	an	AMT	XR60	digital	camera.	As	shown	above,	complete	cell	membrane	and	 full	 intracellular	contents	were	observed	 in	the	untreated	bacteria.	It	can	be	seen	that	the	treated	bacteria	cells	by	magainin	II	peptide	exhibited	obvious	disrupted	integrity	of	the	bacterial	membranes.		
a)	 b)	
c)	 d)	
e)	 f)	
g)	 h)	500	nm	 500	nm	
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To	 identify	 a	 drug	 which	 could	 be	 used	 in	 combination	 with	 magainin	 II,	 silver	nitrate	 (AgNO3)	was	 tested	against	A549	cells	 and	Acanthamoeba	 trophozoites.	 	A	well-established	 antiseptic	 with	 antimicrobial	 properties	 silver	 nitrate	 was	 used	 in	 five	different	concentrations	(200,	100,	50,	25	and	12.5	μM)	with	two	incubation	timings	(24	and	12	h).	All	the	concentrations	used	were	not	sufficient	to	eradicate	all	trophozoites	or	A549	 cells	 in	 12	 h.	 200	 μM	 of	 silver	 nitrate	 in	 12	 h	 demonstrated	 high	 cytotoxicity	 on	A549	cells,	decreasing	viability	by	77	%.	The	similar	concentration	with	incubation	time	exhibited	65	%	antiamoebic	activity.	25	and	12.5	μM	dosages	were	found	to	be	nontoxic	to	both	A549	cells	and	Acanthamoeba	trophozoites	(Figure	3.9).	Finding	ineffective	dosages	were	 important.	 These	 dosages	 could	 be	 applied	 to	 target	 pathogenic	 intracellular	bacteria	inside	host	cells	without	harming	host	cells.		
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Figure	 3.9	 Cytotoxic	 effects	 of	 silver	 nitrate	 on	 a)	 A549	 cells	 and	 antiacanthamoebic	 activity	 on	 b)	
Acanthamoeba	trophozoites.	Acanthamoeba/A549	cells	were	cultured	and	grown	until	confluent.	Then,	the	growth	 medium	 was	 discarded	 and	 washed.	 Different	 concentrations	 of	 silver	 nitrate	 were	 added	 to	different	wells	and	were	 incubated	 for	12	and	24	h.	The	number	of	viable	and	dead	Acanthamoeba/A549	cells	 was	 determined	 by	 adding	 0.4%	 Trypan	 blue.	 Results	 are	 the	 average	 of	 three	 autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.	
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Following	the	above	experiments	microbicidal	effect	of	magainin	II	were	examined	against	internalized	bacteria	could	invade	A549	cells	and	Acanthamoeba.	As	two	bacteria	(Str.	pneumoniae,	H.	influenzae)	were	not	able	to	survive	and	recover	 in	 interacting	with	A549	cells	and	in	Acanthamoeba,	they	were	excluded	from	antimicrobial	drugs	exposure.		Several	other	antimicrobial	agents	were	tested	as	potential	synergists	for	use	with	magainin	 II.	 These	 compounds	were:	 silver	 nitrate,	 vancomycin	 and	 ciprofloxacin.	Most	promising	 of	 these	 was	 silver	 nitrate,	 which	 exhibited	 a	 higher	 antimicrobial	 effect	 on	bacteria	inside	Acanthamoeba	and	A549	cells.		The	 3	 µM	 concentration	 of	 magainin	 II	 was	 used,	 since	 this	 dosage	 had	 been	previously	 found	 least	 cytotoxic	 on	 A549	 cells	 as	 well	 as	 Acanthamoeba	 trophozoites.	Moreover,	 silver	 nitrate	 was	 used	 at	 12.5	 µM	 concentration,	 which	 had	 been	 found	 an	ineffective	 dosage.	 Vancomycin	 antibiotic	 was	 used	 against	 Gram-positive	 intracellular	bacteria,	whereas	ciprofloxacin	was	used	 for	Gram-negative	ones.	The	concentrations	of	antibiotics	 (5	and	10	μM	 for	vancomycin	and	7	and	13	μM	 for	 ciprofloxacin)	 applied	 in	drug	 combination	experiments	were	 ineffective	dosages	on	 intracellular	bacteria	within	A549	cells	and	Acanthamoeba	trophozoites.	The	drugs	when	used	 in	combinations	were	designed	so	 they	do	not	disturb	and	not	cytotoxic	to	host	A549	cells	as	well	as	Acanthamoeba	trophozoites.	
S.	epidermidis	and	MSSA	in	A549	cells	exhibited	normal	growth	when	exposed	to	5	and	 10	 µM	 concentrations	 of	 vancomycin,	 respectively.	 Furthermore,	 in	Acanthamoeba	trophozoites,	 similar	 bacteria	 could	 grow	 without	 any	 disturbance	 with	 antibiotic	concentrations	of	6	µM.	The	ineffective	concentrations	on	Gram-negative	bacteria	such	as	
P.	 aeruginosa	 and	 E.	 coli	 in	 A549	were	 7	 and	 13	 µM,	 and	 for	 the	 same	 bacteria	 inside	
Acanthamoeba	trophozoites	were	8	and	12	µM,	respectively.		Four	different	time	intervals	(2,	4,	6	and	24	h)	were	applied	to	study	the	dynamics	of	drugs	 in	combination.	The	 initial	numbers	of	 intracellular	bacteria	per	A549	cell,	 just	before	exposing	to	drugs,	were	as	follows:	S.	epidermidis-2.6;	MSSA-2.9;	E.	coli-2.5;	and	P.	
aeruginosa-1.4.	 Intracellular	S.	epidermidis	 inside	A549	cells	was	susceptible	 to	drugs	 in	combination.	When	vancomycin	was	applied	in	combination	with	magainin	II	for	24	h,	no	viable	intracellular	bacteria	were	detected.	This	combination	of	drugs	in	just	4	h	reduced	the	 number	 of	 intracellular	 S.	 epidermidis	 by	 55	 %.	 The	 combination	 of	 peptide	 with	
 113 
vancomycin	displayed	greater	antimicrobial	effect	when	compared	to	peptide	with	silver	nitrate.	 Intracellular	 MSSA	 inside	 A549	 cells	 exhibited	 susceptibility	 to	 drugs	 in	combination.	On	 this	 strain,	 the	 combination	of	peptide	and	 silver	nitrate	 exerted	more	cytotoxicity.	In	2	h	of	incubation	over	44	%	of	intracellular	bacteria	were	calculated	to	be	dead.	 Moreover,	 in	 6	 h	 this	 combination	 was	 successful	 in	 reducing	 the	 number	 of	intracellular	MSSA	by	78	%.	Inside	A549	cells,	 intracellular	Gram-negative	bacteria	such	as	 E.	 coli	 and	 P.	 aeruginosa	 largely	 survived	 up	 to	 6	 h	 of	 incubation	 with	 peptide-ciprofloxacin	combination,	exhibiting	more	than	78	%	viability.	The	peptide-silver	nitrate	combination	reduced	 the	number	of	E.	coli	 and	P.	aeruginosa	by	43	%	and	22	%	 in	2	h,	respectively.	The	same	combination	was	capable	of	eradicating	57	%	of	E.	coli	and	55	%	of	
P.	aeruginosa	 in	6	h	(Figure	3.10).	 It	was	essential	 to	design	the	concentrations	of	drugs	used	 against	 intracellular	 bacteria	 as	 low	 as	 possible	 with	 minimal	 effects	 to	
Acanthamoeba	and	A549	cell.																											
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 Figure	3.10	Drugs	in	combinations	tested	against	intracellular	bacteria	inside	A549	cells:	a)	S.	epidermidis;	b)	MSSA.	Magainin	II	(3	μM);	silver	nitrate	(12.5	μM)	and	various	concentrations	of	vancomycin	(5	and	10	μM)	were	applied.	Two	sorts	of	 combinations	were	used	experimentally:	magainin	 II	+	 silver	nitrate;	and	magainin	 II	 +	 antibiotics.	Abbreviations:	MG	 II-	magainin	 II;	 Vanc-vancomycin.	Results	 are	 the	 average	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
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 Figure	 3.10	Drugs	 in	 combinations	 tested	 against	 intracellular	 bacteria	 inside	 A549	 cells:	 c)	E.	 coli;	 d)	P.	
aeruginosa.	Magainin	II	(3	μM);	silver	nitrate	(12.5	μM)	and	various	concentrations	of	ciprofloxacin	(7	and	13	μM)	were	applied.	Two	sorts	of	combinations	were	used	experimentally:	magainin	II	+	silver	nitrate;	and	magainin	II	+	antibiotics.	Abbreviations:	MG	II-	magainin	II;	Cipro-	ciprofloxacin.	Results	are	the	average	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
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The	 effects	 of	 drugs	 in	 combination	 were	 tested	 against	 intracellular	 bacteria	inside	 Acanthamoeba	 trophozoites.	 Magainin	 II	 (3	 µM),	 silver	 nitrate	 (12.5	 µM),	vancomycin	(6	µM	for	S.	epidermidis	and	6	µM	for	MSSA),	and	ciprofloxacin	(12	µM	for	E.	
coli	 and	 8	 µM	 for	 P.	 aeruginosa)	 were	 antimicrobial	 agents	 used	 in	 this	 series	 of	experiments.	The	initial	numbers	of	 intracellular	bacteria	per	Acanthamoeba,	 just	before	exposing	 to	 drugs,	 were	 as	 follows:	 S.	 epidermidis-1350;	 MSSA-820;	 E.	 coli-880;	 and	 P.	
aeruginosa-1480.	At	24	h	of	incubation	with	either	of	the	combination	drugs	(peptide-silver	nitrate;	peptide-antibiotic),	 no	 bacteria	 under	 investigation	 were	 able	 to	 survive	 inside	 host	
Acanthamoeba	trophozoites.	When	chemical	agents	were	used	alone,	100	%	viability	with	abilities	 to	 multiply	 and	 survive	 intracellularly	 was	 documented.	 The	 peptide-silver	nitrate	 combination	 in	 2	 h	 was	more	 bactericidal	 on	 Gram-positive	 bacteria	 compared	with	 Gram-negative	 bacteria.	 MSSA	 displayed	 the	 highest	 susceptibility	 to	 this	combination	of	drugs,	with	numbers	reduced	by	30	%.	On	the	other	hand,	Gram-negative	
P.	aeruginosa	 exhibited	 the	 least	 susceptibility	 displaying	 67	%	 viability	 rate	 at	 6	 h	 co-incubation.	24	h	of	co-incubation	with	both	combination	drugs	were	fatal	for	intracellular	bacteria	inside	Acanthamoeba	trophozoites.		Pathogenic	 strains	 (MSSA	 and	P.	aeruginosa)	 demonstrated	 lower	 viability	when	exposed	 to	 peptide-antibiotic	 (vancomycin,	 ciprofloxacin)	 combination.	 6	 h	 of	 co-incubation	with	the	same	combination	drugs	was	sufficient	to	eradicate	more	than	50	%	of	pathogenic	strains	(MSSA,	P.	aeruginosa	to	69	and	57	%,	respectively)	(Figure	3.11).								
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 Figure	 3.11	 Drugs	 in	 combinations	 tested	 against	 intracellular	 bacteria	 inside	 Acanthamoeba:	 a)	 S.	
epidermidis;	b)	MSSA.	Magainin	II	(3	μM);	silver	nitrate	(12.5	μM)	and	various	concentrations	of	vancomycin	(6	 μM)	 were	 applied.	 Two	 combinations	 were	 used	 experimentally:	 magainin	 II	 +	 silver	 nitrate;	 and	magainin	II	+	antibiotics.	Abbreviations:	MG	II-	magainin	II;	Vanco-vancomycin.	Results	are	the	average	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
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 Figure	3.11	Drugs	in	combinations	tested	against	intracellular	bacteria	inside	Acanthamoeba:	c)	E.coli;	d)	P.	
aeruginosa.	Magainin	II	(3	μM);	silver	nitrate	(12.5	μM)	and	various	concentrations	of	ciprofloxacin	(8	and	12	 μM)	 were	 applied.	 Two	 combinations	 were	 used	 experimentally:	 magainin	 II	 +	 silver	 nitrate;	 and	magainin	II	+	antibiotics.	Abbreviations:	MG	II-	magainin	II;	Cipro-	ciprofloxacin.	Results	are	the	average	of	three	autonomous	experiments	carried	out	in	duplicate.	Error	bars	symbolize	standard	error.		
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3.4	Discussion	It	 is	well	known	that	several	bacterial	pathogens	are	associated	with	CF	and	that	they	 are	 the	 major	 cause	 of	 morbidity	 and	 mortality	 among	 patients.	 However,	 the	understanding	 of	 pathogenesis	 and	 pathophysiology	 of	 these	 infections	 as	 well	 as	 the	number	 of	 effective	 treatments	 remain	 insufficient.	 A	 fundamental	 question	 is	 how	bacteria	 interact	with	 epithelial	 cells	 of	 the	 respiratory	 tract,	 causing	 infections.	 In	 our	previous	 studies	 we	 have	 revealed	 that	 all	 six	 bacteria	 studied	 in	 this	 project	demonstrated	an	ability	to	associate	with	A549	cells	and	Acanthamoeba	trophozoites.	But,	just	 four	 of	 them	 invade	 and	 survive	 internally	 inside	 host	 cells.	 In	 this	 study,	 various	concentrations	 of	 magainin	 II	 exhibited	 an	 antimicrobial	 effect	 on	 Acanthamoeba	trophozoites,	extracellular	and	intracellular	bacteria.		In	 recent	 years,	 the	 rapid	 increase	 in	 drug-resistant	 bacteria	 has	 prompted	 a	growing	 interest	 in	 antimicrobial	 peptides	 as	 an	 alternative	 to	 conventional	 antibiotics.	Comparing	 with	 conventional	 antibiotics,	 which	 act	 by	 interfering	 with	 a	 specific	biochemical	 reaction	 inside	 the	 cell,	 antimicrobial	 peptides	 are	 believed	 to	 disrupt	 the	bacterial	membrane	 in	a	non-receptor-mediated	fashion.	The	exact	mechanism	of	action	has	not	yet	been	fully	described.		Information	on	antimicrobial	effects	of	magainin	II	peptide	against	Acanthamoeba	
castellanii	 and	 internalized	 bacteria	 remains	 insufficient.	 Here,	 various	 time	 intervals	along	 with	 different	 concentrations	 of	 magainin	 II	 were	 found	 to	 demonstrate	antimicrobial	efficacy	in	vitro.	Similar	studies	revealed	that	magainins	had	been	shown	to	be	 effective	 against	 Acanthamoeba	 polyphaga	 which	 had	 been	 isolated	 from	 clinics	(Schuster	 &	 Jacob,	 1992).	 The	 incubation	 of	 Paramecium	 caudatum	with	 magainin	 II	resulted	 in	 the	 contractile	 vacuoles	 immediate	 swelling	 and	 then	 rupture	 (Zasloff	et	al.,	1988).	In	other	studies,	magainins	displayed	effectiveness	against	Leishmania	(Guerrero	et	
al.,	 2004),	 Blastocystis	 hominis,	 Tryponosoma	 cruzi,	 and	 Entamoeba	 histolytica	 in	laboratory	 research	 (Huang	 et	 al.,	 1990).	 Flow	 cytometry	 assays	 demonstrated	 that	negative	 control	wells	had	10-19	%	early	 apoptotic	 cells.	This	 could	happen	because	of	various	 factors,	 such	 as	 time	 of	 incubation	 with	 annexin	 buffer,	 higher	 speeds	 of	centrifugations,	harsh	pipetting	when	re-suspending	etc.	Annexin	 is	an	 indicator	of	very	early	apoptosis.	At	this	early	stage	of	apoptosis,	AnnexinV	conjugates	have	a	direct	access	to	 the	 outer	 PS,	 even	 before	 the	 loss	 of	 membrane	 integrity.	Overall	 the	 dynamics	 of	
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magainin	II	by	increasing	concentration	can	be	correlated	with	that	of	trypan	blue	assay.	Further	 studies	 to	 understand	 the	 mechanisms	 of	 this	 action	 on	 Acanthamoeba	 are	essential.		On	 the	 other	 hand,	 as	 cationic	 antimicrobial	 peptides	 show	 broad-range	 activity	against	 Gram-positive	 and	 Gram-negative	 bacteria	 (Hancock	&	 Sahl,	 2006),	magainin	 II	was	 tested	 against	 bacteria	 employed	 in	 this	 study	 and	 it	 displayed	 significant	antibacterial	 potency.	 Interestingly,	 all	 Gram-positive	 bacteria	 employed	 in	 this	 study	exhibited	 higher	 MIC	 when	 compared	 with	 Acanthamoeba	 trophozoites.	 Moreover,	Magainin	 II	 was	 found	 to	 be	more	 cytotoxic	 to	Acanthamoeba	 when	 compared	 with	 P.	
aeruginosa.	Recently,	a	microbial	flow	cytometry	method	was	described	which	quantified	magainin	 II	 activity	 within	 3	 h,	 called	 Minimum	 Membrane	 Disruptive	 Concentration	(MDC).	 Increasing	 peptide	 concentration	 positively	 correlated	with	 the	 extent	 of	MRSA	and	E.	coli	membrane	disruption	and	the	calculated	MDC	was	equivalent	to	its	Minimum	Bactericidal	Concentration	(MBC)	(O’Brien-Simpson	et	al.,	2016).	Magainin	II	inhibited	the	growth	of	P.	aeruginosa	(Dosler	&	Karaaslan,	2014),	S.	epidermidis	(Imura	et	al.,	2007),	Str.	
pneumoniae	 (Kovács	 et	 al.,	 2006),	and	 H.	 influenzae	 (Bishop-Hurley	 et	 al.,	 2005).	 It	 has	been	shown	with	coarse-grained	computer	simulations	using	MARTINI	force	field,	which	is	 suited	 for	 molecular	 dynamics	 simulations	 of	 biomolecules	 that	 magainin	 produces	water-filled	toroidal	holes	in	biological	membranes	(Santo	&	Berkowitz,	2012).			In	 preliminary	 experiments	 magainin	 II	 showed	 synergistic	 antimicrobial	 effect	against	bacteria	in	extracellular	conditions	when	used	in	combination	with	silver	nitrate	and	antibiotics	such	as	vancomycin	and	ciprofloxacin.	Bacteria	able	to	survive	could	contribute	to	re-infections.	It	is	crucial	to	be	able	to	eradicate	intracellular	bacteria	without	harming	host	cells.	In	this	case,	it	was	A549	cells.	Magainin	 II	 in	 sub-cytotoxic	 concentrations	 was	 not	 able	 to	 eradicate	 intracellular	bacteria,	 but	 could	 do	 so	when	 used	 in	 combination	with	 other	 antimicrobials	 such	 as	silver	 nitrate,	 vancomycin	 and	 ciprofloxacin.	 The	 mechanism	 of	 positive	 synergistic	activity	 between	 peptides	 and	 antibiotics	 appears	 to	 be	 complicated.	Magainin	 II	might	play	role	in	increasing	of	permeability	of	host	cell	membrane	(He	et	al.,	2015).				 Silver	nitrate	has	a	reputable	place	in	the	pharmacopoeia	as	an	effective	and	well-tolerated	 antimicrobial	 reagent	 (Unger	 &	 Luck,	 2012).	 By	 combining	 magainin	 II	 with	silver	nitrate,	greater	activity	was	seen	in	the	experiments	against	 intracellular	bacteria.	
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This	may	allow	 for	use	of	magainin	 II	 and	 silver	nitrate	at	 concentrations	 sub-cytotoxic	concentrations,	 with	 continuous	 activity.	 The	 reasons	 for	 the	 greater	 efficacy	 of	 silver	when	 used	 in	 combination	 with	 magainin	 II	 may	 be	 associated	 with	 influx	 into	 the	
Acanthamoeba	 or	 A549	 cell	 line	 cytoplasm	 as	 a	 result	 of	 increased	 membrane	permeability.	This	hypothesis	can	be	supported	by	results,	where	we	combined	sub-lethal	doses	of	antibiotics	such	as	vancomycin	and	ciprofloxacin	with	magainin	II.	It	was	stated	that	 the	 magainin	 II	 interacted	 synergistically	 with	 all	 tested	 β-lactam	 antibiotics	(Giacometti	et	al.,	2000c).		The	magainin	II	was	found	to	be	cytotoxic	to	the	A549	cell	 line.	This	is	consistent	with	another	study	(Pascariu	et	al.,	2012).	The	greater	cytotoxicity	could	be	related	to	the	outer	 negative	 charge	 of	 cancerous	 cells.	 The	 outer	 leaflet	 of	 eukaryotic	 plasma	membranes	normally	comprises	neutral	phospholipids,	like	phosphatidylcholine	(PC)	and	sphingomyelin	 (SM),	 whereas	 the	 negatively	 charged	 phospholipid	 phosphatidylserine	(PS)	as	well	as	phosphatidylethanolamine	(PE)	are	situated	in	the	inner	leaflet	(Bevers	et	
al.,	 1996).	 It	 has	 been	 stated	 previously	 that	 this	 asymmetry	 could	 be	 lost	 due	 to	decreased	 activity	 of	 the	 ATP	 dependent	 phospholipid	 translocase,	 which	 specifically	transports	PS	and	PE	between	bilayer	leaflets	and	is	susceptible	to	oxidative	damage,	or	due	 to	 the	 activation	 of	 a	 scramblase	 stimulated	 by	 amplified	 intracellular	 Ca2+	 levels	which	leads	to	non-specific	movement	of	phospholipids	(Seigneuret	&	Devaux,	1984).	In	turn,	 this	 loss	 of	 asymmetry	 ends	 up	 in	 exposure	 of	 the	 negatively	 charged	 PS	 on	 the	surface	of	cancerous	and	other	pathological	cells	(Zwaal	et	al.,	2005),	as	well	as	apoptotic	cells	(Martin	et	al.,	1995)	and	thus	PS	represents	a	promising	target	for	cationic	magainin	II	peptide.		In	future	studies,	a	similar	combination	drug	experiment	could	be	conducted	applying	antimicrobial	 agents	 against	 the	 cyst	 stage	 of	 Acanthamoeba.	 Antimicrobial	 reagents	active	 against	 trophic	 Acanthamoeba	 cannot	 equally	 be	 active	 against	 cysts.	 In	 the	majority	 of	 cases,	 cysticidal	 concentrations	 of	 reagents	 are	 substantially	 greater	 than	amoebicidal	 concentration	 amounts	 (Osato	 et	 al.,	 1991).	 Moreover,	 microdilution	checkerboard	 data	 can	 be	 used	 to	 assess	 pharmacodynamic	 interactions	 based	 on	Fractionally	Inhibitory	Concentration	(FIC)	index	analysis.	
 122 
The	outcomes	of	these	investigations	encourage	further	studying	of	magainin	II	and	its	derivatives	 for	 their	 ability	 to	 kill	 Acanthamoeba	 trophozoites	 and	 cysts	 as	 well	 as	pathogenic	bacteria.	Although	these	outcomes	are	preliminary,	they	suggest	that	magainin	II	 in	 combination	 with	 silver	 nitrate	 or	 antibiotics	 have	 in	 vitro	 efficacy	 against	intracellular	 bacteria,	 and	 that	 they	 could	 be	 suitable	 in	 handling	 various	 types	 of	infections	caused	by	Acanthamoeba	and	bacteria.			 	
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“Bacteria-host	cell	interactions	and	antimicrobial	efficacy		
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4.1	Background					Bacterial	respiratory	 infections	are	the	 leading	causes	of	morbidity	and	mortality	in	 CF	 patients	 (Ciofu	 et	al.,	 2013).	 	P.	aeruginosa	and	 S.	aureus	 strains	 are	 identified	 as	opportunistic	 pathogens	which	 trigger	 some	of	 the	most	widespread	 infections	 of	 eyes,	ears,	 wounds	 and	 lung	 (Park	 et	 al.,	 2011).	 These	 pathogens	 are	 notorious	 with	 an	extensive	range	of	drug	resistance	abilities.	Nonetheless,	AMPs	constitute	a	novel	group	of	antimicrobials,	 since	 they	 are	 totally	 different	 from	 the	 antibiotics	 that	 eradicate	pathogens.	 Although	 antibiotics	 require	 definite	 intracellular	 targets	 for	 their	 activity,	AMPs	 usually	 do	 not	 require	 a	 specific	 target	 in	 the	microorganism	 cell	 (Perron	 et	 al.,	2006).	Instead,	AMPs	bind	to	the	bacterial	cell	membrane	and	disassemble	the	membrane	construction.	Moreover,	certain	AMPs	display	selective	 inhibition	of	 intracellular	 targets	within	 the	 microorganism	 cells	 (Giuliani	 et	 al.,	 2007).	 This	 action	 makes	 AMPs	invulnerable	to	bacterial	resistance,	for	which	the	microorganisms	require	to	change	the	whole	 membrane	 lipid	 arrangement.	 Consequently,	 AMPs	 are	 appealing	 for	 their	prospective	therapeutic	effect	against	drug-resistant	microorganisms.	Moreover,	rational	design	 of	 peptides	 could	 produce	 potentially	 therapeutic	 membrane	 active	 drugs	 with	characteristics	tailored	to	their	function	(Mason	et	al.,	2009).	AMPs	 have	 been	 shown	 to	 possess	 antiviral,	 antimicrobial,	 anticoagulant	 and	antifreeze	specifities	by	previous	investigators,	and	the	number	of	novel	AMPs	isolated	is	growing	 (Zasloff,	 2002b).	 	 Since	 primary	 studies	 proposed	 that	 numerous	 AMPs	 target	membranes	 (Matsuzaki	 et	 al.,	 1991),	 	 the	 molecular	 mechanism	 of	 membrane	permeabilization	 has	 been	 investigated	 comprehensively,	 exploiting	 predominantly	model	 membranes.	 For	 instance,	 magainin	 II,	 an	 α-helical	 peptide	 isolated	 from	 the	African	clawed	frog	Xenopus	laevis	(Zasloff,	1987b)	was	proposed	to	form	a	toroidal	pore	with	 a	 diameter	 of	 2–3	 nm,	 stimulating	 lipid	 flip-flop	 and	 the	 translocation	 of	 peptides	into	the	inner	leaflet	of	the	bilayer	coupled	to	membrane	permeabilization	(Huang,	2006).		Pleurocidin,	 a	 cationic	 25-residue	 AMP,	 was	 discovered	 in	 the	 skin-secreted	mucous	fluid	of	winter	 flounder	(Pleuronectes	americanus),	which	was	examined	against	bacterial	 and	 fungal	 clinical	 isolates,	 exhibited	 broad-spectrum	 antimicrobial	 activity	(Cole	 et	 al.,	 2000).	 	 The	 sequence	 of	 the	 pleurocidin	 complete	 molecule,	(GWGSFFKKAAHVGKHVGKAALTHYL),	 indicates	 sequence	 homology	 with	 the	dermaseptin	 and	 ceratotoxin	 classes	 of	 antimicrobial	 peptides	 (Cole	 et	 al.,	 2000).	 	 In	 a	
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study,	where	a	variety	of	spectroscopic	techniques	were	applied	to	study	mechanisms	of	pleurocidin	 antibiotic	 activity	 with	 model	 membranes	 it	 was	 shown	 that	 pleurocidin	interacts	 with	 both	 the	 zwitterionic	 phosphatidylethanolamine	 and	 anionic	phosphatidylglycerol	(PG)	but	disrupts	the	lipid	acyl	chain	order	of	the	anionic	PG	lipids	more	effectively	(Mason	et	al.,	2006c).		The	 elaboration	 of	 antimicrobial	 peptides	 has	 been	 hindered	 by	 numerous	complications.	 One	 of	 these	 difficulties	 is	 salt	 sensitivity	 (Park	 et	 al.,	 2004).	 The	antimicrobial	 ability	 of	 human	 β-defensin-1	 is	 prominently	 dropped	 in	 the	 presence	 of	high	 salt	 concentrations	 in	 broncho-pulmonary	 fluids	 in	 CF	 patients	 (Goldman	 et	 al.,	1997a).	 Analogous	 complications	 were	 spotted	 in	 the	 clinically	 active	 histidine-rich	peptide	P-113,	indolicidins,	gramicidins,	bactenecins,	and	magainins	(Wang	et	al.,	2009b).	Nonetheless,	not	all	AMPs	are	salt	sensitive,	and	some	peptides	demonstrate	potent	salt-insensitive	 antimicrobial	 efficacy	 such	 as	 clavanins	 and	 tachyplesins	 (Tam	 et	al.,	 2002).	NRC-13’s	 action	 is	 similarly	 consistent	with	other	pleurocidin,	 that	 it	 is	 not	 sensitive	 to	salt	conditions	such	as	NaCl,	MgCl2	and	CaCl2	(Cole	et	al.,	2000).	Concerning	interactions	of	AMPs	with	mammalian	cell	membranes,	there	have	been	merely	a	few	researches	(Lau	et	
al.,	2005).	It	is	not	surprising	that	maximum	research	on	AMPs	has	concentrated	on	their	antibacterial	 efficacies.	 Nevertheless,	 the	 cytotoxic	 effects	 of	 AMPs	 also	 need	 to	 be	examined,	because	they	hinder	the	systemic	exploitation	of	AMPs	(Hancock	&	Sahl,	2006).			The	bactericidal	abilities	of	silver	ion	has	been	identified	since	ancient	eras,	and	its	range	is	rather	extensive	(Clement	&	Jarrett,	1994).	Silver	ion	reacts	with	the	thiol	group	in	vital	enzymes	and	inactivates	them	(Liau	et	al.,	1997)	or	interacts	with	DNA	(Feng	et	al.,	2000),	resulting	in	noticeable	development	of	pyrimidine	dimerization	by	a	photodynamic	process	and	probable	inhibition	of	DNA	replication	(Russell	&	Hugo,	1994).	Silver	nitrate	reveals	various	functions	against	bacteria	dependent	upon	its	quantity	(Kumar	Pandian	et	
al.,	2010).	Silver-based	antimicrobials	can	be	efficient	in	the	treatment	of	infections	based	on	non-toxicity	of	active	Ag+	to	human	cells	(Ewald	et	al.,	2006).		CF	 patients	 experience	 chronic	 lung	 infections	 which	 need	 long-term	 antibiotic	therapy	(Jansen	et	al.,	2016).	One	of	the	reasons	for	the	long-term	presence	of	pathogens	could	 be	 the	 presence	 of	Acanthamoeba	 in	 lungs	 of	 the	 CF	 patient.	Acanthamoeba	 is	 a	ubiquitous,	 opportunistic	 protozoan	 pathogen,	 the	 causative	 agent	 of	 granulomatous	encephalitis,	 keratitis	 and	 feeds	 on	bacteria	 (Marciano-Cabral	&	Cabral,	 2003).	Being	 in	the	 CF	 lung	 it	 could	 phagocytize	 pathogenic	 bacteria	 protecting	 them	 and	 giving	 them	
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conditions	 to	 grow	 (Cardas	 et	 al.,	 2012b).	 This	 in	 turn	 could	 result	 in	 reinfections	complicating	 the	 treatment	 of	 patients.	 Under	 unfavorable	 conditions	 or	chemotherapeutic	drugs,	Acanthamoeba	changes	into	a	resistant	double-walled	cyst	form,	resulting	 in	 prolong	 presence	 of	 pathogens,	 and	 causing	 problems	 in	 the	 treatment	 of	bacterial	infections	(Coulon	et	al.,	2010).			Based	 on	 this	 hypothesis,	 the	 aim	 of	 this	 part	 of	 the	 project	 was	 to	 study	 the	growth	 of	 bacteria,	 Acanthamoeba	 and	 A549	 cells	 in	 artificial	 sputum	media	 (ASM)	 to	mimic	 the	 natural	 physiological	 environment	 in	 the	 CF	 lung.	 Bacterial	 intracellular	survival	 was	 examined	 within	 Acanthamoeba	 and	 A549	 cells	 in	 ASM.	 Moreover,	 the	antimicrobial	and	cytotoxic	effects	of	magainin	II	were	tested.																																			
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4.2	Materials	and	Methods	All	chemicals	were	purchased	from	Sigma-Aldrich	(UK),	unless	otherwise	stated.	
	
4.2.1	Preparation	of	Artificial	Sputum	Medium	(ASM)	To	prepare	artificial	 sputum	medium	4	g	of	DNA	 from	 fish	sperm	were	added	 to	250	mL	distilled	water	very	slowly	over	a	period	of	several	h.	The	DNA	takes	a	long	time	to	completely	dissolve	and	can	be	stirred	overnight	at	RT.	Next,	5	g	of	mucin	from	porcine	stomach	 (type	 II)	 were	 added	 slowly	 to	 250	 mL	 sterile	 water	 until	 the	 mucin	 had	dissolved	 completely.	 The	 solution	 can	 be	 stirred	 overnight	 at	 4	 °C	 and	 0.25	 g	 of	 each	essential	and	non-essential	L-amino	acid,	with	the	exception	of	L-tyrosine	and	L-cysteine,	were	dissolved	in	100	mL	sterile	water.	0.25	g	of	L-cysteine	in	25	mL	of	0.5	M	potassium	hydroxide	(KOH)	(56.11	g/mol)	and	0.25	g	of	L-tyrosine	were	dissolved	in	25	mL	sterile	water.	On	top	of	that	5.9	mg	diethylenetriaminepentaacetic	acid	(DTPA),	5	g	NaCl	and	2.2	g	of	KCl	were	added	in	100	mL	of	distilled	water.	The	DNA,	Mucin,	L-amino	acids,	DTPA,	NaCl	and	KCl	were	combined	in	a	1-litre	volume	bottle.	Into	this	mixture	5	mL	of	egg	yolk	emulsion	were	 added	 and	 filled	 to	 approximately	 850	mL	with	 distilled	water.	 pH	was	adjusted	to	6.9	with	1	M	Tris	(pH	8.5;	Mr	121.14)	and	the	volume	was	brought	to	1	litre	with	distilled	water.	The	ASM	was	 sterilized	by	 filtration	using	a	0.22	μm	syringe	 filter.	Unfiltered	and	filtered	ASM	were	stored	at	4	°C	in	the	dark.			
4.2.2	Cell	line	and	cell	culture	A549	cell	line	was	grown	and	cultured	as	described	in	section	2.2.3.		Normal	 human	 urothelial	 cell	 line	 (TERT-NHUC)	 was	 kindly	 provided	 by	 Prof.	Knowles,	 from	 St.	 James’s	 University	 Hospital	 in	 Leeds.	 The	 TERT-NHUC	 cell	 line	 was	provided	as	a	frozen	sample.	The	frozen	sample	is	a	mixture	of	growth	medium	with	10%	DMSO	and	10%	fetal	calf	serum	(FSC).	Cells	were	passaged	into	T25	tissue	culture	flasks	and	incubated	at	37	°C	 in	a	CO2	 incubator	(95	%	humidity,	5	%	CO2)	using	Keratinocyte	Growth	Medium	 2	 (KGM)	 as	 a medium.	 Cells	 became	 confluent	within	 2	 days	 (~4x106	cells).	All	passages	used	in	this	study	were	between	passage	numbers	4	to	7.				
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4.2.3	Acanthamoeba	culture	
Acanthamoeba	 strains	 (T4	 genotype)	 were	 grown	 and	 cultured	 as	 described	 in	section	2.2.1.	
	
4.2.4	Bacterial	cultures	Six	clinical	bacterial	strains	were	utilized	(MSSA,	Str.	pneumoniae,	S.	epidermidis,	P.	
aeruginosa,	H.	 influenzae	 and	 E.	 coli).	 All	 strains	 were	 cultured,	 inoculated	 and	 optical	densities	(OD)	were	measured	by	spectrophotometer	as	described	in	section	2.2.2.		
4.2.5	Intracellular	survival	assays	To	 determine	 the	 long-term	 fate	 of	 bacteria	 inside	 A549	 cells	 or	Acanthamoeba,	intracellular	 survival	 assays	were	performed.	Briefly,	A549	cells	or	Acanthamoeba	were	incubated	 with	 bacteria,	 followed	 by	 the	 addition	 of	 antibiotic	 for	 45	 min.	 After	incubation,	 wells	 were	 washed	 with	 PBS.	 A549	 cells	 were	 incubated	 in	 0.2	 mL	 of	DMEM/ASM,	while	Acanthamoeba	were	incubated	in	0.2	mL	RPMI	1640/ASM	for	24	h	at	30	°C.	Finally,	cells	were	lysed	and	cultured	onto	agar	and	the	number	of	bacteria	survived	inside	cells	counted.		
 
4.2.6	Preparation	of	antimicrobial	agents	Antimicrobial	agents	such	as	magainin	 II,	 silver	nitrate	 (AgNO3),	vancomycin	and	ciprofloxacin	were	utilized	in	this	study.		Magainin	 II	 was	 purchased	 and	 prepared	 as	 described	 in	 section	 3.2.4.	Antimicrobial	activities	of	magainin	II	(with	various	concentrations	for	24	h)	were	tested	against	Acanthamoeba	trophozoites,	bacteria	in	extracellular	and	intracellular	conditions.	In	parallel,	cytotoxic	effects	on	the	A549	cell	line	were	studied.	Pleurocidin	 (NRC-13)	 with	 95	 %	 purity	 and	 molecular	 mass	 2.652	 kDa,	 was	purchased	 from	 Cambridge	 Bioscience	 as	 a	 powder.	 	 The	 solutions	 for	 these	 peptides	were	 prepared	 by	 dissolving	 powder	 in	 sterile	 water.	 Antimicrobial	 activities	 of	pleurocidin	were	 tested	 against	Acanthamoeba	 trophozoites	 (25,	 50,	 100,	 150	 and	 200	μM),	bacteria	 (5	and	10	μM)	 in	 their	own	media	and	ASM	 for	24	h.	Moreover,	 cytotoxic	effects	on	the	A549	cell	line	and	TERT-NHUC	(25,	50,	100,	150	and	200	μM)	cell	line	were	studied.			
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Silver	nitrate	(AgNO3)	is	0.170	kDa	in	mass	and	with	≥	99	%	purity,	was	dissolved	in	sterile	water.	It	was	tested	against	Acanthamoeba	cysts	in	combination	with	magainin	II.	 All	solutions	were	filter	sterilized	using	a	0.2	µm	filter.	Stocks	were	kept	at	-20	°C.	
	
	
4.2.7	Antimicrobial	assays	
	
4.2.7.1	Antibacterial	assays	To	determine	the	antimicrobial	activity	of	magainin	II	to	inhibit	bacterial	growth	in	ASM,	 antimicrobial	 assays	 were	 performed.	 Bacterial	 strains	 were	 grown	 in	 ASM	 and	media	(Luria	broth	(LB)/Brain	heart	infusion	(BHI)/BHI+Fildes	extract	(FE))	overnight	at	37	°C.	Then	ODs	were	measured	by	spectrophotometer	and	the	number	of	viable	bacteria	was	calculated	as	described	in	3.2.5.1.			
4.2.7.2	Antiamoebic	assays	To	 determine	 the	 antimicrobial	 activity	 of	 the	 magainin	 II	 on	 Acanthamoeba	 in	ASM,	 antiamoebic	 assays	 were	 performed.	 Acanthamoeba	were	 cultured	 and	 grown	 as	described	 in	3.2.5.2.	Seven	different	concentrations	of	magainin	 II	 (2.5,	5,	10,	20,	30,	40	and	 50	 μM)	 were	 added	 to	 different	 wells.	 All	 wells	 contained	 150	 μl	 of	 antimicrobial	agent	in	PYG/ASM,	except	wells	of	controls	that	contained	only	150	μl	of	PYG/ASM.	Then	
Acanthamoeba	with	magainin	 II	were	 incubated	at	30	°C	 for	24	h.	The	number	of	viable	and	dead	Acanthamoeba	was	determined	as	described	in	section	3.2.5.2.				
4.2.7.3	Cytotoxicity	assays		To	determine	the	cytotoxic	activity	of	the	magainin	II	on	A549/TERT-NHUC	cells,	cytotoxic	assays	were	performed.	A549/TERT-NHUC	cells	were	cultured	and	grown	in	96-well	 plates	 in	 DMEM/KGM/ASM	 (~1	 x105	 cells	 per	 0.150	 milliliter	 in	 each	 well);	 and	plates	were	 incubated	 till	 confluent.	Then,	 the	growth	medium	was	discarded	and	wells	washed	 with	 PBS	 once	 to	 remove	 non-	 adherent	 cell.	 Five	 different	 concentrations	 of	magainin	 II	 (2.5,	 5,	 10,	 20,	 30,	 40	 and	 50	 μM)	 or	 pleurocidin	 (NRC-13)	were	 added	 to	different	wells.	All	wells	contained	150	μl	of	peptide	in	DMEM/KGM/ASM,	except	wells	of	controls	 that	 contained	 only	 150	 μl	 of	 DMEM/KGM/ASM.	 Then	A549/TERT-NHUC	 cells	
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with	magainin	II/pleurocidin	(NRC-13)	were	incubated	for	24	h	at	37	°C	(humidified	95	%	air,	5	%	CO2).	The	number	of	viable	and	dead	A549/TERT-NHUC	cells	 in	each	well,	was	determined	as	described	in	section	3.2.5.2.		
4.2.7.3	Cysticidal	activity	of	magainin	II	in	combination	with	AgNO3		To	determine	the	cytotoxic	effect	of	drugs	in	combination	(magainin	II-AgNO3)	on	
Acanthamoeba	 cysts,	Acanthamoeba	 trophozoites	were	grown	and	 incubated	 for	up	to	7	days	 onto	 non-nutrient	 agar	 to	 trigger	 their	 encystment.	 Next,	 cysts	 were	 collected,	counted	and	2	x	105	cysts	/	mL	were	incubated	for	24	h	with	different	concentrations	of	drugs	 in	 combination	magainin	 II-silver	 nitrate	 (50,	 100,	 200,	 300	 and	 400	 μM).	Wells	with	cysts,	but	without	drugs	were	used	as	controls.	The	viability	of	cysts	was	calculated	by	exclusion	method	using	trypan	blue	stain	(0.2	%	final	concentration).			
4.2.7.4	Transmission	electron	microscopy	The	 cysticidal	 activities	 of	 magainin	 II	 on	 A.	 castellanii	 cysts	 were	 observed	 by	TEM.	Acanthamoeba	cysts	were	co-incubated	with	either	magainin	II-treated	(400	μM)	or	magainin	 II-untreated	 media	 (ASM)	 overnight.	 Next	 day,	 cysts	 were	 harvested,	centrifuged,	washed	and	fixed.	Images	were	obtained	as	described	in	section	2.2.8.	
	
4.2.8	Presentation	of	results	and	statistical	analysis.		The	 results	 shown	 in	 this	 work	 are	 representative	 of	 three	 independent	experiments	 performed	 in	 triplicate	 by	 identical	methods.	 The	 results	 are	 expressed	 as	means	±	1	standard	deviation.	Differences	were	considered	statistically	significant	if	the	P	value	was	<0.05	by	Student's	t	test.										
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4.3.	Results	
	
4.3.1	Bacterial	survival	in	ASM	To	 determine	 whether	 the	 pathogenic	 bacteria	 under	 investigation	 survive	 in	conditions	mimicking	 the	 CF	 environment,	 ASM	medium	was	 used.	 RPMI,	 BHI,	 BHI+FE	and	LB	were	used	as	controls	(for	S.	epidermidis,	MSSA,	P.	aeruginosa	and	E.	coli)/BHI	(for	
Str.	 pneumoniae)/BHI+FE	 (for	 H.	 influenzae).	 All	 bacteria	 are	 isolates	 from	 CF	 lower	respiratory	tracts.	ASM	has	all	the	components,	which	are	found	in	sputum	of	a	CF	patient.	
S.	 epidermidis	 (4	 x	 107),	MSSA	 (1	 x	 109),	 Str.	 pneumoniae	 (6	 x	 106),	E.	 coli	 (4	 x	 109),	P.	
aeruginosa	(4	x	109)	and	H.	influenzae	(2	x	108)	were	found	to	have	the	ability	to	survive	in	 artificial	 sputum	 medium.	 	 	 S.	 epidermidis	 (6	 x	 107)	 and	 MSSA	 (8	 x	 108)	 displayed	growth	similar	to	those	when	they	are	incubated	in	ASM.	However	for	Str.	pneumoniae,	E.	
coli,	 P.	 aeruginosa	 and	 H.	 influenzae	 the	 growth	 rate	 in	 ASM	 was	 shown	 to	 be	 better	compared	to	RPMI	(1	x	105,	1	x	109,	8	x	109	and	3	x	107	respectively)	(Figure	4.1).	All	bacteria	employed	in	this	project	exhibited	growth	potency	in	ASM.	This	leads	us	to	conclude	that	sputum	environment	in	CF	lung	is	optimal	for	functioning	of	bacteria.							
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	 		Figure	 4.1	 Bacterial	 growth	 in	 different	 media	 such	 as	 Artificial	 Sputum	 Medium	 (ASM);	 Roswell	 Park	Memorial	 Institute	 medium	 (RPMI);	 Luria	 Berthani	 (LB);	 Brain	 heart	 infusion	 (BHI);	 BHI+Fildes	 extract	(BHI+FE).		
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4.3.2	Acanthamoeba	and	A549	cells	survival	in	ASM		The	 hypothesis	 leading	 to	 this	 work	 was	 that	 Acanthamoeba	 could	 have	 all	necessary	 conditions	 for	 growth	 and	 development	 in	 the	 lower	 respiratory	 tract.	 A549	cells	 were	 used	 for	 comparison	 in	 this	 assay.	 The	 aim	 was	 to	 maintain	 a	 similar	environment	to	the	physiological	state	of	the	CF	lung.	To	analyze	whether	Acanthamoeba	could	survive	 in	the	 lungs	of	CF	patients,	ASM	was	used	to	mimic	the	environment.	PYG	and	 RPMI	 media	 were	 used	 as	 controls	 for	 Acanthamoeba	 and	 DMEM	 for	 A549	 cells.	Trypan	blue	exclusion	assays	were	performed	to	analyze	survival	of	both	Acanthamoeba	and	A549	cells.	Acanthamoeba	exhibited	growth	ability	in	ASM	(65	x	105/mL),	RPMI	(40	x	105/mL)	and	PYG	(77	x	105/mL).	A549	cells	also	showed	ability	to	grow	in	ASM	(25	x	105)	whilst	 in	DMEM	 (41	 x	 105).	 ASM	 is	 evidenced	 to	 be	 sufficient	media	 for	Acanthamoeba	growth	(Figure	4.2).	
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	Figure	 4.2	 Acanthamoeba	 and	 A549	 cell	 line	 growth	 patterns	 in	 different	 media.	 Comparison	 of	
Acanthamoeba	 trophozoites	 and	 A549	 cells	 growth	 patterns	 in	 different	 media	 (a).	 A.	 castellanii	trophozoites	were	incubated	with	b)	ASM	and	c)	PYG	and	A549	cells	with	d)	ASM	and	e)	DMEM.	Data	are	represented	 as	 the	 means	 and	 standard	 errors	 of	 at	 least	 three	 independent	 experiments	 performed	 in	duplicate.		Scale	bars,	30	μm.	
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4.3.3	Intracellular	survival	assays		
Acanthamoeba	present	 in	 the	 lower	respiratory	 tract	could	 interact	with	bacteria	by	feeding	on	them.	It	has	been	demonstrated	that	pathogenic	bacteria	after	engulfment	develop	 strategies	 to	 stay	 undigested	 in	 Acanthamoeba	 and	 even	 keep	 the	 ability	 to	multiply.	 Pathogenic	 bacteria	 could	 use	 Acanthamoeba	 as	 a	 “Trojan	 horse”	 in	 lower	respiratory	tracts	of	CF	patients.	Examining	interaction	patterns	between	Acanthamoeba	and	 bacteria	 associated	with	 CF	 in	 ASM	 is	 therefore	 essential.	 To	 determine	 if	 bacteria	survive	 in	 Acanthamoeba	 in	 the	 artificial	 sputum	 environment,	 survival	 assays	 were	performed.	At	 the	beginning	of	assays	10	bacteria	per	Acanthamoeba	were	added.	More	than	840	S.	epidermidis,	620	MSSA,	630	E.	coli	and	1370	P.	aeruginosa	per	Acanthamoeba	survived	 in	ASM	 (Figure	 4.3a).	 It	 is	 obvious	 that	 bacteria-	Acanthamoeba	 interaction	 in	ASM	is	occurring.	However,	survival	was	lower	in	A549	cell:	per	A549	cell	S.	epidermidis,	MSSA,	E.	coli	and	P.	aeruginosa	were	2.49,	2.58,	2.51	and	1.43	respectively	(Figure	4.3b).	
Str.	pneumoniae	and	H.	influenzae	were	unable	to	survive	neither	in	Acanthamoeba	nor	in	A549	cells	in	either	type	of	medium.		
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 Figure	 4.3	 Intracellular	 survival	 rates	 of	 bacteria	 in	 different	 media.	 Above	 it	 is	 shown	 that	 all	 bacteria	exhibit	 intracellular	 survival	 in	 ASM	 inside	Acanthamoeba	 and	 A549	 cells	 except	 Str.	 pneumoniae	 and	H.	
influenzae.	These	two	bacteria	were	found	to	be	encapsulated	which	can	be	the	reason	of	no	invasion	and	survival.	Data	are	represented	as	the	means	and	standard	errors	of	at	least	three	independent	experiments	performed	in	duplicate.			
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4.3.4	Biocidal	assays	
	
4.3.4.1	Antimicrobial	activity	of	magainin	II	on	bacteria	in	ASM	To	 determine	 antimicrobial	 efficacy	 of	 magainin	 II,	 antimicrobial	 assays	 were	carried	out	(Table	4.1).	After	24	h	of	incubation	magainin	II	showed	bactericidal	effects	on	
S.	 epidermidis	 (50	 μM	 in	 LB;	 90	 μM	 in	 ASM),	MSSA	 (50	 μM	 in	 LB;	 90	 μM	 in	 ASM),	 Str.	
pneumoniae	 (40	 μM	 in	 BHI;	 80	 μM	 in	 ASM),	 E.	 coli	 (30	 μM	 in	 LB;	 70	 μM	 in	 ASM),	 P.	
aeruginosa	(40	μM	in	LB;	60	μM	in	ASM),	H.	influenzae	(30	μM	in	BHI+FE;	60	μM	in	ASM).																			
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	Table	4.1	Minimum	inhibitory	concentrations	of	magainin	II	on	bacteria	in	different	media:	in	conventional	(LB/BHI/BHI+FE),	 and	 in	 ASM.	 Data	 are	 represented	 as	 the	means	 and	 standard	 errors	 of	 at	 least	 three	independent	experiments	performed	in	duplicate.				 	 LB/BHI/BHI+FE	 ASM	
S.	epidermidis	 50	μM	 90	μM	
MSSA	 50	μM	 90	μM	
Str.	pneumoniae	 40	μM	 80	μM	
E.	coli	 30	μM	 70	μM	
P.	aeruginosa	 40	μM	 60	μM	
H.	influenzae	 30	μM	 60	μM			
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Pleurocidin,	 another	 antimicrobial	peptide	 less	 sensitive	 to	 salt	was	 examined	 in	the	 salty	 environment	 of	 ASM.	 Two	 different	 concentrations	 (10	 μM	 and	 5	 μM)	 of	pleurocidin	were	tested	against	all	bacteria	employed	in	this	project	(Figure	4.4).	10	μM	of	pleurocidin	eradicated	S.	epidermidis	(91	%	in	ASM,	94	%	in	LB),	MSSA	(73	%	in	ASM,	77	%	in	LB),	Str.	pneumoniae	(96	%	in	ASM,	99	%	in	BHI),	E.	coli	(89	%	in	ASM,	88	%	in	LB),	P.	
aeruginosa	 (80	 %	 in	 ASM,	 81	 %	 in	 LB)	 and	 H.	 influenzae	 (100	 %	 in	 ASM,	 100	 %	 in	BHI+FE).	5	μM	of	pleurocidin	eradicated	S.	epidermidis	(40	%	in	ASM,	41	%	in	LB),	MSSA	(	33	%	in	ASM,	34	%	in	LB),	Str.	pneumoniae	(44	%	in	ASM,	46	%	in	BHI),	E.	coli	(41	%	in	ASM,	38	%	 in	LB),	P.	aeruginosa	 (37	%	 in	ASM,	39	%	 in	LB)	and	H.	influenzae	 (61	%	 in	ASM,	57	%	in	BHI+FE).													
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	Figure	4.4	The	antibacterial	activity	of	pleurocidin	(NRC-13)	against	employed	bacteria	in	ASM	with	control	media	 (LB,	BHI	and	BHI+FE).	Two	various	 final	concentrations	of	pleurocidin	(10	and	5	μM)	were	 tested.	Pleurocidin	 exhibited	 similar	 effects	 on	 bacteria	 regardless	 in	which	media	 bacteria	 present.	 Pleurocidin	shows	salt	tolerance	against	ASM	salinity.	Data	are	represented	as	the	means	and	standard	errors	of	at	least	three	independent	experiments	performed	in	duplicate.	
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4.3.4.2	Amoebacidal	and	cytotoxic	effects	of	magainin	II	on	A549	in	ASM	medium	To	 determine	 the	 amoebacidal	 and	 cytotoxic	 effects	 of	 magainin	 II	 on	 cells,	cytotoxicity	assays	were	performed.	30	μM	of	magainin	II	were	completely	amoebicidal	in	PYG	 and	 50	 μM	 in	 ASM.	 This	 effect	 was	 significant	 using	 t-test	 P<0.5.	 Similar	concentrations	(30	μM	in	DMEM	and	50	μM	in	ASM)	were	100	%	cytotoxic	to	A549	cells.	Magainin	 II	 against	 TRET-NHUC	 cells	 did	 not	 show	 similar	 cytotoxic	 effect	 as	 on	 A549	cells.	50	μM	of	antimicrobial	peptide	were	cytotoxic	to	40	%	in	KGM	and	30	%	in	ASM	to	TERT-NHUC	cells	(Figure	4.5).																					
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	Figure	4.5	Biocidal	effects	of	magainin	II	on	a)	A.	castellanii	trophozoite;	b)	A549	cells;	c)	TERT-NHUC	cells.	Magainin	II	is	less	amoebicidal	in	ASM	when	compared	with	PYG;	Magainin	with	50	μM	final	concentration,	was	100	%	cytotoxic	against	A549	cells	and	30	%	cytotoxic	against	TRET-NHUC	cells.	Data	are	represented	as	the	means	and	standard	errors	of	at	least	three	independent	experiments	performed	in	duplicate.			
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Salt	 tolerant	pleurocidin	(NRC-13),	was	examined	against	Acanthamoeba	 (in	ASM	and	 PYG),	 A549	 cells	 (in	 ASM	 and	 DMEM),	 and	 TRET-NHUC	 (in	 ASM	 and	 KGM).	 Five	various	 concentrations	 of	 cationic	 peptide	 (25,	 50,	 100,	 150	 and	 200	 μM)	were	 tested.	Results	show	150	μM	of	pleurocidin	exhibited	more	than	90	%	cytotoxic	effect	on	A549	cells.	Amoebicidal	effect	was	reached	when	concentration	of	pleurocidin	was	increased	to	200	μM.	The	least	cytotoxic	effect	was	found	on	TRET-NHUC	cells,	where	200	μM	killed	70	%	of	cells	(Figure	4.6).																									
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	Figure	4.6	Biocidal	effects	of	pleurocidin	(NRC-13)	on	A.	castellanii	trophozoites,	A549	cells	and	TERT-NHUC	cells.	 As	 shown	 above	 pleurocidin	 has	 similar	 antiamobic	 effects	 in	 ASM	 and	 PYG.	 With	 the	 final	concentration	of	150	μM,	pleurocidin	is	100	%	cytotoxic	to	A549	cells.	The	200	μM	of	pleurocidin	was	70	%	cytotoxic	to	TERT-NHUC	in	ASM	and	KGM.	Data	are	represented	as	the	means	and	standard	errors	of	at	least	three	independent	experiments	performed	in	duplicate.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
	
	
0	10	
20	30	
40	50	
60	70	
80	90	
100	
Control	 25	μM	 50	μM	 100	μM	 150	μM	 200	μM	
%
	P
er
ce
nt
ag
e	
of
	c
yt
ot
ox
ic
it
y	
Concentrations	of	pleurocidin	(NRC-13)	
	Effects	of	pleurocidin	(NRC-13)	on	cells	in	different	media	
Acanthamoeba		in	PYG	
Acanthamoeba		in	ASM	
A549	in	DMEM	
A549	in	ASM	
TERT-NHUC	in	KGM	
TERT-NHUC	in	ASM	
IC50	 IC50	 IC50	
 145 
4.3.4.3	Cysticidal	activities	of	magainin	II	alone	and	in	combination	with	AgNO3	As	cysts	are	more	resistant	due	to	their	cell	wall,	it	was	aimed	primarily	to	test	the	cysticidal	effect	of	magainin	 II	 in	RPMI.	The	concentration	of	peptide	 to	reach	cysticidal	effect	was	 400	 μM.	 It	was	 decided	 to	 use	 silver	 nitrate	 in	 combination	with	 peptide	 to	reduce	the	concentration	of	peptide	used.	200	μM	of	magainin	II	in	combination	with	200	μM	 of	 silver	 nitrate	 exhibited	 cysticidal	 effect	 after	 24	 h	 of	 co-incubation.	 Magainin	 II	cysticidal	effects	in	ASM	were	less	than	in	RPMI.	At	400	μM	concentration	magainin	II	in	ASM	was	 able	 to	 kill	 40	%	of	 cysts.	 Drugs	 in	 combination	were	 able	 to	 reach	 complete	cysticidal	effect	with	higher	doses	(magainin	II	400	μM	and	silver	nitrate	400	μM)	when	compared	to	those	in	RPMI	(Figure	4.7).																			
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	Figure	4.7	Cysticidal	efficacy	of	magainin	II,	silver	nitrate	and	both	in	combination	in	a)	RPMI	and	b)	ASM.	To	 determine	 the	 cysticidal	 effect	 of	 AMP	 on	 Acanthamoeba	 cysts,	 Acanthamoeba	 trophozoites	 were	incubated	 for	 up	 to	 7	 days	 onto	 non-nutrient	 agar	 to	 facilitate	 encystment.	 Next,	 cysts	 were	 collected,	counted	and	2	x	105	cysts	/	mL	were	 incubated	for	24	h	with	different	concentrations	of	AMP	alone	or	 in	combination	wit	 silver	 nitrate.	 Cysts	without	 antimicrobial	 agents	were	 used	 as	 controls.	 The	 viability	 of	cysts	was	performed	by	trypan	blue	exclusion	assay	(0.2	%	final	concentration).		
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The	MIC	 indices	of	magainin	 II	were	different	 for	all	bacteria,	Acanthamoeba	and	A549	cells	 in	different	media.	MIC	 indices	were	higher	 in	ASM	media	(S.	epidermidis-50,	90;	 MSSA-50,	 90;	 Str.	 pneumoniae-40,	 80;	 E.	 coli-30,	 70;	 P.	 aeruginosa-40,	 60;	 H.	
influenzae-30,	 60;	 Acanthamoeba-30,	 50;	 A549	 cells-30,	 50).	 To	 investigate	 the	ultrastructural	alterations	caused	by	magainin	II	in	the	Acanthamoeba	cysts	TEM	studies	were	performed.	Acanthamoeba	cysts	were	treated	with	antimicrobial	peptide	(400	µM)	for	24	h.	Acanthamoeba	cyst	controls	were	free	of	antimicrobial	peptides.	Encystment	of	the	 Acanthamoeba	 is	 evident.	 Cell	 wall	 is	 present.	 Exposure	 of	 cysts	 to	 magainin	 II	produced	many	of	the	effects	on	cytoplasmic	integrity,	alterations	and	swelling	of	the	cyst	wall. Inside	 the	cyst,	 the	 trophozoite	presents	 signs	of	damage.	Electron-dense	granules	also	appear.	 In	cyst,	 loss	of	 the	 inner	wall	and	cell	wall	disruption	are	observed	 (Figure	4.8).																						
 148 
	Figure	4.8	Transmission	electron	microscopy	of	Acanthamoeba	cysts	untreated	and	treated	with	magainin	II.	 a)	 control,	 without	 peptide;	 b)	 with	 peptide	 (400	 μM);	 c	 &	 d)	 magnification	 of	 Acanthamoeba	 cyst	incubated	with	magainin	II.	Exposure	of	cysts	to	magainin	II	produced	many	of	 the	effects	on	cytoplasmic	integrity,	alterations	and	swelling	of	 the	cyst	wall	 (arrows	 in	b). Inside	 the	cyst,	 the	 trophozoite	presents	signs	of	damage.	 In	 cyst,	 loss	of	 the	 inner	wall	 and	cell	wall	disruption	are	observed	 (arrows	 in	 c	 and	d).	Images	were	acquired	using	an	AMT	XR60	digital	camera.														
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4.4.	Discussion	In	 order	 to	 better	 comprehend	bacterial	 infections	 associated	 with	 CF,	 it	 is	essential	to	generate	model	conditions	to	imitate	those	in	the	CF	lung,	for	example	media	designed	 to	 mimic	 the	 nutritional	 environment	 of	 CF	 sputum	 (Behrends	 et	 al.,	 2013).	Furthermore,	numerous	studies	utilize	a	more-conventional	rich	medium,	such	as	LB,	BHI	and	RPMI.	All	of	 these	media	support	development	of	bacteria	to	high	densities,	but	 the	issue	 remains	 how	 the	 variations	 in	 composition	 affect	 the	 growth,	 physiology	 and	metabolism	 of	 the	 experimented	 bacteria	 and,	 consequently,	 the	 importance	 to	 CF	infections.	 Hence,	 in	 this	 study,	 growth	 patterns	 of	 bacteria,	 Acanthamoeba	 and	 A549;	survival	rate	of	bacteria	within	Acanthamoeba	and	A549	cells;	Antimicrobial	and	cytotoxic	effects	of	magainin	II	assays	were	performed	in	artificial	sputum	medium	to	check	if	it	is	cytotoxic	to	cells	under	treatment	conditions.		Some	of	the	CF	patients	are	suffering	from	prolong	treatment	due	to	the	bacterial	infections	 and	 re-infection	 is	 not	 uncommon.	 	 We	 hypothesise	 that	 the	 presence	 of	
Acanthamoeba	 could	 play	 a	 role	 as	 they	 feed	 on	 bacteria	 and	 protect	 them	 from	unfavourable	 conditions.	 Bacteria	multiply	 inside	 and	 burse	Acanthamoeba	 to	 re-infect	the	 surroundings.	 In	 the	 presence	 of	 any	medication,	Acanthamoeba	 turn	 to	 very	 rigid	double	 walled	 cysts	 which	 is	 very	 hard	 to	 treat.	 Without	 treating	 Acanthamoeba,	 the	bacterial	infection	will	continue	in	the	CF	lungs.		Wide-ranging	 heterogeneity	 was	 observed	 in	 natural	 populations	 of	P.	
aeruginosa	recovered	 from	 CF	 patient	 sputum	 (Mowat	 et	 al.,	 2011).	 Previous	 studies	showed	that	both	phenotypic	and	genotypic	divergence	can	be	detected	during	growth	in	ASM,	making	 it	 an	 appealing	 in	 vitro	model	 of	 the	 CF	 lung	 conditions	 (Sriramulu	 et	 al.,	2005).	ASM	was	exploited	to	examine	biofilm	formation	by	Stenotrophomonas	maltophillia	(Fouhy	 et	 al.,	 2007).	 Bacteria	 (MSSA,	 Str.	 pneumoniae,	 P.	 aeruginosa	 and	 H.	 influenzae)	employed	 in	 this	 study	were	 isolated	 from	 CF	 patients,	which	 previously	mentioned	 in	various	researches	(Lipuma,	2010).	All	bacteria	were	able	to	exhibit	growth	potential	 in	ASM.	The	components	of	artificial	 sputum	such	as	sodium,	chloride,	potassium,	calcium,	ammonium,	and	magnesium	(Sanders	et	al.,	2006)	had	no	 inhibiting	effect	on	growth	of	bacteria.		
Acanthamoeba	is	 an	 opportunistic	 protist	 that	 is	 universally	 dispersed	 in	 the	environment.	 The	 routes	 of	 access	 into	 human	 organism	 for	Acanthamoeba	include	 the	
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respiratory	 tract	(Siddiqui	&	Khan,	 2012).	Acanthamoeba	 feeds	 on	bacteria	 (Martinez	&	Visvesvara,	1997).	It	is	expected	that	each	human	inhales	one	cyst	of	Acanthamoeba	a	day	(Warhurst,	 1968).	 All	 these	 facts	 lead	 to	 the	 importance	 of	 studying	 bacteria-
Acanthamoeba	interactions	in	ASM.	It	would	appear	that	the	presence	of	Acanthamoeba	in	the	 lung	 of	 CF	 patients	 could	 play	 a	 role	 in	 the	 persistence	 of	 bacterial	 infections	 and	prolong	treatment	process.	In	this	project	it	was	demonstrated	that	S.	epidermidis,	MSSA,	
E.	coli	and	P.aeruginosa	were	capable	of	surviving	intracellularly.	These	bacteria	were	able	not	 only	 to	 survive	 but	 even	 to	 multiply	 within	 Acanthamoeba	 and	 A549	 cells.	 Recent	studies	have	demonstrated	that	Vibrio	cholerae	O1	and	O139	are	capable	of	surviving	and	replicating	 inside	 Acanthamoeba	 castellanii	 (Abd	 et	 al.,	 2009).	 Several	 microbes	 have	developed	strategies	to	become	resistant	to	protists,	since	they	are	able	to	survive,	grow,	and	exit	 free-living	amoebae	after	 internalization	 (Greub	&	Raoult,	2004).	 It	was	shown	that	MRSA	and	MSSA	were	able	to	survive	and	multiply	within	Acanthamoeba	(Cardas	et	
al.,	2012b)	which	is	consistent	with	the	results	in	this	study. 	It	was	found	that	magainin	II	was	the	only	peptide	examined	in	one	study,	from	the	group	 of	 antimicrobial	 peptides	 analyzed,	 that	 exerted	 antimicrobial	 efficacy	 against	particular	 strains	of	 the	Burkholderia	cepacia	complex,	which	 is	 associated	with	 chronic	opportunistic	lung	infections	of	CF	patients	(Thwaite	et	al.,	2009).		In	this	project	an	investigation	of	the	antimicrobial	potential	of	magainin	II	against	bacterial	 strains	 associated	with	CF,	with	 the	 ultimate	 goal	 of	 elaborating	 an	 additional	effective	treatment	for	infections	with	these	pathogens	is	reported.	Antimicrobial	activity	of	magainin	II	is	shown	against	bacteria	such	as	S.	epidermidis,	MSSA,	Str.	pneumoniae,	E.	
coli,	 P.	 aeruginosa,	 H.	 influenzae	 and	 Acanthamoeba.	 Magainins	 are	 broad-spectrum,	positively	 charged,	 antimicrobial	peptides	 (Zasloff,	 1987b).	Magainin	 II	has	 earlier	been	shown	 to	 have	 antimicrobial	 potency	 against	 multidrug-resistant	 bacteria	 such	 as	meticillin-resistant	Staphylococcus	aureus	and	Pseudomonas	aeruginosa	(Giacometti	et	al.,	2005).		The	present	work	has	demonstrated	that	magainin	II	activity	was	inhibited	(2-fold)	when	used	in	ASM	compared	to	conventional	laboratory	media.	This	could	be,	because	of	the	increased	salt	concentration	in	ASM.	Magainins	have	been	reported	to	be	salt	sensitive	(Lee	et	al.,	1997).	 It	was	determined	that	healthy	sputum	fluid	had	Cl−	concentrations	of	84	±	9	mM,	whereas	CF	fluid	had	higher	Cl−	concentrations	of	129	±	5	mM	(Gilljam	et	al.,	
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1989).	 Therefore,	 the	 salt	 insensitive	 antimicrobial	 peptide,	 pleurocidin,	 was	 tested	 in	ASM	 including	 conventional	 media.	 	 Pleurocidins	 exert	 broad-spectrum	 antimicrobial	potency	at	micro	molar	concentrations	and	also	exhibit	 synergistic	activity	with	several	antimicrobial	 agents	 (Cole	 et	 al.,	 2000).	 Additionally,	 in	 contrast	 to	 many	 cationic	peptides,	 pleurocidin	 is	 insensitive	 to	 NaCl	 concentrations	 up	 to	 150	 mM,	 and	 could	therefore	 have	 employment	 in	 relatively	 high-salt	 body	 fluids	 and	 in	 treatment	 of	 lung	infections	 in	 CF	 patients,	 who	 possess	 higher	 NaCl	 content	 (Goldman	 et	 al.,	 1997b).	Consistent	 with	 previous	 studies	 in	 this	 project	 pleurocidin,	 unlike	 magainin	 II,	 was	equally	effective	in	all	media	without	significant	difference,	and	showed	salt-insensitivity	properties.	 Although	 here	 we	 hypothesize	 that	 the	 main	 cause	 of	 magainin	 II	 activity	decrease	is	saltiness	it	is	essential	to	note	that	the	potency	of	magainin	II	could	be	effected	by	the	ingredients	of	PYG	and	ASM.	Magainin	 II	 demonstrated	 antimicrobial	 efficacy,	 but	 at	 the	 same	 time	 it	 was	cytotoxic	 on	 A549	 cells.	 	 	 Researches	 have	 revealed	 a	 substantial	 cytotoxic	 effect	 of	magainin	II	against	a	broad	spectrum	of	cancer	cell	lines	comprising	melanoma,	bladder,	breast	and	lung	cancers	as	well	as	lymphomas	and	leukaemia	(Lehmann	et	al.,	2006).	 	It	has	been	proposed	that	the	moderately	greater	quantities	of	anionic	constituents,	such	as	phosphatidyl	 serine	 in	 tumour	 cells,	 may	 predominantly	 attract	 cationic	 magainins	(Iwasaki	et	al.,	2009).	Magainin	 II	was	 less	cytotoxic	against	TERT-NHUC	 in	comparison	with	 A549	 cells.	 Higher	 pleurocidin	 concentrations	 did	 not	 exert	 cytotoxic	 effects	 on	TERT-NHUC	and	exhibited	no	significant	difference	in	either	media	including	ASM.		A	 transmission	 electron	 microscope	 study	 has	 revealed	 both	 structural	 and	cytoplasmic	 membrane	 damage	 to	 A.	 castellanii	 cysts	 when	 treated	 with	 higher	concentrations	of	magainin	II	alone	or	in	combination	with	silver	nitrate.	The	antiamoebic	effect	of	magainins	has	been	previously	established	(Feldman	et	al.,	1991).	Schuster	et	al	showed	 that	magainin	peptide	 in	 combination	with	 silver	nitrate	or	other	antimicrobial	agents	 have	 in	 vitro	 activity	 against	 Acanthamoeba	 trophozoites	 and	 cysts	 (Schuster	 &	Jacob,	1992b).				 Acanthamoeba	 infections	 are	 threatening	 and	 commonly	 noncompliant	 to	antimicrobial	treatment.	An	additional	aspect	of	drug	response	to	take	into	account	is	the	differential	sensitivity	of	trophozoites	and	cysts,	the	former	being	more	sensitive	than	the	latter	(Osato	et	al.,	1991).	Cysticidal	dosages	for	various	antimicrobial	agents	range	from	10-1000	 times	 the	 doses	 effective	 against	 trophozoites	 of	Acanthamoeba	 (Nagington	 &	
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Richards,	 1976).	 Magainin	 II	 alone	 and	 silver	 nitrate	 alone	 were	 used	 against	
Acanthamoeba	 cysts.	 At	 high	 concentrations	 they	 were	 able	 to	 eliminate	 cysts.	 Several	studies	have	suggested	that	magainin	II	acts	synergistically	with	numerous	antimicrobial	agents	 including	 piperacillin,	 ceftazidime,	 imipenem,	 meropenem,	 clarithromycin	polymyxin	 E	 (Giacometti	 et	 al.,	 2000d)	 and	 silver	 nitrate	 (Schuster	 et	 al.	 1992).	A	substantial	advantage	of	the	magainins	is	their	apparent	role	in	increasing	cell	membrane	permeability	 (Zasloff	 et	 al.,	 1988).	 	 This	 has	 been	 exploited	 in	 the	 current	 study	 by	combining	magainin	 II	with	 silver	nitrate	 to	observe	 increased	antimicrobial	potency	 in	
vitro	against	A.	castellanii	cysts.	Silver	nitrate	has	an	reputable	place	in	the	pharmacopoeia	as	an	efficient	and	well-tolerated	antimicrobial	agent,	utilized	in	the	treatment	of	neonatal	ophthalmia	 (Moore	 et	 al.,	 2015).	 By	 combining	 silver	 nitrate	 with	 magainin	 II,	 greater	activity	was	established	in	the	reactions	against	cysts.	The	nature	of	boosted	antimicrobial	potency	of	magainin	II	when	used	in	combination	with	silver	nitrate	may	relate	to	influx	into	the	Acanthamoeba	cytoplasm	as	a	result	of	increased	membrane	permeability.		Here,	 it	has	been	concluded	that	these	findings	are	preliminary,	but	they	indicate	that	magainin	II	has	potential	to	be	used	against	bacterial	pathogens	and	Acanthamoeba	in	CF	patients.																									
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“Magainin	II	inhibits	the	biofilm	formation	of	bacteria		
associated	with	Cystic	Fibrosis”	
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5.1	Background	The	 lung	 of	 CF	 patients	 is	 in	 a	 prolonged	 inflammatory	 condition	 and	 reacts	inadequately	to	antimicrobial	treatment.	CF	patients	normally	suffer	from	tenacious	and	recurrent	 lung	 infections	 instigated	by	pathogens	 in	 the	CF	air	ways	(Heijerman,	2005).		Chronic	bacterial	infections	are	related	to	a	deteriorating	clinical	status	of	the	CF	patients	and	 a	 worsened	 prognosis,	 and	 once	 established,	 existing	 antibiotic	 procedures	 are	impotent	to	eliminate	these	infections	in	airways	(Römling	et	al.,	1994).	The	difficulties	in	the	treatment	efficacy	is	considered	to	be	because	of	the	formation	of	antibiotic	resistant	biofilms	in	the	CF	lungs	(Costerton	et	al.,	1999).	The	capability	of	bacteria	to	develop	and	produce	drug	resistant	biofilms	in	the	airways	of	the	CF	patients	is	assumed	to	be	eased	by	the	hyper-secretion	of	a	gluey	mucus	layer,	which	leads	to	a	low	oxygen	environment,	and	 the	 release	 of	 DNA	 and	 actin	 resulting	 from	 the	 necrosis	 of	 neutrophils	 that	 are	employed	 as	 part	 of	 the	 innate	 immune	 response	 (Boucher,	 2004).	 Bacterial	 biofilms	develop	 when	 microorganisms	 permanently	 adhere	 to	 a	 surface	 and	 manufacture	extracellular	polymers	which	enable	 the	adhesion	and	supply	a	 structural	matrix	which	stabilizes	 the	 biofilm	 (Sasirekha	 et	 al.,	 2015).	 One	 possible	 aspect	 of	 biofilm-mediated	drug	 resistance	 can	 be	 credited	 to	 the	 differential	 gene	 expression	 of	 biofilm	 cells	compared	to	their	planktonic	counterpart	(Whiteley	et	al.,	2001).				Biofilms	 can	 exist	 on	 inner,	 non-living	 surfaces	 like	medical	 equipment	 or	 living	surfaces	 like	 wounded	 tissue	 (Gayvallet-Montredon	 et	 al.,	 1998).	 Furthermore,	 these	biofilm	 cells	 can	 avoid	 the	 host	 immune	 response	 and	 remain	 unrecognized	 by	antimicrobial	agents	in	the	host	(Crossley	et	al.,	2009).		The	worrying	medical	situation	of	medical	 sphere	 is	 that	 the	 biofilm	 population	 contributes	 to	 nearly	 80%	 of	 the	 overall	microbial	infection	(Yakandawala	et	al.,	2007).	Biofilm	likewise	facilitates	swift	horizontal	gene	 transfer	 between	 bacteria	which	 can	 lead	 to	 escalation	 in	 the	 quantity	 of	 virulent	strains	(Lewis,	2001).	AMPs	 are	 considered	 to	 have	 the	 prospective	 for	 use	 as	 anti-biofilm	 agents	 for	their	 diverse	 mechanisms,	 which	 comprise	 membrane-disrupting	 ability,	 functional	inhibition	 of	 proteins,	 adhere	 to	 DNA,	 and	 detoxification	 of	 polysaccharides	(lipopolysaccharide	and	lipoteichoic	acid)	(Waters	&	Bassler,	2005b).					
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5.1.1	P.	aeruginosa		This	 is	 an	 opportunistic,	 leading	 pathogen	 in	 the	 CF	 air	 way,	 and	 by	 late	adolescence	 (Lyczak	 et	 al.,	 2002),	 80	 %	 of	 the	 CF	 patients	 are	 chronically	 infected	contributing	to	the	extreme	level	of	illness	and	death	(Goossens,	2003).	In	the	majority	of	cases	it	has	been	shown	that	the	pathogenesis	triggered	by	them	is	conditional	on	biofilm	development	(Wagner	&	Iglewski,	2008b).		
5.1.2	S.	aureus	It	is	widely	abundant	bacterium	and	is	a	commensal	of	the	human	skin,	particularly	front	 nares	 and	 skin	 wrinkles	 in	 CF	 and	 non-CF.	 An	 estimated	 30–50%	 of	 healthy	individuals	 are	 occasionally	 or	 chronically	 colonised	 by	S.	 aureus,	 with	 chronic	 nasal	carriage	being	a	risk	factor	for	S.	aureus	bacteraemia.	S.	aureus	grows	normally	aerobically	but	additionally	as	facultative	anaerobe	and	is	capable	of	biofilm	formation	(Wertheim	et	
al.,	2004).			
5.1.3	H.	influenzae	It	 is	 a	 critical	 human	 respiratory	 tract	 pathogen	 (Murphy,	 2000).	 It	regularly	infects	the	CF	patients	lungs,	particularly	early	in	childhood and	grows	adherent	biofilms	on	 the	 apical	 surface	 airway	 epithelia	 with	 reduced	 sensitivity	 to	 antimicrobial	 agents	(Starner	et	al.,	2006).			
5.1.4	Str.	pneumoniae	Persistence	 of	 indistinguishable	 clones	 with	 growing	 frequencies	 of	 antibiotic	resistance	 throughout	 prolonged	 periods	 suggests	 the	 opportunity	 of	 biofilm	 based	growth	among	 the	CF	Str.	pneumoniae	isolates	 (del	Campo	et	al.,	 2005).	Besides,	 biofilm	formation	is	accelerated	by	the	anaerobic	or	microaerophilic	environment	that	is	typical	in	the	CF	airways	(García-Castillo	et	al.,	2007).			
5.1.5	Antimicrobial	cationic	peptides		 AMPs	 have	 considerable	 appeal	 attention	 as	 substitute	 antibiotics	 for	 their	prospective	potency,	 fast	action,	and	broad	spectrum	of	activities	against	Gram-negative	and	-positive	bacteria,	viruses,	fungi	and	parasites	(Dosler	et	al.,	2015).	They	can	be	used	against	 biofilms	 or	 in	 the	 prevention	 of	 bacterial	 biofilm	 formation.	 They	 demonstrate	
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numerous	mechanisms	 of	 action	 and,	 subsequently,	 a	 low	 possibility	 to	 induce	de	novo	resistance,	which	restricts	the	use	of	other	antibiotics	(Yeung	et	al.,	2011).			
5.1.5.1	Magainin	II	Magainin	II	was	reported	to	have	anti-biofilm	activity	against	Streptococcus	species	(Wei	 et	 al.,	 2006).	 Human	 cationic	 host	 immune	 peptides	 revealed	 potent	 inhibitory	activity	against	biofilm	formation	of	bacterial	 infections	associated	with	CF	and	reduced	pre-grown	biofilms	(Moreau-Marquis	et	al.,	2008b).	Melittin	and	colistin,	were	capable	of	reducing	 attachment	 of	 P.	 aeruginosa,	 E.	 coli	 and	 Klebsiella	 pneumoniae	 (Dosler	 et	 al.,	2015).			
5.1.6	Artificial	sputum	medium	Acquiring	an	adequate	quantity	of	human	sputum	for	research	is	problematic	and	time	 consuming.	 Various	 studies	 use	 ASM	 to	 culture	 respiratory	 bacteria	 with	 an	environment	 that	 sufficiently	 imitates	 CF	 lung	 sputum	 (Sriramulu,	 2005).	 This	medium	assists	clinical	and	research	scientists	to	pay	attention	at	the	expression	of	specific	genes	and	proteins	in	an	“nearly	in-vivo”	setting	(Palmer	et	al.,	2007).		Meanwhile,	 it	has	been	confirmed	that	medically	essential	antibiotics,	comprising	aminoglycosides,	fluoroquinolones,	and	tetracycline,	among	others,	function	inadequately	in	 chronic	 infections	 and,	 on	 the	 contrary,	 even	 perform	 as	 inter-microbial	 signalling	mediators	 which	 contribute	 to	 bacterial	 biofilm	 formation	 at	 sub-inhibitory	 doses	(Linares	et	al.,	2006),	so	novel	antimicrobial	drugs	are	required	to	fight	chronic	infections.	Lately,	 screening	 techniques	 for	 anti-biofilm	 drugs	 have	 been	 established	 (Pitts	 et	 al.,	2003),	 and	numerous	high-throughput	 screenings	 of	 environmental	 natural	 compounds	were	 carried	 out	 to	 detect	 substances	 with	 anti-biofilm	 characteristics	 that	 could	 be	employed	 as	 potential	 agents	 in	 biofilm-associated	 infections	 (Junker	 &	 Clardy,	 2007).	Nevertheless,	 only	 partial	 achievement	 has	 been	 succeeded	 to	 date.	 The	 anti-biofilm	properties	of	magainin	II,	with	its	antimicrobial	potency,	could	provide	the	foundation	for	the	development	of	novel	drugs	that	could	assist	in	combating	chronic	infections.	In	 the	present	 report,	 all	 efforts	were	directed	 to	 inhibit	 the	biofilms	of	 bacteria	associated	with	CF	so	that	the	level	of	pathogenesis	can	be	monitored.		
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5.2	Materials	and	Methods	All	chemicals	were	purchased	from	Sigma-Aldrich	(UK),	unless	otherwise	stated.		
5.2.1	Preparation	of	Artificial	Sputum	Medium		ASM	was	prepared	as	indicated	in	section	4.2.1		
5.2.2	Bacterial	growth	analyses	
S.	epidermidis,	MSSA,	Str.	pneumoniae,	E.	coli,	P.	aeruginosa	and	H.	influenzae	(~1	x	106	CFU	ml-1)	were	inoculated	in	ASM	and	LB/BHI/BHI+FE	media	in	a	24	well	plate.	The	plate	was	incubated	at	37	°C	for	48	h.	After	the	incubation	period,	the	OD	at	595	nm	was	measured	 for	approximate	growth.	Each	well	was	washed	 three	 times	with	450	μL	PBS	and	air-dried.	The	cells	were	then	fixed	by	adding	250	μL	of	99	%	methanol	for	15	min,	aspirated	and	then	allowed	to	air	dry.	The	wells	were	then	stained	with	1	%	CV	solution	for	5	min.	Excess	stain	was	removed	by	washing	three	times	with	450	μL	PBS.	When	the	wells	 had	dried	 light	microscope	 images	were	 recorded.	 The	 stain	was	 then	 solubilised	with	160	μL	of	33	%	glacial	acetic	acid	and	absorbance	was	read	at	an	OD	of	570	nm	using	a	plate	reader	(Verhoeven	et	al,	2010). The	background	(values	of	 the	negative	control)	was	subtracted	from	experimental	and	control	values.		
5.2.3	Biofilm	formation	assessment	by	crystal	violet	(CV)	Biofilm	formation	of	six	types	of	bacteria	was	monitored	by	performing	CV	assay.	Overnight	saturated	cultures	of	bacteria	were	separately	inoculated	in	equal	numbers	(~1	x	106	CFU	mL-1)	in	different	wells	of	24	well	plate	containing	LB/BHI/BHI+FE/ASM	media	supplemented	with	varied	concentrations	of	sub-MIC	doses	of	magainin	II	(1,	2,	3	μM).	In	the	 control	 set,	 the	 microorganisms	 in	 same	 number	 were	 grown	 in	 the	 absence	 of	antimicrobial	 peptide.	 Plates	 were	 incubated	 at	 37	 °C	 for	 48	 h.	 After	 the	 incubation,	culture	 broths	 from	 each	well	were	 discarded.	Wells	were	washed	with	 distilled	water	twice	and	dried	adequately.	After	that,	to	each	well,	1	%	CV	was	added	and	incubated	for	15	min	 at	RT.	 CV	 solution	was	 then	discarded	 from	each	well,	 and	 then	 the	wells	were	again	washed	with	 distilled	water	 twice	 to	 remove	 any	 unabsorbed	 CV	 from	 the	wells.	Thereafter,	160	μL	of	33	%	glacial	acetic	acid	were	added	to	each	well	to	dissolve	the	CV	
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absorbed	 into	 bacterial	 biofilm	 and	 the	 intensity	 of	 colour	 was	 then	 measured	 by	recording	the	absorbance	at	570	nm. 		
5.2.4	Bacterial	growth	patterns	analyses	To	examine	the	effect	of	the	sub-MIC	doses	of	magainin	II	on	bacteria,	the	growth	pattern	of	both	the	magainin	II	treated	and	untreated	samples	of	bacteria	were	compared.	To	do	 this	 experiment,	 equal	numbers	of	 bacteria	 (~1	x	106	CFU	mL-1)	were	 inoculated	separately	in	different	24	well	plates	containing	media	(S.	epidermidis,	MSSA,	E.	coli	and	P.		were	 inoculated	 in	 LB	 broth,	 Str.	 pneumoniae	 in	 BHI	 and	H.	 influenzae	 in	 BHI	 enriched	with	 Fildes	 Extract).	 After	 that,	 various	 sub-MIC	 doses	 (1,	 2,	 3	 μM)	 of	 antimicrobial	peptide	were	 added	 to	 each	 growth	medium.	 In	 the	 control	 set,	 only	 the	 organism	was	allowed	 to	 grow	 devoid	 of	 peptide.	 All	 the	 experimental	 growth	 media	 were	 then	incubated	at	37	°C	for	48	h.	At	regular	time	intervals	(2,	4,	6	and	48	h),	the	culture	broths	were	separately	 taken	 from	each	growth	medium	and	absorbance	was	recorded	on	595	nm	in	a	spectrophotometer.		
5.2.5	Bacterial	viability	measurements	To	 examine	 the	 viability	 of	 bacteria	 in	 different	 media,	 identical	 numbers	 of	microorganisms	 treated	 with	 various	 sub-MIC	 doses	 of	 magainin	 II	 peptide	 were	inoculated.	 In	the	control	set,	peptide	was	not	added.	All	plates	were	 incubated	at	37	°C	for	 24	 h.	 For	 CFU	 calculation	 between	 peptide	 treated	 and	 untreated	 conditions,	 1/10	dilutions	 were	 performed.	 20	 μL	 of	 these	 diluted	 supernatants	 were	 plated	 onto	 solid	CLED/Blood	agar/Chocolate	agar	plates.	Thereafter,	plates	were	incubated	at	37	°C	for	2	days	and	CFU	were	counted.		
5.2.6	Microscopic	Observation	of	bacterial	attachment	To	 identify	 bacterial	 adherence	 on	 the	 surface	 of	 wells,	 overnight,	 cultures	 of	bacteria	were	 inoculated	 in	 24	well	 plates	 containing	 sterile	media	 supplemented	with	various	 concentrations	of	magainin	 II	 (1,	 2,	 3	μM).	 In	 the	 control	wells,	 no	peptide	was	added.	 	 Each	well	 was	washed	 three	 times	 and	 air-dried.	 The	 cells	 were	 then	 fixed	 by	adding	250	μL	of	99	%	methanol	 for	15	min,	aspirated	and	then	allowed	to	air	dry.	The	wells	were	then	stained	with	1	%	CV.	Excess	stain	was	removed	by	washing	three	times	distilled	water.	When	the	wells	had	dried	light	microscope	images	were	recorded.	
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5.2.7	Statistical	analysis	All	 experiments	 were	 performed	 in	 biological	 duplicates	 and	 repeated	 at	 least	thrice	 in	 independent	 experiments.	 All	 data	 were	 expressed	 as	 arithmetic	 means	 ±	standard	deviations.	 Comparisons	between	groups	were	 carried	out	using	 the	unpaired	Student	 t-test.	 P-values	 were	 determined	 by	 the	 unpaired	 Student	 t-test,	 using	 Excel	software.	Statistical	significance	was	set	at	P<0.05.																																									
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5.3	Results		
5.3.1	Biofilm	formation	assessment	by	CV	
	
5.3.1.1	Comparison	of	biofilm	formation	in	ASM		To	determine	the	effect	of	ASM	on	biofilm	formation,	CV	assays	were	carried	out.	The	 difference	 in	 biofilm	 formation	 in	 ASM	 and	 conventional	 laboratory	 media	 is	highlighted	(Figure	5.1).	ASM	was	hypothesized	to	be	unfavorable	environment	to	growth	as	 well	 as	 for	 biofilm	 formation.	 In	 this	 experiment	 conventional	 media	 were	 used	 as	controls.	 All	 clinical	 isolates	 confirmed	 that	 ASM	 is	 less	 favorable	 condition	 to	 form	biofilms.	 According	 to	 results	 acquired,	P.	 aeruginosa	 demonstrated	 the	 highest	 rate	 of	biofilm	formation	in	ASM,	whereas	the	lowest	was	displayed	by	MSSA.	If	 to	 compare	 the	ability	of	biofilm	 formation	between	Gram-negative	and	Gram-positive	 bacteria,	 it	 is	 obvious	 that	 the	 Gram-positive	 bacteria	 are	 less	 able	 of	 biofilm	formation.	It	 is	 interesting	that	S.	epidermidis	exhibited	highest	biofilm	formation	among	Gram-positive	bacteria,	as	it	 is	associated	with	medical	complexities	by	forming	biofilms	in	 medical	 devices	 such	 as	 catheters.	 However,	 the	 biofilm	 formation	 in	 ASM	 was	 not	significantly	 lower	when	compared	with	biofilm	formation	in	conventional	media	that	 is	known	to	be	favorable	condition.																			
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	Figure	5.1	Formation	of	Bacterial	biofilm	 in	ASM.	Biofilm	formation	was	observed	by	carrying	out	 the	CV	assay.	 Overnight	 cultures	 of	 bacteria	were	 inoculated	 in	media.	 Plates	were	 incubated	 for	 48	 h.	 CV	was	added,	incubated	and	were	washed.	Glacial	acetic	acid	was	added	to	dissolve	the	bound	CV	and	the	intensity	of	colour	was	measured	by	recording	the	absorbance.	Results	are	obtained	from	at	least	three	independent	experiments.	Error	bars	represent	standard	error.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
E. coli P. aeruginosa H. influenzae S. epidermidis MSSA Str. pneumoniae 
A
bs
or
ba
nc
e 
at
 5
70
 n
m
 
Bacterial strains 
Bacterial biofilm formation  
LB/BHI/BHI+FE 
ASM 
 162 
5.3.1.2	Antibiofilm	activity	of	magainin	II		In	order	to	test	anti-biofilm	activity	of	magainin	II,	biofilm	formation	assays	were	carried	 out	 by	 using	 the	 CV	 technique.	 The	 results	 revealed	 that	 all	 the	 tested	 sub-MIC	concentrations	 of	 antimicrobial	 peptide	 exhibited	 significant	 biofilm	 attenuation	compared	to	controls	where	the	microorganisms	were	grown	and	allowed	to	form	biofilm	in	absence	of	peptide.	 It	was	noticed	 that	biofilm	 formation	was	 sub-MIC	 concentration	dependant	 (Figure	 5.2).	 The	 anti-biofilm	 activity	 of	 magainin	 II	 against	 Gram-positive	bacteria	was	 lower	 in	ASM	media	when	compared	with	LB	or	BH.	The	greatest	sub-MIC	dose,	3	μM,	in	ASM	medium,	decreased	biofilm	formation	of	S.	epidermidis,	MSSA	and	Str.	
pneumoniae	 to	72	%,	57%	and	77%	respectively.	However,	 in	LB/BHI	the	same	bacteria	potential	dropped	to	81	%,	66%	and	85%	respectively.	Among	Gram-positive	bacteria,	Str.	
pneumoniae	 was	 the	 most	 sensitive	 to	 magainin	 II	 in	 both	 types	 of	 media.	 The	 Gram-negative	bacteria,	E.	coli,	P.	aeruginosa	and	H.	influenzae	were	less	susceptible	to	magainin	in	 ASM	media	 (65	%,	 81%	 and	 79	 respectively)	 than	 in	 LB/BHI	 (69	%,	 86%	 and	 87%	respectively).	 Magainin	 II	 demonstrated	 efficacy	 in	 preventing	 biofilm	 formation	 by	pathogenic	Gram-negative	bacteria	in	ASM	and	conventional	media.																				
	
	
	
			
	
			
	
			
	
 163 
		
		
		Figure	5.2	Antibiofilm	activities	of	magainin	II	 in	ASM	of	bacteria	such	as	S.	epidermidis	 (a),	MSSA	(b),	Str.	
pneumoniae	(c),	E.	coli	(d),	P.	aeruginosa		(e)	and	H.	influenzae	(f).	Conventional	media	were	used	as	controls.	Overnight	cultures	of	bacteria	were	inoculated	with	various	concentrations	of	sub-MIC	doses	of	magainin	II.	Plates	were	incubated	for	48	h.	Next,	CV	was	added,	incubated	and	washed.	Glacial	acetic	acid	was	added	to	dissolve	the	bound	CV	and	the	intensity	of	colour	was	measured	by	recording	the	absorbance.	Results	are	obtained	from	at	least	three	independent	experiments.	Error	bars	represent	standard	error.		
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Identification	of	bacterial	 adherence	on	 the	surface	of	a	well,	 supplemented	with	various	concentrations	of	magainin	II	(1,	2,	3	μM)	was	carried	out.	MSSA,	Str.	pneumoniae,	
S.	epidermidis,	E.	coli,	P.	aeruginosa	and	H.	influenzae	were	examined	in	ASM.	Conventional	media	such	as	LB,	BHI	and	BHI+FE	were	used	as	controls	for	ASM	medium.	In	the	control	wells,	no	peptide	was	added.	Images	that	obtained	from	bright	field	microscope	indicated	that	the	sub-lethal	concentrations	of	magainin	II	were	able	to	decrease	bacterial	surface	attachment.	Interestingly,	bacterial	attachment	was	less	where	the	highest	sub-MIC	doses	were	used	showing	dose	dependant	efficacy	(Figure	5.3).				
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 166 
		Figure	5.3	Microscopic	observation	of	bacterial	attachment.	Micrographs	of	CV	stained	bacterial	population	on	 the	 surface	 of	wells	 under	 different	 treatment:	 a)	 0	 μM;	 b)	 1	 μM;	 c)	 2	 μM	 and	 d)	 3	 μM.	 The	 figure	 is	representative	of	 images	obtained	 from	bright	 field	microscope	and	 from	three	 independent	experiments.	The	scale	bar,	80	μm.		
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5.3.2	Growth	Pattern	Analyses	To	 examine	 the	 effect	 of	 sub-MIC	 doses	 of	 magainin	 II	 on	 the	 growth	 cycle	 of	bacteria	associated	with	CF	infections,	bacteria	were	co-incubated	with	different	sub-MIC	concentrations	of	 antimicrobial	 peptide	 (1,	 2,	 3	 μM).	S.	epidermidis,	MSSA,	E.	coli	 and	P.	
aeruginosa		were	inoculated	in	LB	broth,	Str.	pneumoniae	in	BHI	and	H.	influenzae	in	BHI	enriched	with	Fildes	Extract.	After	the	identical	period	of	incubations	(2,	4,	6	and	48	h)	it	was	observed	that	the	magainin	II	treated	and	untreated	(control)	microbes	exactly	follow	the	 same	 trend	 in	 their	 growth	 cycle	 (Figure	 5.4).	 The	 trends	 of	 growth	 of	 all	 bacteria	were	compared	with	that	of	in	ASM.	The	growth	of	bacteria	was	less	in	ASM	but	sub-MIC	doses	 of	 magainin	 II	 did	 not	 impact	 on	 growth	 patterns	 of	 Gram-positive	 as	 much	 as	Gram-negative	bacteria.	These	results	suggest	that	sub-MIC	doses	of	magainin	II	tested	in	the	experiments	do	not	alter	the	normal	growth	behaviour	of	the	microorganisms	seen	in	either	their	own	bacterial	growth	media	(LB,	BHI	and	BHI+FE)	or	ASM.																			
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		Figure	5.4	Growth	patterns	of	bacteria	in	ASM	with	sub-MIC	doses	of	magainin	II.	To	examine	the	effect	of	the	 sub-MIC	doses	of	magainin	 II	 on	bacterial	 growth	patterns	 treated	and	untreated	 samples	of	bacteria	were	 studied.	 Bacteria	 were	 incubated	 with	 various	 sub-MIC	 doses	 of	 AMP	 and	 incubated	 for	 48	 h.	 At	regular	 time	 intervals	 absorbance	 was	 recorded.	 Results	 are	 obtained	 from	 at	 least	 three	 independent	experiments.	Error	bars	represent	standard	error.	
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5.3.3	Bacteria	viability	measurements		To	gain	further	information	about	effects	of	sub-MIC	doses	of	antimicrobial	peptide	on	the	growth	of	bacteria,	bacterial	viability	was	measured.	All	bacteria	inoculated	for	24	h	with	sub-MIC	doses	of	magainin	 II	 (1,	2,	3	μM)	either	 in	bacterial	own	media	or	ASM.	Control	 wells	 were	 inoculated	 without	 peptides.	 After	 incubation	 time,	 media	 were	diluted	 and	 inoculated	 onto	CLED	 agar	 (S.	epidermidis,	MSSA,	E.	coli	 and	P.	aeruginosa),	Blood	agar	(Str.	pneumoniae)	and	Chocolate	agar	(H.	influenzae).	Following	the	incubation	of	plates	the	CFU	was	counted.	No	significant	differences	were	observed	in	the	number	of	CFU	between	peptide	treated	and	untreated	cultures	(Figure	5.5).	This	assay	showed	that	none	of	the	tested	sub-MIC	doses	of	magainin	II	exhibited	cytotoxicity	or	growth	arresting	properties.		
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			Figure	5.5	Bacterial	viability	measurements.	To	examine	the	viability	of	bacteria	in	different	media,	identical	numbers	of	microorganisms	were	inoculated	and	treated	with	various	sub-MIC	doses	of	magainin	II	peptide.	In	the	control	set,	peptide	was	not	added.	All	plates	were	incubated	at	37	°C	for	24	h	and	plated	onto	solid	CLED/Blood	agar/Chocolate	agar	plates.	Results	are	obtained	from	at	least	three	independent	experiments.	Error	bars	represent	standard	error.	
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5.4	Discussion	The	 infected	 lung	of	CF	patients	 is	 in	a	 chronic	 inflammatory	 state	and	 responds	inadequately	 to	 antimicrobial	 treatments.	 	This	 deficiency	 in	 treatment	 efficiency	 is	thought	to	be	due	in	part	to	the	formation	of	antibiotic	resistant	biofilms	forming	in	the	CF	lung	(Moreau-Marquis	et	al.,	2008c).	The	occurrence	of	quorum-sensing	molecules	in	CF	sputum,	 utilized	 by	P.	 aeruginosa,	 S.	 aureus	 and	 H.	 influenzae	 for	 cell	 to	 cell	communication	in	 vitro	 (Fuqua	 et	 al.,	 2001)	 has	 been	 reported	 as	 indication	 that	P.	
aeruginosa		in	the	CF	lung	produce	biofilms	(Singh	et	al.,	2000).	Biofilm	 formation	 is	 an	 essential	 strategy	 for	 bacterial	 sustainability	 and	 the	expansion	 of	 disease	 (Donlan,	 2002).	 A	 reduction	 in	 biofilm	 growth	 could	 be	 seen	 as	 a	prospective	 approach	 to	 make	 the	 bacterial	 population	more	 susceptible	 to	 antibiotics	(Bjarnsholt	et	al.,	2013).		In	 this	 study	 the	 anti-biofilm	 activity	 of	 magainin	 II	 against	 P.	 aeruginosa,	 H.	
influenzae,	 E.	 coli,	 MSSA,	 Str.	 pneumoniae	 and	 S.	 epidermidis	 was	 examined.	 Artificial	sputum	 medium	 was	 used	 to	 mimic	 physiological	 circumstances	 in	 the	 CF	 lung.	 The	results	showed	that	all	the	tested	sub-MIC	doses	(1,	2	and	3	μM)	of	magainin	II	for	all	six	types	 of	 strains	 demonstrated	 significant	 biofilm	 attenuation	 for	 all	 six	 types	 of	 strains	compared	with	 controls	where	bacteria	were	grown	and	allowed	 to	 form	biofilm	 in	 the	absence	 of	 magainin	 II.	 Previously,	 magainin	 II	 showed	 anti-biofilm	 activity	 against	
Streptococcus	mutans	 (Wei	et	al.,	2006).	 It	has	been	reported	that	a	human	cationic	host	immunity	peptide,	LL-37,	exhibited	a	potent	 inhibitory	activity	 in	biofilm	 formation	at	a	concentration	 of	 2	 μM	 against	P.	 aeruginosa	 biofilm	 (Moreau-Marquis	 et	 al.,	 2008c).	Moreover,	 Dashper	et	 al.	 stated	 that	 kappacin,	 non-glycosylated	 κ-casein,	 displayed	 a	significant	reduction	of	Streptococcus	biofilm	(Dashper	et	al.,	2013).	All	 the	 observations	 under	 the	 microscope	 with	 sub-MIC	 doses	 of	 magainin	 II	showed	 ability	 to	 attenuate	 microbial	 attachment	 to	 the	 well	 surface	 considerably	compared	 to	 the	 controls.	 It	 was	 observed	 that	 in	 the	 control	 sets,	 where	 the	 bacteria	were	untreated,	a	dense	microbial	biofilm	developed	over	the	well	surface.	But	in	peptide	treated	conditions,	 it	was	 seen	 that	with	 the	 increase	 in	peptide	concentrations,	biofilm	formation	 became	 compromised.	 Similar	 research	 has	 shown	 that	 cathelicidin,	antimicrobial	polypeptides	 found	 in	 lysosomes	of	macrophages	 and	polymorphonuclear	
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leukocytes,	 and	 keratinocytes	 were	 able	 to	 inhibit	 both	 the	 attachment	 potency	 and	development	of	biofilms	by	Staphylococci	(Overhage	et	al.,	2008b).	The	 effect	 of	 sub-MIC	 doses	 of	 magainin	 II	 on	 the	 growth	 cycle	 of	 bacteria	 and	viability	were	measured	 by	 counting	 CFU.	 These	 experiments	 showed	 that	 none	 of	 the	tested	 sub-MIC	doses	of	 antimicrobial	peptide	displayed	 cell	 killing	or	 growth	arresting	properties	but	that	they	only	interfere	with	biofilm	forming	ability.	Lactoferrin	is	an	iron-binding	glycoprotein	present	in	milk	and,	to	a	lesser	extent,	in	exocrine	fluids	such	as	bile	and	 tears.	 It	 was	 similarly	 shown	 to	 have	 anti-biofilm	 activity	 at	 concentrations	 below	those	that	were	cytotoxic	and	growth	arresting	for	bacteria	(Singh	et	al.,	2002).	All	 these	 observations	 suggest	 that	 all	 the	 tested	 sub-MIC	 doses	 of	 magainin	 are	potentially	 capable	 of	 inhibiting	 the	microbial	 biofilm	 formation	without	 damaging	 the	microbial	cell	itself.	Although	 it	was	 identified	 that	 the	 antimicrobial	 peptide,	magainin	 II,	 attenuates	biofilm	development,	the	fundamental	mechanisms	of	this	biofilm	inhibition	has	not	been	investigated.	 It	 is	 hypothesized	 that	magainin	 II	may	 interfere	with	 those	 proteins	 and	enzymes	which	 are	 essential	 for	microbial	 adherence,	 or	 formation	 of	 quorum	 sensing	that	 resulted	 in	 the	 reduction	 of	 biofilm	 formation	 by	 the	 bacteria	 in	 the	 presence	 of	peptide.	 Further	 researches	 are	 requisite	 to	 interpret	 the	 underlying	 mechanisms	 of	microbial	biofilm	inhibition	by	using	magainin	II.		Exploring	 new	 agents	 that	 can	 attenuate	 microbial	 biofilm	 formation	 may	 shed	light	on	 therapeutic	strategies	 for	 infections	with	microbes	such	as	P.	aeruginosa	whose	pathogenic	potential	strongly	depends	on	successful	biofilm	formation	within	the	host.	In	this	 event,	 antimicrobial	 peptides	 could	 be	 the	 next	 generation	 of	 antibiotics	 for	contending	 multi-drug	 resistant	 and	 biofilm	 forming	 bacterial	 infections.	 Even	 though	there	 are	 obstacles	 to	 the	 administration	 of	 peptides	 as	 therapeutics,	 such	 as	 low	bioavailability,	cytotoxicity	and	high	costs,	these	complications	may	be	overcome	since	a	huge	effort	is	being	carried	out	to	bypass	the	complications	related	to	various	approaches.	These	 findings	 suggest	 that	magainin	 II	 holds	 promise	 to	 counteract	 biofilm	 formation.	Therefore,	 it	 is	 estimated	 that	 antimicrobial	 peptides	 will	 be	 considered	 the	 drugs	 of	choice	for	emerging	bacterial	infections	in	the	following	years.				
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6.1	Overview	Bacterial	pathogens	such	as	S.	aureus,	P.	aeruginosa	and	H.	influenzae	are	notorious	for	causing	infections	in	CF	patients	which	lead	to	health	complexities,	and	even	to	death.	The	 number	 of	 effective	 treatments	 remains	 insufficient.	 It	 is	 essential	 to	 study	 the	interactions	 between	 bacterial	 pathogens	 and	 epithelial	 cells	 of	 the	 respiratory	 tract.	Another	 factor	 to	 take	 into	 account	 is	 the	presence	of	Acanthamoeba	 in	 the	 respiratory	tract	that	could	contribute	to	exacerbation	of	pulmonary	infections.		Similar	 projects	 showed	 that	 S.	 aureus	 and	 P.	 aeruginosa	 adhere,	 invade	 and	survive	 within	 epithelial	 cells	 (Ichikawa	 et	 al.,	 2000).	 Virulence	 factors	 of	 S.	 aureus	(Gordon	&	Lowy,	2008)	and	P.	aeruginosa	play	key	roles	in	binding	to	and	invading	host	cells	(Ben	Haj	Khalifa	et	al.,	2011).		To	identify	if	bacteria	interact	with	epithelial	cells	and	Acanthamoeba,	 interaction	assays	were	 performed.	 Interaction	 assays	 consist	 of	 association,	 invasion	 and	 survival	assays.	 In	 association	 the	 attachment	 of	 bacteria	 on	 the	 host	 cell	 was	 examined.	 In	invasion	 assays,	 the	 number	 of	 bacteria	 invading	 the	 host	 cell	 was	 identified	 and	 in	survival	 assays,	 the	 number	 of	 bacteria	 surviving	 overnight	 after	 invading	 the	 host	 cell	was	tested.	For	these	purposes	six	types	of	bacteria	(pathogenic	MSSA,	H.	influenzae,	Str.	
pneumoniae,	 P.	 aeruginosa,	 non-pathogenic	 S.	 epidermidis	 and	 E.	 coli),	 isolated	 from	 CF	patients,	 human	 epithelial	 lung	 carcinoma	 (A549)	 cell	 line	 and	 Acanthamoeba	trophozoites	were	 studied.	 The	 results	 clearly	 showed	 that	S.	 epidermidis,	MSSA,	E.	 coli	and	P.	aeruginosa	have	the	ability	to	associate,	invade	and	survive	within	A549	cells.		
Acanthamoeba	was	identified	as	able	to	host	Escherichia	coli	(Alsam	et	al.,	2006),	P.	
aeruginosa	 (Michel	 et	al.,	 1995)	 and	MRSA	 (Cardas	 et	al.,	 2012a)	 protecting	 them	 from	extracellular	undesirable	functions.		Findings	of	this	study	indicate	that	Acanthamoeba	(genotype	T4),	was	able	to	host	
S.	epidermidis,	MSSA,	E.	coli	and	P.	aeruginosa.	This	is	interesting	as	Acanthamoeba	could	play	an	additional	role	in	pulmonary	exacerbated	infections	associated	with	CF.	Moreover,	bacteria	can	remain	and	multiply	 inside	Acanthamoeba	within	a	harsh	environment	that	may	 lead	 to	 distribution	 of	 bacterial	 pathogens	 to	 susceptible	 hosts	 and	 also	 to	reinfection.		
 177 
However,	H.	 influenzae	 and	 Str.	 pneumoniae	exhibited	 very	 low	 ability	 to	 invade	and	 even	 no	 ability	 to	 survive	within	 both	 A549	 cells	 and	Acanthamoeba	 trophozoites.	This	could	be	because	of	the	presence	of	bacterial	capsules,	which	prevent	phagocytosis.		Both	H.	 influenzae	and	Str.	pneumoniae	 have	 encapsulated	 and	 non-encapsulated	phenotypes.	Bacterial	capsule	possession	is	one	of	the	key	virulent	factor	which	prevents	host	 phagocytosis	 (Merino	 &	 Tomás,	 2015).	 In	 similar	 study	 it	 was	 shown	 that	 the	H.	
influenzae	capsule	inhibits	ingestion	by	macrophages	(Noel	et	al.,	1992).	Str.	pneumoniae	polysaccharide	capsules	were	able	to	resist	host	phagocytosis	(Hyams	et	al.,	2010).		In	order	to	identify	the	presence	of	capsules	in	H.	influenzae	and	Str.pneumoniae,	PCR	and	Electron	Microscopy	Imaging	assays	were	performed.	Consistent	with	both	results	it	was	identified	that	both	strains	are	encapsulated.		The	presence	of	antimicrobial	substances	in	microorganisms	is	a	fact	and	they	are	accepted	 to	be	an	ancient	defence	 system	against	other	microorganisms.	The	predatory	role	of	Acanthamoeba	in	the	regulation	of	bacterial	populations	 in	the	ecosystem	as	well	as	 the	 capability	 of	 the	 amoeba	 to	 perform	 as	 a	 “Trojan	 horse”	 of	 the	microbial	 world	suggests	 that	 bacteria-amoeba	 are	 involved	 in	 complex	 communications	 (Jousset	 et	 al.,	2010).	 The	 exact	 nature	 of	 such	 complicated	 interactions	 remains	 unclear,	 but	 it	 is	identified	in	this	project	that	both	bacteria	and	amoebae	are	competent	to	counter-attack	one	 another	 and	 the	 overwhelming	 micro-organismal	 populations	 by	 discharging	antimicrobial	 substances.	 Proteases	 produced	 by	Acanthamoeba	are	 used	 as	 significant	markers	 to	differentiate	between	pathogenic	and	non-pathogenic	Acanthamoeba	species	(Khan	et	al.,	2000;	Sissons	et	al.,	2006;	Dudley	et	al.,	2008).	Acanthamoeba	proteases	have	antimicrobial	effects	against	different	types	of	bacteria	including	MRSA	and	P.	aeruginosa	(Iqbal	et	al.,	2014).	Among	six	bacteria	tested,	it	is	attention-grabbing	that	ACM	exhibited	selective	 and	 effective	 activity	 against	 Str.	 pneumoniae,	 which	 is	 a	 pathogen	 of	 acute	infections,	 many	 of	 which	 may	 possess	 strong	 epidemiological	 consequences,	 such	 as	meningitis,	 otitis	 media,	 pneumonia,	 and	 sinusitis.	 Simultaneously	 some	 clones	 of	 Str.	
pneumoniae	 may	 be	 implicated	 in	 initial	 stages	 of	 lung	 inflammation	 in	 CF	 patients	(Rosenfeld	et	al.,	2003).	The	selective	and	potent	nature	of	ACM	against	Str.	pneumoniae	and	partially	against	MSSA	and	P.	aeruginosa,	but	not	against	S.	epidermidis,	E.	coli	and	H.	
influenzae	should	be	further	studied.		
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A	 great	 quantity	 of	 microorganisms	 has	 been	 examined	 for	 the	 isolation	 of	hypothetically	advantageous	antimicrobials,	while	 there	has	been	effort	 in	searching	 for	new	antibiotics	from	other	sources	(Iqbal	et	al.,	2014).	It	 is	possible	that	bacteria	resistant	to	ACM	and	Acanthamoeba	develop	strategies	to	protect	 themselves	and	withstand	amoebic	attack	 (Pantosti	&	Venditti,	2009).	Still	 to	come	 are	 examinations	 where	 ACM	 will	 be	 tested	 against	 a	 broad	 range	 of	 bacterial	pathogens	 to	 identify	 broad-spectrum	 or	 species-specific	 antibacterial	 properties.	 The	detection	 of	 antibacterial	 compounds	 from	Acanthamoeba	will	 perhaps	 lead	 to	 ideas	 for	future	investigations	in	other	free-living	protists	as	a	prospective	source	of	antibiotics	for	the	treatment	of	bacterial	pathogens.	Due	to	emerging	tendencies	in	antibiotic	resistance	in	 various	 pathogenic	 bacteria	 (Alanis,	 2005),	 the	 current	 findings	 in	 this	 study	 show	some	promise	in	our	future	ability	to	fight	infections	caused	by	bacteria.		Correspondingly,	among	various	bacterial	strains	studied,	BCM	of	Str.	pneumoniae,	
P.	 aeruginosa	 and	 H.	 influenzae	 displayed	 quantifiable	 amoebistatic	 and	 amoebicidal	activities.		Upcoming	 investigations	 will	 determine	 the	 fact	 of	 whether	 these	 BCM	 possess	selective	effects	on	Acanthamoeba	or	possess	broad-spectrum	activities	on	diverse	protist	pathogens.		Surprisingly,	 neither	 ACM	 nor	 BCM	 were	 significantly	 cytotoxic	 to	adenocarcinomic	human	alveolar	basal	epithelial	cells	in	vitro.		The	 current	 findings	 may	 lead	 to	 identifying	 complementary	 sources	 of	antimicrobials	 with	 novel	 modes	 of	 action	 to	 challenge	 pulmonary	 infections.	 As	antimicrobial	 resistance	 of	 pathogens	 rises,	 discovery	 of	 novel	 antimicrobial	 agents	 is	essential.	In	 recent	 years,	 the	 rapid	 increase	 in	 multi-resistant	 bacteria	 has	 prompted	 a	growing	 interest	 in	 antimicrobial	 peptides	 as	 an	 alternative	 to	 conventional	 antibiotics.	Compared	 with	 conventional	 antibiotics,	 which	 act	 by	 interfering	 with	 a	 specific	biochemical	 reaction	 inside	 the	 cell,	 antimicrobial	 peptides	 are	 believed	 to	 disrupt	 the	bacterial	membrane	 in	a	non-receptor-mediated	fashion.	The	exact	mechanism	of	action	has	not	yet	been	fully	described.		This	is	a	first	study	to	examine	antimicrobial	effects	of	magainin	II	peptide	against	
Acanthamoeba	castellanii	and	internalized	bacteria	associated	with	CF.			
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In	 this	 study,	 various	 time	 intervals	 along	 with	 different	 concentrations	 of	magainin	 II	 were	 found	 to	 demonstrate	 antimicrobial	 efficacy	 in	 vitro.	 Similar	 studies	revealed	that	magainins	had	been	shown	to	be	effective	against	Acanthamoeba	polyphaga	(Schuster	 &	 Jacob,	 1992),	 Paramecium	 caudatum	 (Zasloff	 et	 al.,	 1988)	 Leishmania	(Guerrero	et	al.,	2004),	Tryponosoma	cruzi,	and	Entamoeba	histolytica	(Huang	et	al.,	1990).		On	 the	 other	 hand,	 as	 cationic	 antimicrobial	 peptides	 show	 broad-range	 activity	against	 Gram-positive	 and	 Gram-negative	 bacteria	 (Hancock	&	 Sahl,	 2006),	magainin	 II	was	 tested	 against	 bacteria	 employed	 in	 this	 study	 and	 it	 displayed	 significant	antibacterial	potency.	 	Recently,	a	study	quantified	magainin	II	activity	within	3	hrs,	and	increasing	peptide	concentration	positively	correlated	with	the	extent	of	MRSA	and	E.	coli	membrane	disruption	(O’Brien-Simpson	et	al.,	2016).		Similar	studies	showed	magainin	II	inhibited	the	growth	of	P.	aeruginosa	(Dosler	&	Karaaslan,	2014),	S.	epidermidis	(Imura	et	al.,	2007),	Str.	pneumoniae	(Kovács	et	al.,	2006),	and	H.	influenzae	(Bishop-Hurley	et	al.,	2005).			Bacteria	 able	 to	 survive	 could	 contribute	 to	 reinfections.	 It	 is	 crucial	 to	 be	 able	 to	eradicate	intracellular	bacteria	without	harming	host	cells.	In	this	case,	it	was	A549	cells.	Magainin	 II	 in	 sub-cytotoxic	 concentrations	 was	 not	 able	 to	 eradicate	 intracellular	bacteria,	 but	 could	 do	 so	when	 used	 in	 combination	with	 other	 antimicrobials	 such	 as	silver	nitrate,	vancomycin	and	ciprofloxacin.			 In	the	current	project,	by	combining	magainin	II	with	silver	nitrate,	an	effective	and	well-tolerated	 antimicrobial	 reagent	 (Unger	&	Luck,	 2012),	 greater	 activity	was	 seen	 in	the	experiments	against	intracellular	bacteria.	This	allowed	use	of	magainin	II	and	silver	nitrate	at	concentrations	lower	than	minimum	cytotoxic	concentrations,	with	continuous	activity.	 The	 reasons	 for	 the	 greater	 efficacy	 of	 silver	 when	 used	 in	 combination	 with	magainin	 II	 may	 be	 associated	 with	 influx	 into	 the	 Acanthamoeba	 or	 A549	 cell	 line	cytoplasm	 as	 a	 result	 of	 increased	 membrane	 permeability.	 This	 hypothesis	 can	 be	supported	by	results	obtained	in	this	study,	where	sub-lethal	doses	of	antibiotics	such	as	vancomycin	and	ciprofloxacin	were	combined	with	magainin	II.		Magainin	II	was	found	to	be	cytotoxic	to	the	A549	cell	line.	This	is	consistent	with	another	study	(Pascariu	et	al.,	2012).	The	greater	cytotoxicity	could	be	related	to	the	outer	negative	charge	of	cancerous	cells.	Exposure	of	the	negatively	charged	phosphatidylserine	(PS)	on	the	surface	of	cancerous	and	other	pathological	cells	(Zwaal	et	al.,	2005),	as	well	
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as	 apoptotic	 cells	 (Martin	 et	 al.,	 1995)	 and	 thus	 PS	 represents	 a	 promising	 target	 for	positively	charged	magainin	II.		It	is	fundamental	to	generate	model	media	to	mimic	those	in	the	CF	lung	(Behrends	
et	al.,	2013).	Conventional	media	such	as	LB,	BHI	and	RPMI	support	growth	of	bacteria,	but	the	issue	remains	how	the	nutritional	environment	affects	the	growth	and	interaction	of	bacteria	with	host	cells.	All	bacteria	employed	in	this	study	were	able	to	exhibit	growth	potential	 in	ASM.	The	 ionic	components	of	artificial	 sputum	such	as	 sodium,	chloride,	potassium,	calcium,	ammonium,	and	magnesium	(Sanders	et	al.,	2006)	had	no	 inhibiting	effect	on	growth	of	bacteria.		
Acanthamoeba	is	 an	 opportunistic	 protist	 that	 is	 universally	 dispersed	 in	 the	environment.	 The	 routes	 of	 access	 into	 human	 organism	 for	Acanthamoeba	include	 the	respiratory	 tract	(Siddiqui	 &	 Khan,	 2012).	 Moreover,	 Acanthamoeba	 feeds	 on	 bacteria	(Martinez	&	Visvesvara,	 1997).	These	data	 lead	 to	 the	 importance	of	 studying	bacteria-
Acanthamoeba	interactions	in	ASM.	In	the	conditions	similar	to	CF	sputum,	S.	epidermidis,	MSSA,	 E.	 coli	 and	 P.	 aeruginosa	 demonstrate	 ability	 to	 survive	 intracellularly.	 These	bacteria	 were	 able	 not	 only	 to	 survive	 but	 also	 to	 multiply	 within	 host	 cells	 such	 as	
Acanthamoeba	and	A549	cells.		Magainin	 II	 was	 shown	 to	 express	 a	 bactericidal	 effect	 on	Burkholderia	 cepacia,	which	is	associated	with	chronic	opportunistic	lung	infections	of	CF	patients	(Thwaite	et	
al.,	2009).	In	order	to	analyse	the	antimicrobial	effect	of	Magainin	II,	antimicrobial	assays	were	performed.	The	cationic	peptide	was	identified	as	bactericidal	against	S.	epidermidis,	MSSA,	Str.	pneumoniae,	E.	coli,	P.	aeruginosa,	H.	influenzae	as	well	as	amoebicidal	against	A.	
castellanii	 trophozoites. In	 earlier	 studies	 Magainin	 II	 has	 been	 shown	 to	 have	antimicrobial	 potency	 against	 pathogenic	 S.	 aureus	 and	P.	 aeruginosa	 (Giacometti	 et	 al.,	2005).  Interestingly,	 the	 present	 work	 has	 demonstrated	 that	 magainin	 II	 activity	 was	inhibited	 (2-fold)	when	 used	 in	 ASM	 compared	 to	 conventional	 laboratory	media.	 This	could	 be	 because	 of	 the	 increased	 salt	 concentration	 in	 ASM	 (Gilljam	 et	 al.,	 1989).	Magainins	have	been	reported	to	be	salt	sensitive	(Lee	et	al.,	1997).	The	less	salt	sensitive	pleurocidin	 (Goldman	 et	 al.,	 1997b)	 was	 examined	 for	 antimicrobial	 potency	 in	 ASM.	Consistent	 with	 previous	 studies	 in	 this	 project	 pleurocidin,	 unlike	 magainin	 II,	 was	
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equally	effective	in	all	media	without	significant	difference,	and	showed	salt-insensitivity	properties.		Cytotoxic	 effects	 of	magainin	 II	 on	 Normal	 human	 urothelial	 cells	 (TERT-NHUC)	were	 tested	 to	 compare	 with	 A549	 cells.	 Magainin	 II	 was	 less	 cytotoxic	 against	 TERT-NHUC	(at	least	2	fold)	in	comparison	with	A549	cells.	Higher	pleurocidin	concentrations	did	not	exert	cytotoxic	effects	on	TERT-NHUC	cells	and	exhibited	no	significant	difference	in	either	media	 including	ASM.	The	antiamoebic	effect	of	magainins	has	been	previously	established	 (Feldman	 et	 al.,	 1991).	 Schuster	 et	 al	 showed	 that	 magainin	 peptide	 in	combination	with	silver	nitrate	or	other	antimicrobial	agents	have	in	vitro	activity	against	
Acanthamoeba	trophozoites	and	cysts	(Schuster	&	Jacob,	1992b).		
Acanthamoeba	 infections	 are	 threatening	 and	 commonly	 noncompliant	 to	antimicrobial	treatment.	An	additional	aspect	of	drug	response	to	take	into	account	is	the	differential	sensitivity	of	trophozoites	and	cysts,	the	former	being	more	sensitive	than	the	latter	(Osato	et	al.,	1991).	Cysticidal	dosages	for	various	antimicrobial	agents	range	from	10-1000	 times	 the	 doses	 effective	 against	 trophozoites	 of	Acanthamoeba	 (Nagington	 &	Richards,	1976).		Consistent	with	similar	studies,	a	transmission	electron	microscope	examination	in	the	current	project	has	revealed	both	structural	and	cytoplasmic	membrane	damage	to	A.	
castellanii	 (T4	 genotype)	 cysts	when	 treated	with	 higher	 concentrations	 of	magainin	 II	alone	or	in	combination	with	silver	nitrate.		The	 lung	 of	 CF	 patients	 is	 in	 a	 chronic	 inflammatory	 state	 and	 responds	inadequately	to	antimicrobial	treatments.		This	deficiency	in	treatment	efficiency	might	be	due	 in	 part	 to	 the	 formation	 of	 antibiotic	 resistant	 biofilms	 forming	 in	 the	 CF	 lung	(Moreau-Marquis	 et	 al.,	 2008c).	 The	 occurrence	 of	 quorum-sensing	 molecules	 in	 CF	sputum,	 utilized	 by	P.	 aeruginosa,	 S.	 aureus	 and	 H.	 influenzae	 for	 cell	 to	 cell	communication	in	 vitro	 (Fuqua	 et	 al.,	 2001)	 has	 been	 reported	 as	 indication	 that	P.	
aeruginosa		in	the	CF	lung	produce	biofilms	(Singh	et	al.,	2000).	In	the	current	study	the	antibiofilm	activity	of	magainin	II	against	P.	aeruginosa,	H.	
influenzae,	 E.	 coli,	 MSSA,	 Str.	 pneumoniae	 and	 S.	 epidermidis	 was	 examined.	 Artificial	sputum	 medium	 was	 used	 to	 mimic	 physiological	 circumstances	 in	 the	 CF	 lung.	 The	results	 show	 that	 all	 the	 tested	 sub	MIC	doses	of	magainin	 II	 for	 all	 six	 types	of	 strains	demonstrated	significant	biofilm	attenuation	compared	 to	controls	where	bacteria	were	grown	and	allowed	to	form	biofilm	in	the	absence	of	magainin	II.		
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Previously,	magainin	 II	 showed	 antibiofilm	 activity	 against	 Streptococcus	mutans	(Wei	et	al.,	2006).	It	has	been	reported	that	a	human	cationic	host	immunity	peptide,	LL-37,	 exhibited	 a	 potent	 inhibitory	 activity	 in	 biofilm	 formation	 at	 low	 concentrations	against	P.	aeruginosa	biofilm	(Moreau-Marquis	et	al.,	2008c).		All	 the	 observations	 under	 the	 microscope	 with	 sub	 MIC	 doses	 of	 magainin	 II	showed	 ability	 to	 considerably	 decrease	 microbial	 attachment	 to	 the	 well	 surface	compared	 to	 the	 controls.	 It	 was	 observed	 that	 in	 the	 control	 sets,	 where	 the	 bacteria	were	 untreated,	 a	 dense	 microbial	 biofilm	 developed	 over	 the	 well	 surface.	 Similar	research	 has	 shown	 that	 cathelicidin	 of	 macrophages	 are	 able	 to	 inhibit	 both	 the	attachment	 potency	 and	 development	 of	 biofilms	 by	 Staphylococci	 (Overhage	 et	 al.,	2008b).	None	of	the	tested	sub	MIC	doses	of	antimicrobial	peptide	displayed	cell	killing	or	growth	 arresting	 properties	 but	 that	 they	 only	 interfere	 with	 biofilm	 forming	 ability	similar	 to	 lactoferrin	 which	 was	 shown	 to	 have	 antibiofilm	 activity	 at	 concentrations	below	those	that	were	cytotoxic	(Singh	et	al.,	2002).	All	 these	 observations	 suggest	 that	 all	 the	 tested	 sub	 MIC	 doses	 of	 magainin	 II	 are	potentially	capable	of	inhibiting	the	microbial	biofilm	formation.	Although	 it	 was	 demonstrated	 that	 the	 antimicrobial	 peptide,	 magainin	 II,	attenuates	 biofilm	 development,	 the	 fundamental	mechanisms	 of	 this	 biofilm	 inhibition	have	not	been	 investigated.	 It	 is	hypothesized	that	magainin	 II	may	 interfere	with	 those	proteins	 and	 enzymes	 which	 are	 essential	 for	 microbial	 adherence,	 or	 formation	 of	quorum	sensing	that	resulted	in	the	reduction	of	biofilm	formation	by	the	bacteria	in	the	presence	of	peptide.		The	overuse	and	misuse	of	antibiotics	result	in	mutations	of	bacteria,	which	lead	to	antibiotic	resistance.	For	this	reason,	antimicrobial	peptides	could	be	the	next	generation	of	antibiotics	for	contending	multi-drug	resistant	and	biofilm	forming	bacterial	infections.	Even	though	there	are	obstacles	to	the	administration	of	peptides	as	therapeutics,	such	as	low	 bioavailability,	 cytotoxicity	 and	 high	 costs,	 these	 complications	 may	 be	 overcome	since	 a	 huge	 effort	 is	 being	 carried	 out	 to	 bypass	 the	 complications	 related	 to	 various	approaches.	Findings	in	this	project	suggest	that	magainin	II	holds	promise	to	counteract	pulmonary	 infections	 associated	 with	 CF.	 Therefore,	 it	 is	 estimated	 that	 antimicrobial	peptides	will	 be	 considered	 the	drugs	 of	 choice	 for	 emerging	bacterial	 infections	 in	 the	near	future.	
 183 
6.2	Limitations	of	the	study	The	 use	 of	 two	 types	 of	 cell	 lines,	Acanthamoeba,	 three	 Gram-positive	 (MSSA,	 S.	
epidermidis,	 Str.	 pneumoniae)	 and	 three	 Gram-negative	 (P.	 aeruginosa,	 E.	 coli,	 H.	
influenzae)	bacteria	was	a	unique	 feature	of	 this	study.	Several	 techniques	were	used	 in	this	 project	 including	 interaction	 assays,	 antimicrobial	 activity	 (MBC	 and	 MIC),	 LDH	cytotoxicity	 colorimetric	 assays,	 electron	 microscopy,	 flow	 cytometry,	 PCR	 and	bioimaging.	On	the	other	hand,	there	were	limitations	of	this	study.			One	 of	 the	 limitations	was	 that	 the	 A549	 epithelial	 cell	 line	was	 derived	 from	 a	cancerous	tissue	and	does	not	represent	the	epithelial	tissue	of	a	healthy	individual.	This	cell	line	may	not	express	the	same	receptors	as	normal	healthy	epithelial	cells,	therefore	the	interaction	of	bacteria	with	the	A549	epithelial	cell	line	may	not	be	representative	of	the	interaction	which	would	take	place	in	a	healthy	individual.			Clinical	 isolates	of	MSSA,	S.	epidermidis,	Str.	pneumoniae,	P.	aeruginosa,	E.	coli	and	
H.	influenzae	were	used	in	this	study.	The	virulence	factors	of	individual	strains	have	not	been	 characterized.	 To	 study	 individual	 virulence	 factors,	 inhibitors	 or	 mutant	 strains	lacking	one	or	more	virulence	factors	could	be	used.		
	
Acanthamoeba	 employed	 in	 this	 study	was	 not	 isolated	 from	 CF	 patients.	 It	was	planned	 to	 investigate	 the	 lower	 respiratory	 sputum	 samples	 for	 the	 presence	 of	
Acanthamoeba.	 Despite	 all	 efforts	 of	 the	 author	 to	 get	 ethical	 approval	 for	 isolation	 of	
Acanthamoeba	from	lower	respiratory	tract	of	CF	patients	due	to	bureaucratic	barriers	it	was	 not	 possible	 to	 obtain	 permission	 to	 perform	 experiments	 in	 Colchester	 General	Hospital,	Microbiology	Laboratory.									
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6.3	Recommendations	for	future	work	The	findings	presented	in	this	thesis	highlighted	some	aspects	of	an	Acanthamoeba	role	 in	 pulmonary	 infections	 in	 CF	 lung,	 along	 with	 the	 pathogenesis	 of	 MSSA,	 Str.	
pneumoniae,	 H.	 influenzae	 and	 P.	 aeruginosa,	 and	 the	 promise	 of	 using	 antimicrobial	cationic	 peptide	magainin	 II	 as	 an	 alternative	 therapeutic	method.	 There	 are,	 however,	needs	 for	 further	 investigations	 to	 give	 a	 better	 picture	 for	 Acanthamoeba’s	 role	 in	pulmonary	infections	as	well	as	use	of	magainin	derivatives	as	an	antibiotic.			1.	 Experiments	 for	 the	 identification	 of	 Acanthamoeba	 presence	 in	 CF	 sputum	 are	essential.	 These	 will	 include:	 Ethical	 approvals	 application,	 collecting	 sputum	 from	 CF	patients,	grow	and	isolate	Acanthamoeba	and	genotype	identification.		2.	 Epidemiological	 retrospective	 study	 of	 last	 10	 years	 to	 identify	 the	 incidence	 of	 AGE	among	CF	patients	is	essential.	3.	Further	 investigations	of	 the	virulence	 factors	most	responsible	 for	cytotoxicity	could	be	 worth	 studying.	 To	 assess	 that,	 a	 few	 cell	 types	 derived	 from	 healthy	 human	 lung	epithelial	tissue	are	required.	In	addition,	different	bacterial	strains	lacking	one	or	more	of	the	virulence	factors	could	be	used	on	the	above-mentioned	cells.	Many	techniques	would	be	 helpful	 to	 assess	 that:	 for	 the	 level	 of	 proteins,	 flow	 cytometry,	 fluorescence	microscopy,	 and	 western	 blot	 using	 antibodies;	 and	 at	 the	 gene	 level,	 such	 as	 PCR,	sequencing	 and	 bioinformatics.	 Regarding	 BCM,	Nuclear	Magnetic	 Resonance	 technique	could	be	employed	to	identify	lactate	or	other	by	products	of	fermentative	growth.		4.	Conditioned	media	of	Acanthamoeba	and	bacteria	employed	in	this	project	were	found	to	have	antimicrobial	properties.	Further	investigations	will	determine	the	fact	of	whether	these	ACM/BCM	possess	selective	effects	on	microorganisms	or	possess	broad-spectrum	activities	on	diverse	microbial	pathogens.	5.	 Here,	 it	 was	 shown	 that	 the	 antimicrobial	 peptide,	 magainin	 II,	 attenuates	 biofilm	development,	and	the	fundamental	mechanisms	of	this	biofilm	inhibition	has	to	be	further	investigated.	 Magainin	 II	 may	 interfere	 with	 those	 proteins	 and	 enzymes,	 which	 are	essential	for	microbial	adherence,	or	formation	of	quorum	sensing.			 		
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Appendix	1:	List	of	reagents	and	chemicals		
	
7.1	List	of	reagents	and	chemicals		
Dulbecco’s	Modified	Eagle’s	Medium	(DMEM)		 (GibcoTM	61965026)		
MEM	Non-Essential	Amino	Acid	Solution	(100×)		 (Sigma	7145)		Fetal	Bovine	Serum		 (Fisher	Scientific10117272)	Phosphate	buffered	saline	(PBS)		 (Sigma	P4417)	Bacteriological	agar		 (Sigma	A5306)		CLED	Agar		 (Sigma	55420)		Ringers	solution		 (Sigma	96724)		D-(+)-Glucose		 (Sigma	G8270)		Peptone	Water		 (Sigma	70179)		Yeast	Extract		 (Sigma	92144)		Trypsin-EDTA	solution		 (Sigma	T4174)		Sodium	chloride	(NaCl)		 (Sigma	S7653)		Tryptone		 (Sigma	T7293)		Accutase®	solution		 (Sigma	A6964)		Magnesium	sulfate	heptahydrate		 (Sigma	M1880)		Calcium	chloride	dihydrate		 (Sigma	223506)									
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7.1.1	Antibiotics	and	antimicrobial	agents			Silver	nitrate	(AgNO3)		 (Sigma	792276)	Pleurocidin		 (AnaSpec	ANA64981)	Magainin	2		 (AnaSpec	ANA20639)	Vancomycin		 (Sigma	V2002)		Ciprofloxacin		 (Sigma17850)		
	
7.1.2	Reagent	for	Electron	Microscopy	Sodium	phosphate	monobasic	 (Sigma	74092)	Sodium	phosphate	dibasic	 (Sigma	71653)		Glutaraldehyde	solution	 (Sigma	G7526)	Sodium	cacodylate	trihydrate	 (Sigma	C0250)	
	
7.1.3	Reagent	for	Fluorescence	Microscopy	Rose	Bengal	 (Sigma	198250)	Lysotracker	Green	 (ThermoFisher	L7526)	
	
7.1.4	Kits		QIAamp	DNA	Micro	Kit		 (QIAGEN	56304)		QIAquick	Gel	Extraction	Kit		 (QIAGEN	28704)		Cytotoxicity	Detection	Kit	(LDH)		 (ROCHE	11644793001)		
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7.1.5	Reagents	for	flow	cytometry		
	Annexin	V-FITC	 (BioLegend	640906)		Annexin	V	Binding	Buffer		 (BioLegend	422201)		Cell	staining	buffer		 (BioLegend	420201)		Zombie	NIR		 (BioLegend	423106)		
	
7.1.6	Reagents	for	PCR	and	gel	electrophoresis		Agarose		 (Fisher	Scientific	10776644)		dNTP	Mix		 (Thermo	ScientificTM	R0241)		Taq	DNA	Polymerase		 (Thermo	ScientificTM	EP0401)		SafeView	Nucleic	Acid	Stain		 (NBS-Biologicals	NBS-SV1)		GeneRuler	1	kb	DNA	Ladder		 (Thermo	ScientificTM	SM0311)		
	
7.1.7	General	reagents		Ethylenediaminetetraacetic	acid	(EDTA)	(10×)		 (Sigma	E9884)		Acetone		 (Fisher	Scientific	10045800)		CelLyticTM	M		 (Sigma	C2978)		Virkon		 (Fisher	Scientific	12358667)		Ethanol		 (Fisher	Scientific	BP2818)		Dimethyl	Sulfoxide	(DMSO)		 (Sigma	D2650)		
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Appendix	2:	List	and	preparation	of	buffers	and	cultured	medium		
7.2	List	and	preparation	of	buffers	and	cultured	medium		
7.2.1	Saline		
7.2.1.1	Page's	Amoeba	Saline:		Solution1:		Sodium	phosphate	dibasic	(Na2HPO4)			 0.142	g		Potassium	phosphate	monobasic	(KH2PO4)			 0.136	g		DI	Water			 500.0	ml		• Autoclave	at	121oC	for	15	min			Solution2:			Magnesium	Sulfate	Heptahydrate	(MgSO4.7H2O)			 4.0	mg		Calcium	chloride	dehydrate	(CaCl2.2H2O)		 4.0	mg		Sodium	chloride	(NaCl)			 0.120	g		Distilled	Water			 500.0	ml		• Autoclave	at	121°C	for	15	min			• Combine	solutions	1	and	2	when	cooled	to	room	temperature.			
7.2.1.2	Ringers	solution	1/4	strength	tablets:	One	tablet	is	sufficient	for	500ml	contained:		Calcium	chloride	 0.12	g/l																										Potassium	chloride	 0.105	g/l		Sodium	bicarbonate	 0.05	g/l		Sodium	chloride	 2.25	g/l		
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Phosphate	buffered	saline	(PBS)	tablets:	One	tablet	dissolved	in	200	ml	of	distilled	water	giving	0.01	M	phosphate	buffer	contained:		Potassium	chloride			 0.0027	M			Sodium	chloride			 0.137	M			• Autoclave	at	121°C	for	15	min.	pH	7.4,	at	25	°C			
 
7.2.2	Human	cell,	amoebal,	and	bacterial	culture	medium   DMEM	for	A549	cells	(v/v):	DMEM	80	%,	and	FBS	10	%.		PYG	(w/v):	proteose	peptone	0.75	%,	yeast	extract	0.75	%,	and	glucose	1.5	%	distilled	water	prior	to	autoclaving	121°C	for	15	min.		Luria	Bertani	broth	(w/v):	10	g	tryptone,	5	g	yeast	extract	and	10	g	NaCl	in	distilled	water	to	a	final	volume	of	1000	ml,	adjusting	the	pH	to	7.5	before	autoclaving	at	121°C	for	15	min.		CLED	(w/v):	36.15	g	of	CLED	agar	dissolved	up	to	1000	ml	distilled	water	prior	to	autoclaving	121°C	for	15	min.		Nutrient	agar	(w/v):	23	g	of	nutrient	agar	dissolved	up	to	1000	ml	distilled	water	prior	to	autoclaving	121°C	for	15	min.		Non-nutrient	agar	(w/v):	30	g	bacteriological	agar	dissolved	in	to	1000	ml	Ringers	solution,	or	in	Page	amoeba	saline	prior	to	autoclaving	121°C	for	15	min.		Trypsin	1x	(v/v):	10	ml	up	to100	ml	PBS.	10	%	SDS	(w/v):	10	g	dissolved	up	to	100	ml	distilled	water.			
7.2.3	Antibiotics	and	antimicrobial	peptides		Vancomycin	(w/v):	stock	solution:	1	mg/ml	dissolved	in	distilled	water		Ciprofloxacin	(w/v):	stock	solution:	1	mg/ml	dissolved	in	distilled	water	with	0.05mM	HCl		Magainin	II	(w/v):	stock	solution:	1	mg/ml	dissolved	in	distilled	water.		Pleurocidin	(w/v):	stock	solution:	1	mg/ml	dissolved	in	distilled	water.		
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Silver	nitrate	(w/v):	stock	solution:	10	mg/ml	dissolved	in	distilled	water.			
7.2.4	Primers	preparation		• Spin	the	tubes	at	top	speed	for	10	minutes	to	ensure	that	there	are	no	lyophilized	primers	stuck	to	the	cap.			• To	make	a	typical	100	mM	(100X)	stock	concentration	of	primers,	dissolve	the	primers	in	a	volume	of	sterile	distilled	water	that	is	10X	the	amount	of	nmoles	in	the	tube,	using	μL	of	water.	This	value	is	printed	on	the	side	of	the	tube.	For	example,	if	your	tube	contains	53.4	nmoles	of	primer,	then	you	would	dissolve	using	534	μL	of	water.	This	will	now	be	at	a	100	μM	concentration.			i.e.	53.4	nmoles	of	primer	dissolve	in	534	μl	of	water	=(53.4	nmoles/l)	(x	moles/534	x	10-6	l)	=	0.0001	mole/l	=	0.0001	M	=	0.1	mM=100	μM	3.	To	prepare	primers	for	use:	Dilute	this	stock	1:10,	to	give	a	concentration	of	10	μM.		4. Store	all	sets	of	primers	at	-20°C.			5. Typically	use	0.1-1.0	μM	final	concentrations	in	a	PCR	mix.	i.e.	if	your	reaction	volume		is	25	mL,	then	using	2.5	μL	for	each	separate	primer,	will	give	you	a	final	concentration	of	1μM.			
	
7.2.5	Disinfections	used	in	the	laboratory:		1	%	virkon	(w/v):	1	mg	of	virkon	powder	in	100	ml	PBS		70	%	ethanol	(v/v):	70	ml	of	concentrated	ethanol	in	100	ml	H2O		
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Appendix	3:	List	of	cell	lines;	microorganisms;	storage	and	thawing	
methods		
7.3	List	of	cell	lines;	microorganisms;	storage	and	thawing	methods		
	
7.3.1	List	of	Cell	lines  A549	cells	(adenocarcinomic	human	alveolar	basal	epithelial	cells)	TERT-NHUC	(hTERT-immortalised	normal	human	urothelial	cells)		
7.3.2	Acanthamoeba	strain			
Acanthamoeba	castellanii	T4	(ATCC	30234)		
7.3.3	Storage	method	for	cells	and	Acanthamoeba		Cells	 and	 Acanthamoeba	were	 stored	 as	 axenic	 cultures	 at	 -80	 °C	 and	 liquid	 nitrogen.	Briefly,	growing	cells	or	amoebae	were	re-suspended	at	a	density	of	1-5	x	106	cells/ml	in	the	freezing	medium	[90	%	FBS,	and	10	%	DMSO	(v/v)	for	human	cells;	90	%	PYG,	and	10	%	DMSO	(v/v)	for	Acanthamoeba]	and	placed	into	a	cryotube.	The	freezing	process	were	done	 gradually	 in	 ice,	 then	 -20	 °C	 for	 60	 minutes	 followed	 by	 their	 storage	 at	 -80°C	freezer.	Some	of	cryotubes	were	transferred	after	overnight	incubation	in	-80	°C	to	store	in	liquid	nitrogen.		
7.3.4	Thawing	method	for	cells	and	Acanthamoeba		Thawing	and	recovery	of	stored	cells	and	Acanthamoeba	from	both	liquid	nitrogen	and	-80	 °C	 freezer	was	done	quickly.	The	cryotubes	were	placed	 immediately	 in	 the	wormer	incubator	37	°C	for	3	minutes	after	taken	out	from	liquid	nitrogen	or	-80	°C	freezer.	Cells	or	Acanthamoeba	were	 transferred	 into	a	15	ml	 tube	with	warmed	medium	(DMEM	 for	A549	cell	line,	KGM	for	TERT-NHUC,	and	PYG	for	Acanthamoeba)	and	centrifuged	at	2000	x	g	for	5	minutes.	Next,	 supernatants	were	discarded,	 then	pellets	were	resuspended	 in	owned	 medium	 (DMEM	 for	 A549	 cell	 line,	 KGM	 for	 TERT-NHUC,	 and	 PYG	 for	
Acanthamoeba)	and	transferred	into	a	T25	tissue	flasks.	Flasks	were	incubated	at	37	°C,	5	%	 CO2	 and	 95	 %	 humidity	 for	 A549	 and	 TERT-NHUC	 cells	 or	 30	 °C	 air	 incubator	 for	
Acanthamoeba	until	the	cells	reached	an	enough	number	to	passage.		
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7.3.5	Bacterial	strains		Clinical	 isolates	 of	 MSSA,	 S.	 epidermidis,	 Str.	 pneumoniae,	 E.	 coli,	 H.	 influenzae	 and	 P.	
aeruginosa	 were	 generously	 provided	 by	 Dr	 Tony	 Elston	 from	 Colchester	 General	Hospital.	
7.3.6	Storage	of	bacterial	cultures		By	using	a	disposable	sterile	loop,	about	20-30	isolated	colonies	of	bacteria	were	picked	up	 from	 the	 agar	 plate	 and	 inoculated	 in	 a	 10	ml	 of	 bacterial	 freezing	medium	 [70	%	Luria-Bertani	broth	and	30	%	glycerol	(v/v)].	Then,	the	mixture	of	freezing	medium	with	bacteria	were	divided	into	cryotubes	final	volume	of	each	tube	was	0.5	ml	and	stored	in	a	-20	°C	freezer.		
7.3.7	Thawing	and	re-culturing	bacteria		To	re-culture	bacteria,	a	disposable	sterile	loop	was	inserted	into	the	frozen	cryotube	and	then	streaked	on	fresh	agar	plate	and	incubated	at	37	°C	air	incubator	overnight.	After	the	incubation,	 the	 plate	was	 carefully	 examined	 if	 the	 colonies	 have	 similar	morphologies	such	as	textures,	colors	and	border	shapes	and	stored	at	4	°C	for	up	to	a	month.				
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The	 Microbiology	 Society	 Annual	 Conference	 2016,	 Liverpool,	 21–24	 March.	 Poster	presentation:	“An	investigation	of	the	effects	of	an	antimicrobial	peptide	on	the	survival	of	
Acanthamoeba	 and	 intracellular	 bacteria	 associated	 with	 Cystic	 Fibrosis”	 B.	Tashmukhambetov,	G.	Mitchell	and	S.	Alsam		3Rd	 Research	 Forum	 For	 Central	 Asia	 2016,	 University	 of	 Cambridge,	 11	 March.	 Oral	presentation:	 “Complications	 in	 genetic	 diseases	 such	 as	 Cystic	 Fibrosis	 “	 B.	Tashmukhambetov,	G.	Mitchell	and	S.	Alsam		The	Molecular	 and	 Cellular	 Bioscience	 Group	 (MCBG)	 Seminar	 2015,	 9	 July.	 Oral	presentation:	“	Using	antimicrobial	peptides	to	fight	bacterial	infections	in	Cystic	Fibrosis	lung”	B.	Tashmukhambetov,	G.	Mitchell	and	S.	Alsam		13th	Annual	Graduate	Forum	2014,	Essex	University,	10th	September.	Oral	presentation:	“Interaction	of	Acanthamoeba	and	bacteria	associated	with	CF”	B.	Tashmukhambetov,	G.	Mitchell	and	S.	Alsam		Bolashak	Educational	Forum	2014,	University	of	Cambridge,	29	April.	Oral	presentation:	“Contemporary	 issues	 within	 the	 educational	 system	 in	 Kazakhstan”	 B.	Tashmukhambetov		
	
